In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells

By controlling marker expression with TGFβ, Wnt, and ERBB activators, the differentiation of pluripotent stem cells into functional β-cells is enhanced, addressing inefficiencies in current methods and achieving rapid in vitro production of insulin-producing cells.

KR103043674B1Active Publication Date: 2026-11-06VIACYTE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020247027970
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2013-12-13
Filing Date
2014-03-13
Publication Date
2026-11-06
Estimated Expiration
2034-03-13

AI Technical Summary

Technical Problem

Current methods for differentiating pluripotent stem cells into functional pancreatic β-cells in vitro are inefficient, requiring long maturation times in vivo due to imbalanced expression of markers like NGN3 and NKX2.2, which disrupt the formation of non-endocrine pluripotent pancreatic progenitor subpopulations.

Method used

A method involving the use of TGFβ superfamily growth factors, Wnt family members, and ERBB receptor kinase activators to control the expression of NGN3 and NKX2.2, enhancing the population of non-endocrine pluripotent pancreatic progenitor cells (CHGA-) while promoting PDX1/NKX6.1 co-expression, thereby facilitating in vitro differentiation into insulin-producing β-cells.

Benefits of technology

This approach significantly accelerates the differentiation process, resulting in a higher proportion of functional β-cells capable of producing insulin in response to glucose stimulation, both in vitro and in vivo, with improved cell yield and reduced maturation time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure R1020247027970_ABST
    Figure R1020247027970_ABST
Patent Text Reader

Abstract

A human immature endocrine cell population and a method for producing an immature endocrine cell population are provided. Specifically, immature beta cells and a method for producing immature beta cells are described. The immature beta cells co-express INS and NKX6.1, are unipotent, and thus develop into mature beta cells in vivo when transplanted. Mature beta cells in vivo can produce insulin in response to glucose stimulation.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] Cross-reference regarding related applications

[0002] The present application claims priority to U.S. Provisional Application No. 61 / 781,005 filed on March 14, 2013, and U.S. Utility Model Application No. 14 / 106,330 filed on December 13, 2013, the full text of which is incorporated herein by reference.

[0003] Field of invention

[0004] The present invention generally relates to the isolation, maintenance, and use of cell cultures. More specifically, it relates to a cell composition and method for differentiating in vitro pluripotent stem cells into a pancreatic endoderm cell (PEC) culture in which non-endocrine multipotent pancreatic progenitor subpopulations (CHGA-) are enhanced but endocrine-assigned cells (CHGA+) are relatively sufficient. Furthermore, this specification describes for the first time a cell composition and method for differentiating in vitro pluripotent stem cells into endocrine cells that produce insulin in response to glucose stimulation in vivo after transplantation into a mammal. This specification also describes a cell composition and method for differentiating in vitro pluripotent stem cells into endocrine cells that produce insulin in vitro. Background Technology

[0005] Developing an expanded population of human pancreatic β-cells that can be used for cell transplantation is a major goal of diabetes research. In recent years, interest has focused on using pluripotent stem cells as a potential renewable source for β-cells. Due to the complex nature of pancreatic endocrine differentiation, which remains unexplained, the differentiation of pluripotent stem cells into functionally mature β-cells has not been efficiently achieved in vitro. To date, only progenitor cells, such as pancreatic endoderm cells (PEC), have been transplanted into rodents and demonstrated human-specific β-cell function after 8–12 weeks. The PEC cell population comprises at least two cell populations: non-endocrine pluripotent pancreatic progenitor subpopulations (CHGA-) and cells transferred to the endocrine lineage (CHGA+). Upon PEC transplantation, it was found that the non-endocrine pluripotent pancreatic progenitor subpopulations (CHGA-) mature in vivo to form β-cells. Transplanting PEC cell populations requires a long maturation time (8-12 weeks) in vivo, which can be shortened or eliminated if (a) the in vitro PEC population contains a larger proportion of cell types that mature into β-cells in vivo (i.e., non-endocrine pluripotent pancreatic progenitor cells (CHGA-)), (b) final (β-cell) differentiation is achieved in vitro, or (c) an in vitro progenitor population that follows a differentiation pathway more closely than currently used, i.e., a developmentally advanced cell population, is identified.

[0006] Without limiting the present invention to any theory, a possible explanation for why pluripotent stem cells do not mature into sufficiently functional β-cells in vitro is that the marker expression in cells derived in vitro is not the same at the same time as during mammalian pancreatic development in vivo. For example, NGN3 expression during differentiation in vitro occurs earlier than in mammalian pancreatic development in vivo. Indeed, in traditional four-stage differentiation protocols as described in the applicant’s numerous publications and patents, the full text of which is incorporated herein by reference, it has been observed that the PEC population expresses NGN3 and NKX2.2. Therefore, suppressing or inhibiting NGN3 expression until differentiation of the PDX1 / NKX6.1-expressing co-positive non-endocrine pluripotent pancreatic progenitor subpopulation is an important step in achieving differentiation of pluripotent stem cells into functionally mature β-cells in vitro or differentiation of a PEC population containing more non-endocrine pluripotent pancreatic progenitor cells (CHGA-) compared to endocrine-assigned cells (CHGA+).

[0007] It is not clear which protocol delays the expression of NGN3 and NKX2.2, because the differentiation protocol must not destroy the formation of the non-endocrine pluripotent pancreatic progenitor subpopulation (CHGA-), preferably increase it, and minimize cell loss; or at least maintain adequate cell mass and cell yield (i.e., micrograms, grams, kilograms of cells).

[0008] Additionally, since NGN3 expression is required for the initiation of endocrine cell differentiation, the promotion of islet cell maturation, and the maintenance of islet function, stimulating or inducing NGN3 expression in endocrine-ordered cells (CHGA+) is an important step in achieving in vitro differentiation of pluripotent stem cells into functionally matured β-cells.

[0009] In one aspect, an in vitro method for producing a cell population comprising human PDX1-positive pancreatic endoderm cells is provided. The method comprises producing a cell population comprising PDX1-positive pancreatic endoderm cells by contacting a cell population comprising definitive endoderm lineage cells with a TGFβ superfamily growth factor and a Wnt family member. In embodiments, the TGFβ superfamily growth factor is selected from the group consisting of Nodal, Activin A, Activin B, BMP2, BMP4, GDF8, GDF-10, GDF-11, and GDF-15. In embodiments, the method further comprises contacting a cell population comprising definitive endoderm lineage cells with an ERBB receptor kinase activator. In embodiments, the TGFβ superfamily growth factor is Activin A. In embodiments, the Wnt family member is Wnt3a. In embodiments, the ERBB receptor kinase activator is Heregulin.

[0010] In embodiments, a cell population containing PDX1-positive pancreatic endoderm cells is contacted with 25 ng / mL or more of TGFβ superfamily growth factor. In embodiments, a cell population containing PDX1-positive pancreatic endoderm cells is contacted with 50 ng / mL or more of TGFβ superfamily growth factor. In embodiments, a cell population containing PDX1-positive pancreatic endoderm cells is contacted with 75 ng / mL or more of TGFβ superfamily growth factor.

[0011] In embodiments, a cell population containing PDX1-positive pancreatic endoderm cells is in contact with 25 ng / mL or more of Wnt family members. In embodiments, a cell population containing PDX1-positive pancreatic endoderm cells is in contact with 50 ng / mL or more of Wnt family members. In embodiments, a cell population containing PDX1-positive pancreatic endoderm cells is in contact with 75 ng / mL or more of Wnt family members.

[0012] In embodiments, the cell population is contacted with ERBB receptor kinase activator at a rate 5 to 15 times lower than that of the TGFβ superfamily growth factor and the Wnt family member, respectively. In embodiments, at least about 50% of the cell population containing PDX1-positive pancreatic endoderm cells are PDX1-positive pancreatic endoderm cells. In embodiments, at least about 60% of the cell population containing PDX1-positive pancreatic endoderm cells are PDX1-positive pancreatic endoderm cells. In embodiments, at least about 70% of the cell population containing PDX1-positive pancreatic endoderm cells are PDX1-positive pancreatic endoderm cells. In embodiments, at least about 80% of the cell population containing PDX1-positive pancreatic endoderm cells are PDX1-positive pancreatic endoderm cells. In embodiments, at least about 90% of the cell population containing PDX1-positive pancreatic endoderm cells are PDX1-positive pancreatic endoderm cells.

[0013] In embodiments, PDX1-positive pancreatic endoderm cells additionally express NKX6.1 and substantially do not express NGN3. In embodiments, PDX1-positive pancreatic endoderm cells do not express CHGA. In embodiments, PDX1-positive pancreatic endoderm cells additionally express NKX6.1 and PFT1A and substantially do not express NGN3. In embodiments, PDX1-positive pancreatic endoderm cells are pluripotent cells capable of differentiating into unipotent immature beta cells.

[0014] In one aspect, a human pancreatic endoderm cell culture comprising definitive endoderm lineage cells, TGFβ superfamily growth factor, and a Wnt family member is provided. In embodiments, the TGFβ superfamily growth factor is selected from the group consisting of nodal, activin A, activin B, BMP2, BMP4, GDF8, GDF-10, GDF-11, and GDF-15. In embodiments, the method further comprises contacting a cell population comprising definitive endoderm lineage cells with an ERBB receptor kinase activator. In embodiments, the TGFβ superfamily growth factor is activin A. In embodiments, the Wnt family member is Wnt3a. In embodiments, the ERBB receptor kinase activator is hereguline.

[0015] In another aspect, in vitro unipotent human immature beta cells are provided. In embodiments, unipotent human immature beta cells express INS and NKX6.1 and substantially do not express NGN3. In embodiments, unipotent human immature beta cells can differentiate into mature beta cells. In embodiments, differentiation is in vivo differentiation. In embodiments, unipotent human immature beta cells form part of a cell population. In embodiments, 10% or more of the cell population are immature beta cells. In embodiments, 20% or more of the cell population are immature beta cells. In embodiments, 30% or more of the cell population are immature beta cells. In embodiments, 40% or more of the cell population are immature beta cells. In embodiments, 50% or more of the cell population are immature beta cells. In embodiments, 60% or more of the cell population are immature beta cells. In embodiments, more than 80% of the cell population are immature beta cells. In embodiments, more than 90% of the cell population are immature beta cells. In embodiments, more than 98% of the cell population are immature beta cells. In embodiments, human immature beta cells are monohormonal. In embodiments, unipotent human cells express MAFB.

[0016] In one aspect, a method for producing unipotent human immature beta cells is provided. This method comprises generating immature beta cells by contacting human definitive endoderm lineage cells in vitro with a TGFβ superfamily member and a Wnt family member. In embodiments, unipotent human immature beta cells express INS and NKX6.1 and substantially do not express NGN3. In embodiments, the TGFβ superfamily member is selected from the group consisting of nodal, activin A, activin B, BMP2, BMP4, GDF8, GDF-10, GDF-11, and GDF-15. In embodiments, this method further comprises contacting human definitive endoderm lineage cells in vitro with an ERBB receptor kinase activator. In embodiments, the TGFβ superfamily growth factor is activin A. In embodiments, the Wnt family member is Wnt3a. In embodiments, the ERBB receptor kinase activator is hereguline. In embodiments, the TGFβ superfamily growth factor is a BMP.

[0017] In embodiments, this method further comprises contacting human definitive endoderm lineage cells in vitro with nicotinamide, retinoic acid or a retinoic acid analog, an rho kinase inhibitor, or a gamma secretase inhibitor. In embodiments, the retinoic acid is selected from the group consisting of all-trans-retinoic acid (RA), 13-cis-retinoic acid (13-cis-RA), and arotenoid acid (TTNPB). In embodiments, the retinoic acid is all-trans-retinoic acid (RA). In embodiments, the retinoic acid is 13-cis-retinoic acid (13-cis-RA). In embodiments, the retinoic acid is arotenoid acid (TTNPB). In embodiments, the rho kinase inhibitor is selected from the group consisting of Y-27632, Fasudil, H-1152P, Wf-536, and Y-30141. In embodiments, the rho kinase inhibitor is Y-27632.

[0018] In embodiments, the gamma secretase inhibitors are gamma secretase inhibitor I (GSI I), gamma secretase inhibitor II (GSI II), gamma secretase inhibitor III (GSI III), gamma secretase inhibitor IV (GSI IV), gamma secretase inhibitor V (GSI V), gamma secretase inhibitor VI (GSI VI), gamma secretase inhibitor VII (GSI VII), gamma secretase inhibitor IX (GSI IX), (DAPT), gamma secretase inhibitor XI (GSI XI), gamma secretase inhibitor XII (GSI XII), gamma secretase inhibitor XIII (GSI XIII), gamma secretase inhibitor XIV (GSI XIV), gamma secretase inhibitor XVI (GSI XVI), gamma secretase inhibitor XVII (GSI XVII), gamma secretase inhibitor XIX (GSI It is selected from the group consisting of XIX), gamma secretase inhibitor XX (GSI XX), gamma secretase inhibitor XXI (GSI XXI), gamma 40 secretase inhibitor I, gamma 40 secretase inhibitor II, and RO4929097. In embodiments, the gamma secretase inhibitor is RO4929097. In embodiments, the gamma secretase inhibitor is GSI IV.

[0019] In another aspect, a method for producing mature beta cells in vivo is provided. The method comprises the steps of: (a) generating immature beta cells by contacting human definitive endoderm lineage cells in vitro with a member of the TGFβ superfamily and a member of the Wnt family; (b) transplanting the immature beta cells of step (a) into a mammalian subject; and differentiating the immature beta cells in vivo to produce a population of cells including mature beta cells. In embodiments, the method further comprises causing the mature beta cells to produce insulin in response to glucose stimulation. In embodiments, the TGFβ superfamily growth factor is selected from the group consisting of nodal, activin A and activin B, GDF-8, GDF-11 and GDF-15. In embodiments, the method further comprises contacting human definitive endoderm lineage cells in vitro with an ERBB receptor kinase activator. In embodiments, the TGFβ superfamily growth factor is activin A. In embodiments, the member of the Wnt family is Wnt3a. In embodiments, the ERBB receptor kinase activator is heregulin.

[0020] In embodiments, human definitive endoderm lineage cells are contacted with TGFβ superfamily growth factor at a concentration of 25 ng / mL or more. In embodiments, human definitive endoderm lineage cells are contacted with TGFβ superfamily growth factor at a concentration of 50 ng / mL or more. In embodiments, human definitive endoderm lineage cells are contacted with TGFβ superfamily growth factor at a concentration of 75 ng / mL or more.

[0021] In embodiments, human definitive endoderm lineage cells are contacted with Wnt family members at a concentration of 25 ng / mL or more. In embodiments, human definitive endoderm lineage cells are contacted with Wnt family members at a concentration of 50 ng / mL or more. In embodiments, human definitive endoderm lineage cells are contacted with Wnt family members at a concentration of 75 ng / mL or more.

[0022] In embodiments, human definitive endoderm lineage cells are contacted with ERBB receptor kinase activators at levels 5–15 times lower than those of TGFβ superfamily growth factors and Wnt family members. In embodiments, more than 10% of the cell population consists of immature beta cells. In embodiments, more than 20% of the cell population consists of immature beta cells. In embodiments, more than 30% of the cell population consists of immature beta cells. In embodiments, more than 40% of the cell population consists of immature beta cells. In embodiments, more than 50% of the cell population consists of immature beta cells. In embodiments, more than 60% of the cell population consists of immature beta cells. In embodiments, more than 70% of the cell population consists of immature beta cells. In embodiments, more than 80% of the cell population consists of immature beta cells. In embodiments, more than 90% of the cell population consists of immature beta cells. In embodiments, immature beta cells express INS and NKX6.1 and substantially do not express NGN3. In embodiments, immature beta cells express INS, NKX6.1 and MAFB and substantially do not express NGN3.

[0023] In one aspect, in vitro unipotent human immature beta cells are provided. In embodiments, unipotent human immature beta cells express INS and NKX6.1 and substantially do not express NGN3. In embodiments, unipotent human immature beta cells can be matured into mature beta cells.

[0024] In one aspect, a method for producing mature beta cells in vivo is provided. The method comprises: a. generating immature beta cells by contacting human definitive endoderm lineage cells in vitro with a member of the TGFβ superfamily and a member of the Wnt family; b. transplanting the immature beta cells of step (a) into a mammalian subject; and c. allowing the immature beta cells to mature in vivo to produce a population of cells including insulin-secreting beta cells.

[0025] In one aspect, unipotent human immature beta cells expressing INS and NKX6.1 and substantially not expressing NGN3 are provided. In embodiments, unipotent human immature beta cells can be matured into mature beta cells. In embodiments, unipotent human immature beta cells further express MAFB.

[0026] In one aspect, in vitro unipotent human immature beta cells expressing INS and NKX6.1 and substantially not expressing NGN3 are provided. In embodiments, unipotent human immature beta cells can be matured into mature beta cells. In embodiments, unipotent human immature beta cells further express MAFB.

[0027] In one aspect, a method for producing unipotent human immature beta cells is provided. This method comprises producing unipotent human immature beta cells by contacting human definitive endoderm lineage cells in vitro with a TGFβ superfamily member and a Wnt family member. In embodiments, the unipotent human immature beta cells express INS, NKX6.1 and substantially do not express NGN3. In embodiments, this method further comprises contacting human definitive endoderm lineage cells in vitro with an ERBB receptor kinase activator. In embodiments, the TGFβ superfamily growth factor is activin A. In embodiments, the Wnt family member is Wnt3a. In embodiments, the ERBB receptor kinase activator is hereguline.

[0028] In one aspect, a method for producing mature beta cells in vivo is provided. The method comprises: a. generating immature beta cells by contacting human definitive endoderm lineage cells in vitro with a TGFβ superfamily member and a Wnt family member; b. transplanting the immature beta cells of step (a) into a mammalian subject; and c. allowing the immature beta cells to mature in vivo to produce a population of cells including insulin-secreting beta cells. In embodiments, the method further comprises contacting human definitive endoderm lineage cells in vitro with an ERBB receptor kinase activator. In embodiments, the TGFβ superfamily growth factor is activin A. In embodiments, the Wnt family member is Wnt3a. In embodiments, the ERBB receptor kinase activator is hereguline. In embodiments, human definitive endoderm lineage cells are contacted with TGFβ superfamily growth factor at a concentration of 50 ng / mL or more. In embodiments, human definitive endoderm lineage cells are contacted with 25 ng / mL or more of a Wnt family member. In embodiments, human definitive endoderm lineage cells are contacted with TGFβ superfamily growth factor and ERBB receptor kinase activator at 5-15 times less than that of a Wnt family member. In embodiments, immature beta cells express INS and NKX6.1 and substantially do not express NGN3. In embodiments, immature beta cells express INS, NKX6.1 and MAFB and substantially do not express NGN3.

[0029] One embodiment provides a composition and a method for differentiating pluripotent stem cells or progenitor cells derived from pluripotent stem cells into endocrine and non-endocrine populations. In one aspect, the endocrine cells express at least CHGA (or CHGA+), and the non-endocrine cells do not express CHGA (or CHGA-). In one aspect, these cell populations are referred to as endocrine (CHGA+) and non-endocrine (CHGA-) subpopulations, or simply as CHGA+ or CHGA- subpopulations, or simply as endocrine and non-endocrine subpopulations. In another aspect, these endocrine and non-endocrine subpopulations may be pluripotent progenitor / progenitor subpopulations, such as a non-endocrine pluripotent pancreatic progenitor subpopulation or an endocrine pluripotent pancreatic progenitor subpopulation; or unipotent subpopulations, such as immature endocrine cells, preferably immature beta cells, immature glucagon cells, etc.

[0030] One embodiment provides a composition and a method for differentiating in vitro pluripotent stem cells into pancreatic endoderm cell (PEC) cultures comprising both endocrine and non-endocrine subpopulations, wherein the expression of NGN3 is suppressed. In one aspect, the expression of NKX2.2 is also suppressed in the PEC culture. In one aspect, the expression of CHGA is also suppressed in the PEC culture. In one aspect, the expression of PDX1 and NKX6.1 is co-expressed on a single cell in the PEC culture. In one aspect, less than 50% of the cells in the PEC culture, preferably 40%, less than 30%, more preferably 20%, 10%, 5%, 2%, or less than 1% express NGN3, NKX2.2, or CHGA. In one aspect, the PEC culture is enhanced for a non-endocrine pluripotent pancreatic progenitor subpopulation (CHGA-). In one aspect, PEC cultures express markers (PDX1 and / or NKX6.1) for the non-endocrine multipotent pancreatic progenitor subpopulation (CHGA-). In one aspect, PEC cultures rich in the non-endocrine multipotent pancreatic progenitor subpopulation (CHGA-) are transplanted into a mammalian host, and the graft matures to produce insulin in response to glucose in vivo. In one aspect, PEC cultures rich in the non-endocrine multipotent pancreatic progenitor subpopulation (CHGA-) mature more rapidly in vivo than PEC cultures not rich in the non-endocrine multipotent pancreatic progenitor subpopulation (CHGA-). In one aspect, transplanted PEC cultures rich in non-endocrine multipotent pancreatic progenitor subgroups (CHGA-) show more than 2× improvement in in vivo function, as measured by C-peptide (insulin) production in response to glucose stimulation, about 10 or 12 weeks after transplantation, compared to transplanted PEC cultures not rich in non-endocrine multipotent pancreatic progenitor subgroups (CHGA-).

[0031] One embodiment provides a composition and a method for differentiating pluripotent human stem cells in vitro, wherein the expression of genes typical for endocrine differentiation and development, such as NGN3 and NKX2.2, is suppressed until after the production of non-endocrine pluripotent pancreatic progenitors (CHGA- and PDX1 / NKX6.1 co-expression).

[0032] One embodiment provides a method for differentiating pluripotent stem cells in vitro into a PEC culture, comprising the steps of: (a) obtaining a population of PDX1-negative foregut endoderm cells; and (b) contacting the cell population from step (a) with an agent that activates a member of the TGFβ receptor family to produce a cell culture comprising a PEC that substantially does not express a marker selected from the group comprising CHGA, NGN3, or NKX2.2. In one aspect, the PEC comprises a subpopulation of cells co-expressing PDX1 and NKX6.1. In one aspect, the PEC comprises a subpopulation of non-endocrine pluripotent pancreatic progenitor (CHGA-) cells. In one aspect, the agent that activates a member of the TGFβ receptor family is selected from the group consisting of nodal, activin A, activin B, BMP2, BMP4, GDF8, GDF-10, GDF-11, GDF-15, and mixtures thereof. In one aspect, Activin A is added at 100 ng / mL, 75 ng / mL, 50 ng / mL, 25 ng / mL, or 10 ng / mL in step 3, and at 15 ng / mL, 10 ng / mL, or 5 ng / mL in step 4. In one aspect, PEC cultures formed by adding Activin A to a PDX1-negative foregut endoderm cell population show an in vivo function, as measured by C-peptide (insulin) production in response to glucose stimulation, that is improved by more than 2× compared to PEC cultures not rich in the non-endocrine multipotent pancreatic progenitor subpopulation (CHGA-).

[0033] In one aspect, PEC cultures containing non-endocrine multipotent pancreatic progenitor subgroups (CHGA-) show more than 2× improvement in in vivo function, as measured by insulin production in response to glucose stimulation, compared to PEC cell cultures not rich in non-endocrine multipotent pancreatic progenitor subgroups (CHGA-).

[0034] One embodiment provides a method for differentiating pluripotent stem cells in vitro into a cell population comprising PEC, comprising the steps of: (a) obtaining a population of PDX1-negative foregut endoderm cells; and (b) contacting the cell population from step (a) with an agent that activates a member of the TGFβ receptor family to generate a PEC population that substantially does not express a marker selected from the group comprising CHGA, NGN3, or NKX2.2. In one aspect, the PEC population comprises cells co-expressing PDX1 and NKX6.1. In one aspect, the PEC population comprises non-endocrine pluripotent pancreatic progenitor cells (CHGA-). In one aspect, the agent that activates a member of the TGFβ receptor family is selected from the group consisting of nodal, activin A, activin B, BMP2, BMP4, GDF8, GDF-10, GDF-11, GDF-15, and mixtures thereof. In one aspect, the agent that activates a member of the TGFβ receptor family is activin A. In one aspect, Activin A is added at 100 ng / mL, 75 ng / mL, 50 ng / mL, 25 ng / mL, or 10 ng / mL in step 3, and at 15 ng / mL, 10 ng / mL, or 5 ng / mL in step 4. In one aspect, the EGF family ligand is selected from the group comprising heregulin (also known as Neuregulin 1 (NRG1)), Neuregulin 2 (NRG2), Neuregulin 3 (NRG3), Neuregulin 4 (NRG4), EGF (Epidermal Growth Factor), and betacellulin. In one aspect, the EGF family ligand is heregulin. In one aspect, heregulin is added at 2 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL, 15 ng / mL, 30 ng / mL, 40 ng / mL, 50 ng / mL, 60 ng / mL, 70 ng / mL or 80 ng / mL.In one aspect, PEC cultures formed by adding activin A and hereguline to a PDX1-negative foregut endoderm cell population show more than 2× improvement in in vivo function, as measured by C-peptide (insulin) production in response to glucose stimulation, compared to PEC cultures not rich in the non-endocrine multipotent pancreatic progenitor subpopulation (CHGA-).

[0035] One embodiment provides a method for differentiating pluripotent stem cells in vitro into a cell culture containing PEC, comprising the steps of: (a) obtaining a population of PDX1-negative foregut endoderm cells; and (b) contacting the cell population from step (a) with an agent activating at least a member of the TGFβ receptor family, an EGF family ligand, or an agent activating the Wnt signaling pathway (alone or in combination) to produce a cell culture containing PEC that substantially does not express a marker selected from the group comprising CHGA, NGN3, or NKX2.2. In one aspect, the PEC culture comprises cells co-expressing PDX1 and NKX6.1. In one aspect, the PEC cell culture comprises a non-endocrine pluripotent pancreatic progenitor subpopulation (CHGA-). In one aspect, the agonist activating a member of the TGFβ receptor family is selected from the group consisting of nodal, activin A, activin B, BMP2, BMP4, GDF8, GDF-10, GDF-11, GDF-15, and mixtures thereof. In one aspect, the agonist activating a member of the TGFβ receptor family is activin A. In one aspect, the agonist activating the Wnt signaling pathway is a member of the Wnt family selected from the group consisting of WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, WNT16, and Wnt3A. In one aspect, the member of the Wnt family is Wnt3A. In one aspect, Activin A is added at 100 ng / mL, 75 ng / mL, 50 ng / mL, 25 ng / mL, or 10 ng / mL in step 3, and at 15 ng / mL, 10 ng / mL, or 5 ng / mL in step 4.In one aspect, hereguline is added in an amount of 2 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL, 15 ng / mL, 30 ng / mL, 40 ng / mL, 50 ng / mL, 60 ng / mL, 70 ng / mL, or 80 ng / mL. In one aspect, WNT is added in an amount of 5 ng / mL, 25 ng / mL, 50 ng / mL to 75 ng / mL, more preferably 50 ng / mL.

[0036] In one aspect, Activin A is added to Step 3 alone or in combination with WNT. In another aspect, Activin A is added to Step 3 with WNT or with WNT and hereguline. In yet another aspect, Activin A is added to Step 4 alone or in combination with hereguline.

[0037] In one aspect, more than 10%, preferably more than 20%, 30%, 40%, more preferably more than 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 100% of the cells in the cell population are non-endocrine pluripotent striatum subpopulations (CHGA-). In one aspect, PEC cell cultures formed by adding activin A, hereguline, and WNT to a PDX1-negative foregut endoderm cell population show in vivo function, as measured by insulin production in response to glucose stimulation, improved by more than 2× compared to PEC cell cultures not rich in non-endocrine pluripotent striatum subpopulations (CHGA-).

[0038] One embodiment provides a composition and a method for differentiating pluripotent stem cells in vitro into a PEC culture comprising cells entrusted to a minimal endocrine lineage (CHGA+). In one aspect, the cells entrusted to an endocrine lineage are characterized by the expression of CHGA. In one aspect, less than 50%, preferably less than 40%, less than 30%, more preferably less than 20%, 10%, 5%, 2%, and 1% of the cells in the PEC culture are cells entrusted to an endocrine lineage (CHGA+).

[0039] One embodiment provides a composition and a method for substantially differentiating pluripotent stem cells in vitro into PEC cultures and further differentiating the PEC cultures in vitro into endocrine cells. In one aspect, the endocrine cells express CHGA. In one aspect, the endocrine cells can produce insulin in vitro. In one aspect, the endocrine insulin-secreting cells in vitro can produce insulin in response to glucose stimulation. In one aspect, more than 10% of the cells in the cell population, preferably more than 20%, 30%, 40%, more preferably more than 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 100% are endocrine cells.

[0040] One embodiment provides a method for differentiating pluripotent stem cells into endocrine cells in vitro, comprising the steps of: (a) obtaining a cell population containing PEC; and (b) generating endocrine cells by contacting the cell population from step (a) with a growth factor selected from the group consisting of bone morphogenetic protein (BMP), hedgehog inhibitor, platelet-derived growth factor (PDGF), a member of the fibroblast growth factor family, retinoids, insulin growth factor 1 and 2 (IGF1 and IGF2), and nicotinamide. In one aspect, the endocrine cells express CHGA. In one aspect, the endocrine cells are immature insulin-producing beta-cells in vitro. In one aspect, the endocrine cells are loaded into a implantable semipermeable encapsulation device and matured so as to produce insulin in vivo in response to glucose stimulation. In one aspect, more than 10% of the cells in the cell population, preferably more than 20%, 30%, 40%, more preferably more than 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 100% are endocrine cells. In one aspect, SSH is added at 10 g / mL to 100 ng / mL. In one aspect, PDGF is added at 10 ng / mL to 100 ng / mL. In one aspect, BMP is added at 10 g / mL to 20 ng / mL. In one aspect, FGF2 is added at 2 ng / mL to 20 ng / mL. In one aspect, IGF1 or IGF2 is added at 25 ng / mL to 100 ng / mL. In one aspect, the above compounds are administered in combination with each other. In one aspect, a member of the fibroblast growth factor family is FGF2. In one aspect, retinoids are retinoic acid and / or retinoic acid analogs such as TTNPB or TT3, insulin-like growth factor I (IGF-I or IGF1) and -II (IGF-II or IGF2). In another aspect, bone morphogenetic protein is BMP4.In one aspect, Hedgehog inhibitors are sonic Hedgehog, KAAD-cyclopamine, KAAD-cyclopamine analogs, jervine, jervine analogs, Hedgehog pathway blocking antibodies, and any other Hedgehog pathway function inhibitor known to a person skilled in the art.

[0041] One embodiment provides a method for differentiating pluripotent stem cells into endocrine cells in vitro, comprising the steps of: (a) obtaining a cell population containing PEC; and (b) producing endocrine cells in vitro by contacting the cell population from step (a) with a gamma secretase inhibitor. In one aspect, the endocrine cells express CHGA. In one aspect, the endocrine cells are immature insulin-producing beta-cells in vitro. In one aspect, the endocrine cells are insulin-secreting cells that produce insulin in response to glucose stimulation in vitro. In one aspect, the endocrine cells are loaded into a transplantable semipermeable encapsulation device and matured so as to produce insulin in response to glucose stimulation in vivo. In one aspect, gamma-secretase inhibitors include N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT), RO44929097, 1-(S)-endo-N-(1,3,3)-trimethylbicyclo[2.2.1]hept-2-yl)-4-fluorophenyl sulfonamide, WPE-III31C, S-3-[N'-(3,5-difluorophenyl-alpha-hydroxyacetyl)-L-alanylyl]amino-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine-2-one, (N)-[(S)-2-hydroxy-3-methyl-butyryl]-1-(L-alaninyl)-(S)-1-amino-3-methyl--4,5,6,7-tetrahydro-2H-3-benzazepine-2-one, BMS-708163 (Avagacestat), BMS-708163, Semagacestat (LY450139), Semagacestat (LY450139), MK-0752, MK-0752, YO-01027, YO-01027 (Dibenzazepine, DBZ), LY-411575, LY-411575, or LY2811376 is selected from the group comprising. In some embodiments, gamma secretase inhibitors are present in cell cultures or cell populations at concentrations of about 0.01 μM to about 1000 μM.In a preferred embodiment, the gamma secretase inhibitor is present in a cell culture or cell population at a concentration of about 0.1 μM to about 100 μM. In one aspect, the gamma secretase inhibitor is removed after its addition.

[0042] The embodiments described herein provide a composition and a method for differentiating pluripotent human stem cells into endocrine cells in vitro. In one aspect, the endocrine cells express CHGA. In one aspect, the endocrine cells can produce insulin in vitro. In one aspect, the endocrine cells are immature endocrine cells, such as immature beta cells. In one aspect, the insulin-producing cells in vitro can produce insulin in response to glucose stimulation.

[0043] One embodiment provides a method for producing insulin in vivo in a mammal, comprising: (a) loading an endocrine cell population into a transplantable semipermeable device; (b) transplanting the device containing the endocrine cells into a mammalian host; and (c) maturing the endocrine cell population in vivo, wherein at least some of the endocrine cells are insulin-secreting cells that produce insulin in response to glucose stimulation in vivo, thereby producing insulin in vivo in a mammalian host. In one aspect, the endocrine cells are derived from a cell composition containing a higher PEC of a non-endocrine multipotent pancreatic progenitor subpopulation (CHGA-). In another aspect, the endocrine cells are derived from a cell composition containing a reduced PEC of an endocrine subpopulation (CHGA+). In yet another aspect, the endocrine cells are immature endocrine cells, preferably immature beta cells.

[0044] In one aspect, endocrine cells produced in vitro from pluripotent stem cells express more PDX1 and NKX6.1 compared to the PDX-1 positive pancreatic endoderm population or the PDX1 / NKX6.1 positive non-endocrine (CHGA-) subpopulation. In one aspect, endocrine cells produced in vitro from pluripotent stem cells express relatively more PDX1 and NKX6.1 than the PEC non-endocrine pluripotent pancreatic progenitor subpopulation (CHGA-). In one aspect, bone morphogenetic protein (BMP) and retinoic acid (RA) analogs are added to the cell culture alone or in combination, and endocrine cells with increased expression of PDX1 and NKX6.1 compared to the PEC non-endocrine pluripotent progenitor subpopulation (CHGA-) are obtained. In one aspect, the BMP is selected from the group consisting of BMP2, BMP5, BMP6, BMP7, BMP8, and BMP4, and more preferably BMP4. In one aspect, the retinoic acid analog is selected from the group consisting of all-trans retinoic acid and TTNPB (4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid arotenoic acid), or 0.1-10 μM AM-580 (4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid), and more preferably TTNPB.

[0045] One embodiment provides a method for differentiating pluripotent stem cells in vitro into endocrine and immature endocrine cells, preferably immature beta cells, comprising the dissociation and reassembly of aggregates. In one aspect, dissociation and reassembly occur at Step 1, Step 2, Step 3, Step 4, Step 5, Step 6, or Step 7, or a combination thereof. In one aspect, determinative endoderm, PDX1-negative foregut endoderm, PDX1-positive foregut endoderm, PEC, and / or endocrine and endocrine progenitor / progenitor cells are dissociated and reassemble. In one aspect, the Step 7 dissociated and re-aggregated cell aggregates consist of fewer non-endocrine (CHGA-) subgroups compared to endocrine (CHGA+) subgroups. In one aspect, more than 10%, preferably more than 20%, 30%, 40%, more preferably more than 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 100% of the cells in the cell population are endocrine (CHGA+) cells.

[0046] One embodiment provides a method for differentiating pluripotent stem cells into endocrine cells in vitro by reinforcing non-endocrine pluripotent pancreatic progenitor (CHGA-) subpopulations that are PDX1+ and NKX6.1+ by removing endocrine cells produced during step 4 PEC production.

[0047] One embodiment provides a method for differentiating in vitro pluripotent stem cells into endocrine cells, wherein step 6 and step 7 cells as defined in Table 17 are cultured in a low level of Matrigel of about 0.02% to 2%, preferably about 0.02% to 0.05%, preferably about 0.05% to 1%, preferably 0.05%.

[0048] One embodiment provides a method for improving cell adhesion of PEC and endocrine cell aggregates by treating cell cultures with Matrigel and a rho-kinase or ROCK inhibitor. In one aspect, the rho-kinase or ROCK inhibitor is Y-27632.

[0049] In one embodiment, a PEC culture enhanced for the non-endocrine multipotent progenitor subpopulation (CHGA-) is prepared by not adding a Noggin family member in step 3 and / or step 4. In one embodiment, a PEC culture relatively sufficient for endocrine-assigned cells (CHGA+) is prepared by not adding a Noggin family member in step 3 and / or step 4. In one aspect, the Noggin family member is a compound selected from the group comprising Noggin, Chordin, Follistatin, Follistatin-like protein, Cerberus, Coco, Dan, Gremlin, Sclerostin, and PRDC (proteins associated with Dan and Cerberus).

[0050] One embodiment provides a method for maintaining endocrine cells in a culture state by culturing endocrine cells in a medium containing high levels of exogenous glucose, wherein the exogenous glucose is about 1 mM to 25 mM, about 1 mM to 20 mM, about 5 mM to 15 mM, about 5 mM to 10 mM, or about 5 mM to 8 mM. In one aspect, the medium is a medium based on DMEM, CMRL, or RPMI.

[0051] One embodiment provides a method for differentiating pluripotent stem cells into endocrine cells in vitro with or without dissociating and reassembling cell aggregates. In one aspect, undissociated cell aggregates or dissociated and reassembling cell aggregates are cryopreserved or frozen in step 6 and / or step 7 without affecting the in vivo function of the endocrine cells. In one aspect, the cryopreserved endocrine cell culture functions in vivo when thawed, cultured, and transplanted.

[0052] Another embodiment provides a culture system for differentiating pluripotent stem cells into endocrine cells, comprising at least an agent capable of suppressing or inhibiting endocrine gene expression during an early differentiation stage and an agent capable of inducing endocrine gene expression during a late differentiation stage. In one aspect, an agent capable of suppressing or inhibiting endocrine gene expression is added to a culture system composed of pancreatic PDX1-negative foregut cells. In one aspect, an agent capable of inducing endocrine gene expression is added to a culture system composed of PDX1-positive pancreatic endoderm progenitor cells or PECs. In one aspect, the agent capable of suppressing or inhibiting endocrine gene expression is an agent that activates the TGF-beta receptor family, preferably activin, and preferably a low level of activin followed by a high level of activin. In one aspect, an agent capable of inducing endocrine gene expression is N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT), RO44929097, DAPT (N--[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester), 1-(S)-endo-N-(1,3,3)-trimethylbicyclo[2.2.1]Hept-2-yl)-4-fluorophenyl sulfonamide, WPE-III31C, S-3-[N'-(3,5-difluorophenyl-alpha-hydroxyacetyl)-L-alanyl]amino-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine-2-one, (N)-[(S)-2-hydroxy-3-methyl-butyryl]-1-(L-alanyl)-(S)-1-amino-3-methyl-- 4,5,6,7-tetrahydro-2H-3-benzazepine-2-one, BMS-708163 (Abagasestat), BMS-708163, Semagasestat (LY450139), Semagasestat (LY450139), MK-0752, MK-0752, It is a gamma-secretase inhibitor selected from the group consisting of YO-01027, YO-01027 (dibenzazepine, DBZ), LY-411575, LY-411575, or LY2811376. In one aspect, high levels of activin refer to levels exceeding 40 ng / mL, 50 ng / mL, and 75 ng / mL. In one aspect, high levels of activin are used during stage 3 or prior to the production of pancreatic foregut endoderm cells. In one aspect, low levels of activin refer to levels less than 30 ng / mL, 20 ng / mL, 10 ng / mL, and 5 ng / mL. In one aspect, low levels of activin are used during stage 4 or for PEC production. In one aspect, the endocrine gene that is inhibited or induced is NGN3. In another aspect, Activin A and Wnt3A are used alone or in combination to suppress endocrine expression before the production of pancreatic foregut endoderm cells or preferably during step 3, preferably to suppress NGN3 expression. In one aspect, a gamma secretase inhibitor, preferably RO44929097 or DAPT, is used in the culture system to induce the expression of endocrine genes after PEC production or preferably during steps 5, 6, and / or 7.

[0053] An in vitro cell culture comprising endocrine cells, wherein at least 5% of the human cells express endocrine markers selected from the group consisting of insulin (INS), NK6 homeobox 1 (NKX6.1), pancreatic and duodenal homeobox 1 (PDX1), transcription factor-associated locus 2 (NKX2.2), paired box 4 (PAX4), neurogenic differentiation 1 (NEUROD), forkhead box A1 (FOXA1), forkhead box A2 (FOXA2), snail family zinc finger 2 (SNAIL2), and myofascial fibrosarcoma oncogene families A and B (MAFA and MAFB), and neurogenin 3 (NGN3), islet 1 (ISL1), hepatocyte nuclear factor 6 (HNF6), GATA binding protein 4 (GATA4), GATA binding protein 6 (GATA6), and pancreas-specific transcription factor 1a In vitro cell cultures that substantially do not express a marker selected from the group consisting of (PTF1A) and SRY (sex determining region Y)-9 (SOX9), and said endocrine cells are unipotent and can mature into pancreatic beta cells.

[0054] It is desirable for the endocrine cells to be immature beta cells.

[0055] It is desirable that at least 10% of the above human cells are immature beta cells.

[0056] It is desirable that at least 20% of the above human cells are immature beta cells.

[0057] It is desirable that at least 50% of the above human cells are immature beta cells.

[0058] It is desirable that the cells be non-recombinant cells.

[0059] It is preferable that the cells be derived from human pluripotent stem cells selected from the group consisting of human embryonic stem cells (hESCs), induced pluripotent stem cells (iPSCs), parthenogenetic cells, embryonic carcinoma (EC) cells, mesoendodermal cells, definitive endoderm cells, PDX1-1 negative pancreatic foregut endoderm cells, PDX1-positive pancreatic foregut endoderm cells, and pancreatic endoderm cells (PEC).

[0060] A method for producing immature beta cells, comprising: a) a step of producing a PDX1-positive pancreatic endoderm cell population by contacting a PDX1-negative foregut endoderm cell population with a factor activating a member of the TGFβ receptor family; and b) a step of producing immature beta cells expressing INS and NKX6.1 by contacting a PDX-positive pancreatic endoderm cell population with a gamma secretase inhibitor.

[0061] It is desirable for a PDX1-negative foregut endoderm cell population to come into contact with Wnt and heregulin family members.

[0062] It is preferable that the TGF beta-receptor family member be selected from the group consisting of activin A, activin B, nodal, GDF-8, GDF-10, GDF-11, and GDF15.

[0063] It is preferable that the members of the TGF beta-receptor family are activin A, GDF-8, and GDF-11.

[0064] It is desirable that a member of the TGF beta-receptor family be activin A.

[0065] It is preferable that the Wnt family members be selected from the group consisting of WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, WNT16, and WNT3A.

[0066] It is desirable that the member of the Wnt family be Wnt3a.

[0067] It is preferable that the members of the hereguline (HRG) family are HRG1, HRG2, HRG3, and HRG4.

[0068] It is desirable that the members of the HRG family be HRG1 and HRG2.

[0069] a) a step of producing a PDX1-positive pancreatic endoderm cell population by contacting a PDX1-negative foregut endoderm cell population with a factor that activates a member of the TGFβ receptor family; and b) a step of producing immature beta cells expressing INS and NKX6.1 by contacting the PDX-positive pancreatic endoderm cell population with a gamma secretase inhibitor; c) a step of transplanting the immature beta cells from step (b); and d) a step of maturing the cells into mature beta cells that secrete insulin in vivo in response to glucose stimulation, comprising a method for producing insulin in vivo.

[0070] Preferred features and aspects of the present invention are as follows.

[0071] At step 7, agents can still modulate gene expression. It is preferable that a member of the FGF superfamily be added at step 7. It is preferable that FGF2 be added at step 7. FGF2 can increase SST expression and / or inhibit INS, GCG, or GHRL expression. It is preferable that BMP be added at step 7. BMP can increase INS, PDX1, or IDI expression.

[0072] An immature beta cell population resulting in in vivo function. It is desirable that the immature beta population is CHGA+. It is desirable that the immature beta cell population be able to function in vivo, that is, to secrete insulin in response to blood glucose upon transplantation. It is desirable that the endocrine cell population be able to develop and mature into functional pancreatic islet cells upon transplantation. It is desirable that endocrine cells be enhanced (or non-endocrine cells be depleted) in the immature beta cell population. In a preferred embodiment, more than about 50% of the cells in the immature beta cell population are CHGA+. In a more preferred embodiment, more than 60%, 70%, 80%, 90%, 95%, 98%, or 100% of the cells in the immature beta cell population are CHGA+. In a preferred embodiment, less than about 50% of the cells in the immature beta cell population are CHGA-. In a more preferred embodiment, less than about 15% of the cells in the immature beta cell population are CHGA-. In a more preferred embodiment, about 10%, 5%, 3%, 2%, 1%, less than 0.5%, or 0% of the cells in the immature beta cell population are CHGA-. Additionally, the expression of specific markers may be suppressed during the production of immature beta cells, such as NGN3 expression during Step 3. It is preferable that the immature beta cell population is monohormonal (e.g., INS alone). It is preferable that the immature beta cell population co-expresses other cell markers including NKX6.1 and PDX1. It is preferable that the immature beta cell population is monohormonal and also co-expresses other cell markers including NKX6.1 and PDX1. It is preferable that the immature beta cell population has more monohormonal-expressing INS cells as a percentage of the total INS population. It is preferable that the immature beta cell population has 50% or more monohormonal-expressing INS cells as a percentage of the total INS population.It is preferable that the immature beta cell population is CHGA+ / INS+ / NKX6.1+ (triple positive). In a preferred embodiment, more than about 25% of the cells in the immature beta cell population are CHGA+ / INS+ / NKX6.1+ (triple positive). In a preferred embodiment, more than about 30% or 40% or 50% or 60% or 70% or 80% or 90% or 95% of the cells in the immature beta cell population, or more than 100%, are CHGA+ / INS+ / NKX6.1+ (triple positive).

[0073] Enhanced immature beta cell population produced by the dissociation and re-aggregation of cell aggregates. It is preferable that the enhanced immature beta cell population dissociates and re-aggregates in step 7. It is preferable that the immature beta cell population dissociates and re-aggregates approximately on day 25, day 26, or day 27, day 28, day 29, or day 30 or thereafter.

[0074] The complex medium is important for the maintenance of endocrine cells. It is preferable that the complex medium be CMRL or RPMI. It is preferable that the complex medium be used in Step 6 or Step 7, or both Step 6 and Step 7. CMRL increased endocrine marker expression. RPMI increased endocrine marker expression.

[0075] Cryopreservation does not reduce the immature beta cell population at step 7. Cryopreservation does not reduce CHGA+ expression at step 7.

[0076] Stage 7 cells are NKX6.1 positive. Stage 7 cells are C-peptide positive. Stage 7 cells are NKX6.1 and C-peptide co-positive. Stage 7 cells are monohormonal. Stage 7 cells express INS and GCG alone.

[0077] Step 7 The dissociation and re-aggregation of cells do not affect in vivo function.

[0078] Step 7 Cryopreservation of cells does not affect in vivo function.

[0079] Step 7 Cells can be cryopreserved and maintain their in vivo functions.

[0080] Increasing glucose concentration increases INS, GCG, or SST expression. It is desirable for glucose concentration to be increased at step 6 or step 7, or both. It is desirable for GHRL expression to be decreased along with the increase in glucose concentration.

[0081] Mono-hormonal (INS alone) in vitro immature beta cells.

[0082] In vitro immature beta cells co-expressing NKX6.1 and PDX1.

[0083] In vitro immature beta cells that are mono-hormonal (INS alone) and co-express NKX6.1 and PDX1.

[0084] In vitro immature beta cells that are mono-hormonal (INS alone), co-express NKX6.1 and PDX1, and can mature in vivo into cells capable of secreting insulin in response to blood glucose.

[0085] In vitro immature beta cells capable of maturing in vivo into cells that can secrete insulin in response to blood glucose.

[0086] In vitro immature beta cells that are CHGA+, INS+, and NKX6.1+. It is preferable that more than 10% of the total in vitro cell population consists of immature beta cells that are CHGA+, INS+, and NKX6.1+. It is preferable that more than 50% of the total in vitro cell population consists of immature beta cells that are CHGA+, INS+, and NKX6.1+. It is preferable that more than 80% of the total in vitro cell population consists of immature beta cells that are CHGA+, INS+, and NKX6.1+.

[0087] Purified immature beta cells. Purified immature beta cell precursors. It is preferable that immature beta cells or beta cell precursors be purified from the Step 7 cell population using a zinc sensor. It is preferable that dark fluorescence due to the presence of a zinc-bound Py1 sensor is enhanced for beta cells. It is preferable that bright fluorescence due to the presence of a zinc-bound Py1 sensor is enhanced for alpha cells. Method for purifying beta cells using a zinc sensor. Method for purifying alpha cells using a zinc sensor. Purified alpha cells. Purified alpha cell precursors.

[0088] Enhanced cell population expressing beta cell lineage markers such as INS, IAPP, PDX1, NKX6.1, PAX4, PCSK1, G6PC2, GCK, or SLC30A8.

[0089] Enhanced cell populations expressing alpha cell lineage markers, such as GCG, ARX, or SLC30A8

[0090] An enhanced cell population in which more than 50% of the cells are INS-positive. It is preferable that the cell population contains more than 90% INS-positive cells. In a preferred embodiment, 50% to 99% of the cells are INS-positive cells.

[0091] A method for producing insulin in vivo, comprising: a) obtaining a population of CHGA+ cells in vitro; and b) producing insulin in vivo by transplanting CHGA+ cells.

[0092] It is desirable for CHGA+ cells to dissociate and re-aggregate in step 7.

[0093] It is desirable for CHGA+ cells to express PDX1 and NKX6.1.

[0094] It is desirable for CHGA+ cells to express INS and NKX6.1.

[0095] It is preferable that CHGA+ cells be cultured in CMRL or RPMI.

[0096] It is desirable for CHGA+ cells to be cryopreserved and thawed before transplantation.

[0097] It is desirable for CHGA+ cells to be cultured in a medium containing high glucose.

[0098] In vitro endocrine cells capable of producing physiologically functional insulin-secreting cells in vivo.

[0099] Precisely specified immature beta cells in vitro that can result in physiologically functional insulin-secreting cells in vivo.

[0100] It is desirable that precisely identified immature beta cells dissociate and re-aggregate in step 7.

[0101] It is desirable that precisely specified immature beta cells express PDX1 and NKX6.1.

[0102] It is desirable that precisely identified immature beta cells express INS and NKX6.1.

[0103] It is preferable that precisely identified immature beta cells be cultured in CMRL or RPMI.

[0104] It is desirable that precisely identified immature beta cells be cryopreserved and thawed before transplantation.

[0105] It is desirable that precisely identified immature beta cells be cultured in a medium containing high glucose.

[0106] A method for producing an enhanced immature beta cell population in vitro, comprising the steps of obtaining a population of CHGA+ cells and sorting. A method for producing an enhanced cell population expressing INS, IAPP, PDX1, NKX6.1, or PAX4 in vitro, comprising the steps of obtaining a population of CHGA+ cells and sorting.

[0107] A method for producing an enhanced alpha cell population in vitro, comprising the steps of obtaining a population of CHGA+ cells and classifying them.

[0108] A method for producing an enhanced cell population expressing GCG or ARX in vitro, comprising the steps of obtaining a population of CHGA+ cells and sorting.

[0109] It is desirable that enhanced populations of alpha or beta cells be classified using a Py 1 zinc sensor.

[0110] In embodiments, immature beta cells express INS and NKX6.1 and substantially do not express NGN3. In embodiments, immature beta cells express INS, NKX6.1 and MAFB and substantially do not express NGN3. Brief explanation of the drawing

[0111] FIG. 1 is a photograph of an aggregate suspension culture of reprogrammed dedifferentiated cells (also referred to herein as iPS cells). See Example 1. Figures 2a–1 are bar graphs representing the relative gene expression levels of OCT4 (Fig. 2a), Brachiuri (Fig. 2b), CER1 (Fig. 2c), GSC (Fig. 2d), FOXA2 (Fig. 2e), FOXA1 (Fig. 2f), HNF6 (Fig. 2g), PDX1 (Fig. 2h), PTF1A (Fig. 2i), NKX6.1 (Fig. 2j), NGN3 (Fig. 2k), and INS (Fig. 2l). Expression levels are standardized against the average expression levels of the housekeeping genes cyclophyllin G and TATA-binding protein (TBP). The graphs illustrate the fold upregulation relative to the lowest data point within the dataset. See Example 1. Figure 3 is a micrograph of the immunocytochemistry (ICC) of human iPS cell cultures (PDX1-positive pancreatic endoderm cells) from stage 4 differentiation using antibodies specific to (Panel A) PDX-1; (Panel B) NKX6.1; (Panel C) PTF1A; and (Panel D) Dapi (E2021 using G4 hIPS cell line). See Example 2. Figure 4 is a photograph of the immunocytochemistry (ICC) of iPS cell cultures from stage 5 differentiation (E2021 using G4 hIPS cell line) using ligands specific to (Panel A) glucagon; (Panel B) insulin; (Panel C) somatostatin; and (Panel D) Dapi. See Example 2. FIGS. 5a and 5b are array position maps and array keys provided by R&D Systems’ Proteome Profiler™ human phospho-RTK antibody array. The position map in FIG. 5a indicates the coordinates or locations of the RTK antibodies. The identity or name of the RTK family and antibody is indicated in the key in FIG. 5b. Thus, a positive signal observed in the developed film can be confirmed by overlaying a transparent material as in FIG. 5a and identifying the signal by referring to the coordinates on the overlay ( FIG. 5a) and the name of the RTK in FIG. 5b. See Example 4. Figure 6 is an RTK array analysis of iPS cell-derived pancreatic endoderm cells (PEC) under four different conditions (Panels A, B, C, and D) described in Example 5. Tyrosine phosphorylation of specific RTKs is observed by identifying high-intensity versus low-intensity signals. Members of the IGF1R / IR and ERBB (EGFR) families are identified or indicated by boxes. See Example 5. Figures 7a-c are graphs showing the concentrations of human C-peptide and insulin in the serum of transplanted mice for experiments E2314, E2356, and E2380 (Figure 7a), E2347 (Figure 7b), and E2354 (Figure 7c). Figure 7a: Treatment of PDX1-expressing cells with hereguline in vitro improves glucose-stimulated insulin secretion during transplantation and in vivo maturation. Figure 7b: Glucose-stimulated C-peptide levels 23 weeks after transplantation and 3 weeks prior to STZ-induced in a mouse diabetes model. PEC-transplanted mice were analyzed for serum levels of human C-peptide at the indicated post-engraftment time points, on an empty stomach, 30 minutes after intraperitoneal glucose administration, and 60 minutes after administration of glucose. In FIG. 7c, PEC was encapsulated in a cell encapsulation device (Encaptra® EN20, or EN20, ViaCyte (San Diego, California)), and in some cases, the device had microperforations (pEN20, ViaCyte (San Diego, California)). Such a device is described in U.S. Patent No. 8,278,106. See Example 7. Figures 8a and 8b are graphs showing the results of blood glucose analysis in STZ-treated mice for Experiment #2347. It is suggested that glucose-responsive insulin-secreting beta cells derived from transplanted iPECs control blood glucose in an STZ-induced diabetes model. Figure 8a: Blood glucose for each of the 13 mice (baseline in the presence or absence of herregulin). Figure 8b: Combined mean measurements for each treatment (baseline in the presence or absence of herregulin). Randomized non-fasting blood glucose measurements are presented for 13 mice transplanted with iPEC grafts up to 14 days prior to the STZ treatment day (Day 0), and for the same mice after STZ treatment and after the graft was transplanted in vitro. STZ was administered to the STZ-treated animals approximately 26 weeks after graft transplantation (Day 0). Approximately 2 weeks after the start of STZ treatment and approximately 28 weeks after graft transplantation, the iPEC graft was in vitro transplanted (removed). Non-fasting blood glucose measurements were collected over time for each animal. See Example 7. Figures 9a–e are bar graphs showing the relative gene expression levels of PDX1 (Figure 9a), NKX6.1 (Figure 9b), PTF1A (Figure 9c), NKX2.2 (Figure 9d), and NGN3 (Figure 9e). See Example 8. Figure 10 is a photograph of aggregate suspension cultures in which PDX1-negative foregut endoderm cells (step 2) differentiated into PDX1-positive foregut endoderm (step 3) upon the addition of 50 ng / mL Activin A. See Example 8. FIG. 11 is a photograph of the aggregate suspension culture at the end of Step 3 (Day 8, upper panel) and Step 4 (Day 12, lower panel) using Activin A at 5 ng / mL (ACT5) or 10 ng / mL (ACT10) in Step 3, or Activin at 5 ng / mL (ACT5) in Steps 3 and 4. See Example 8. Figure 12 is a photographic image of the aggregate suspension culture during step 4 (ae, upper panel) or at the end of step 4 (ae, lower panel). The upper panel indicates that 10 ng / mL activin A and 2 ng / mL hereguline (ACT 10 HGN 2), or 20 ng / mL activin A and 2 ng / mL hereguline (ACT 20 HGN 2), or 20 ng / mL activin A and 10 ng / mL hereguline (ACT 20 HGN 10), or 10 ng / mL activin A, 2 ng / mL hereguline, and 50 ng / mL WNT (ACT 10 HGN 2 WNT 50) were added in step 3. The bottom panel indicates that 25 ng / mL Activin A (ACT 25), 50 ng / mL Activin A (ACT 50), 75 ng / mL Activin A (ACT 75), or 100 ng / mL Activin A (ACT 100) was added in Step 3. Under all conditions, low Activin and hereguline were provided in Step 4. See Example 9. Figures 13a-c are bar graphs showing the relative gene expression levels of NGN3 (Fig. 13a), NKX2.2 (Fig. 13b), and NKX6.1 (Fig. 13c) when activin, heregulin, and WNT (AHW) were added in step 3 and activin and heregulin (AH) were added in step 4, as described in Example 9. Figures 14a-b are bar graphs showing the relative gene expression levels of NKX6.1 (Figure 14a) and NGN3 (Figure 14b) when activin, heregulin, and WNT (AHW) are added in step 3 and activin and heregulin (AH) are added in step 4 as described in Example 10. Figure 15 is a graph showing the concentration of human C-peptide in the serum of mice transplanted with encapsulated PEC (control) and encapsulated modified PEC (produced using activin, heregulin, and WNT (AHW) of step 3, and activin and heregulin (AH) of step 4). Expression levels were analyzed 11 weeks after engraftment, on an empty stomach, 30 minutes after intraperitoneal glucose administration, and 60 minutes after engraftment. See Example 10. Figure 16 is a graph showing the concentration of human C-peptide in the serum of mice transplanted with encapsulated PEC (control) and encapsulated modified PEC (produced using activin, heregulin, and WNT (AHW) of Step 3, and activin and heregulin (AH) added in Step 4). Expression levels were analyzed 14 weeks after engraftment, on an empty stomach, 30 minutes after intraperitoneal glucose administration, and 60 minutes after engraftment. See Example 10. FIG. 17 is a bar graph showing the relative gene expression levels of Neurogenin 3 on days 13, 15, and 17 after treatment with a gamma-secretase inhibitor in step 5 as described in Example 11. Figures 18a-d are bar graphs showing the relative gene expression levels of PDX1 (Figure 18a), NKX6.1 (Figure 18b), SOX9 (Figure 18c) and PTF1A (Figure 18d) after differentiation according to Table 17 for steps 1-5, and for steps 6 and 7, only FBS, Matrigel, and rho-kinase inhibitor were used in addition to the basic DMEM medium as described in Example 12. Figures 19a-d are bar graphs showing the relative gene expression levels of INS (Figure 19a), GCG (Figure 19b), GHRL (Figure 19c), and SST (Figure 19d) under the same differentiation conditions as in Figure 18 as described in Example 12. Figure 20 is a graph showing the concentration of human C-peptide in the serum of mice transplanted with the encapsulated endocrine device prepared as described in Example 12 (E2395, Rag 2, Week 10 GSIS). Expression levels were analyzed 10 weeks after engraftment, on an empty stomach and 60 minutes after intraperitoneal glucose administration. See Example 12. Figure 21 is a graph showing the concentration of human C-peptide in the serum of mice transplanted with the encapsulated endocrine device prepared as described in Example 12 (E2395, Rag 2, Week 15 GSIS). Expression levels were analyzed 15 weeks after engraftment, both on an empty stomach and 60 minutes after intraperitoneal glucose administration. See Example 12. Figures 22a–d are micrographs showing differentiated and matured endocrine cell aggregates in vivo as described in Example 12. The cell field is stained with DAPI (Figure 22a) or an antibody against NKX6.1 (Figures 22b & 22c, nuclear staining), and chromogranin A (Figures 22b & 22d, cytoplasm). The same field is presented in all images. See Example 12. Figures 23a–c are micrographs showing endocrine cell aggregates as described in Example 12. Figure 23a shows the field of cells stained for INS (cytoplasm) and NKX6.1 (nucleus). Figure 23b shows the same field of cells stained for INS (cytoplasm) and PDX1 (nucleus). Figure 23c shows the same field of cells stained with DAPI. See Example 12. Figures 24a-d are bar graphs showing nanostring mRNA data representing the relative gene expression levels of INS (Figure 24a), NKX6.1 (Figure 24b), PDX1 (Figure 24c) and ID1 (Figure 24d) under the differentiation conditions described in Example 13. Figures 25a-c are micrographs showing endocrine cell aggregates as described in Example 13. Figure 25a is a control group without the addition of TT or BMP, Figure 25b shows the addition of TT in Step 7, and Figure 25c shows the addition of BMP in Step 7. Figures 25a-c show staining for C-peptide (cytoplasm) and PDX1 (nucleus). Figures 26a and 26b are micrographs showing endocrine cell aggregates as described in Example 13. Figure 26a shows treatment with TT and BMP in steps 6 and 7, and Figure 26b shows the addition of TT and BMP in step 7. Figures 26a and 26b show staining for C-peptide (cytoplasm) and PDX1 (nucleus). Figures 27a-c are micrographs showing endocrine cell aggregates as described in Example 13, illustrating the same field as in Figure 25. Figure 27a is a control without the addition of TT or BMP, Figure 27b shows the addition of TT in Step 7, and Figure 27c shows the addition of BMP in Step 7. Figures 27a-c show staining for C-peptide (cytoplasm) and NKX6.1 (nucleus). Figures 28a and 28b are micrographs showing endocrine cell aggregates as described in Example 13, illustrating the same field as in Figure 26. Figure 28a shows treatment with TT and BMP in steps 6 and 7, and Figure 28b shows the addition of TT and BMP in step 7. Figures 28a and 28b show staining for C-peptide (cytoplasm) and NKX6.1 (nucleus). FIGS. 29a-e is a bar graph showing the relative gene expression levels of endocrine aggregates analyzed on day 21, treated with nicotinamide in step 6 as described in Example 13 (right bar; d21 gi- d13-d15) or not treated (left bar; d21 gi- d13-d15+NIC d15). FIG. 30 shows photographic images (Days 21, 22, and 23) of endocrine cell aggregate suspension cultures added with FBS alone (Panel A), both FBS and 0.05% Matrigel (MG; Panel B), both FBS and 10 μM Y-27632 (Y; Panel C), or all three of FBS, 0.05% Matrigel (MG) and 10 μM Y-27632 (Y; Panel D) after dissociation and re-aggregation at the start of Step 7 as described in Example 14. Figures 31a–d are bar graphs showing the relative gene expression levels of NKX6.1 (Fig. 31a), NKX2.2 (Fig. 31b), PDX1 (Fig. 31c), and INS (Fig. 31d) comparing differentiation conditions with and without nogin for days 1, 2, and 3. See Example 15. Figures 32a–c are bar graphs showing nanostring mRNA data representing the relative gene expression levels of INS and GCG (Fig. 32a), GHRL and SST (Fig. 32b), and PDX1 and ID1 (Fig. 32c), describing the effect of the indicated factors on gene expression. See Example 16. Figures 33a–c are bar graphs representing nanostring mRNA data showing the relative gene expression levels of PDX1, NKX6.1, PTF1A, SOX9 (Fig. 33a); INS, GCG, PPY,GHRL (Fig. 33b); and PCSK1, GCK, SLC30A8, G6PC2 (Fig. 33c), describing the endocrine (CHGA+) and non-endocrine (CHGA-) subgroups in reaggregated cultures compared to non-reaggregated cultures. See Example 17. FIG. 34 is a graph showing the concentration of human C-peptide in the serum of mice transplanted with encapsulated endocrine cells (reaggregated samples) prepared as described in Example 18, in which the endocrine (CHGA+) cell type is enhanced by dissociation and reaggregation at the start of Step 7, compared to cells differentiated in the same manner but not reaggregated (control samples). Expression levels were analyzed 21 weeks after engraftment on an empty stomach, 30 minutes after intraperitoneal glucose administration, and 60 minutes after engraftment. See Example 18. Figures 35a–c are bar graphs showing nanostring mRNA data representing the relative gene expression levels of CHGA, INS, GCG, GHRL, PPY, SST (Fig. 35a); GCK, G6CP2, UCN3, PCSK1 (Fig. 35b); HNF1a, HNF4A, SLC30A8, CADH1 (Fig. 35c), illustrating the effects of DMEM and CMRL-based media during Step 7. See Example 19. Figures 36a-c are micrographs showing endocrine cell aggregates from step 7 as described in Example 20. These aggregates did not re-aggregate in step 7. The same fields in Figures 36a and 36b were stained for INS (cytoplasm) and GCG (cytoplasm), respectively, and Figure 36c was stained for NKX6.1 (nucleus) and C-peptide (cytoplasm). Figures 37a-c are micrographs showing endocrine cell aggregates from step 7 as described in Example 20. These aggregates were re-aggregated in step 7. The same fields in Figures 37a and 37b were stained for INS (cytoplasm) and GCG (cytoplasm), respectively, and Figure 37c was stained for NKX6.1 (nucleus) and C-peptide (cytoplasm). FIG. 38 is a graph showing the concentration of human C-peptide in the serum of mice transplanted with encapsulated endocrine cells prepared as described in Example 20, in which the cell culture was frozen (cryopreserved) and thawed (F / T) and did not dissociate or reaggregate (left), or in which the cell culture was not frozen (fresh) and dissociated and reaggregated at the start of Step 7 (right). Expression levels were analyzed 12 weeks after engraftment on an empty stomach, 30 minutes after intraperitoneal glucose administration, and 60 minutes after engraftment. See Example 21. Figures 39a-b are bar graphs showing nanostring mRNA data representing the relative gene expression levels of INS, GCG (Figure 39a) and SST, GHRL (Figure 39b), illustrating the effect of exogenous high-glucose during step 6 on endocrine hormone expression. See Example 21. Figures 40a-b are micrographs showing step 7 endocrine cell aggregates as described in Example 21 with exogenous high-glucose during step 7. Figure 40a shows staining for INS (cytoplasm), and Figure 40b shows staining for GCG (cytoplasm). FIG. 41 is a flow cytometry graph showing the enrichment of immature endocrine beta cells from step 7, first treated with the zinc binder Py1 and classified by fluorescence. See Example 24. Figures 42a–c are bar graphs representing nanostring mRNA data showing the relative gene expression levels of INS, GCG, GHRL, IAPP, SST, and SST (Fig. 42a); PAX4, PDX1, ARX, NKX6.1 (Fig. 42b); and PCSK1, GCK, G6PC2, and SLC30A8 (Fig. 42c), characterizing and identifying cells enhanced from zinc classification. See Example 24. Figure 43 is a schematic diagram of steps 1–4 for the production of pancreatic endoderm cells (PEC) in vitro and their maturation into insulin-secreting beta cells in vivo. This schematic diagram also illustrates the two major subgroups of PEC: endocrine (CHGA+) and non-endocrine (CHGA-) cells. Embryonic stem cells (ESC), mesoendoderm (ME), definitive endoderm (DE), foregut (FG), anagenous foregut (pFG), and pancreatic epithelium or pancreatic endoderm (PE). Figure 44 is a schematic diagram of steps 1–7 for the production of endocrine cells in vitro. This schematic diagram also illustrates that the removal of low levels of activin and WNT (step 4), followed by high levels of activin (step 3), inhibits or suppresses NGN3 expression, which is later expressed upon the addition of a gamma-secretase inhibitor during step 5. Embryonic stem cells (ESC), mesoendoderm (ME), definitive endoderm (DE), foregut (FG), anagenous foregut (pFG), and pancreatic epithelium or pancreatic endoderm (PE). Figure 45 is a schematic diagram of steps 1–7 for the production of endocrine cells in vitro. This schematic diagram also indicates the steps, growth factors, cell types, and signature markers of each cell type: embryonic stem cells (ESC), mesoendoderm (ME), definitive endoderm (DE), foregut (FG), tereophegut (pFG), pancreatic epithelium or pancreatic endoderm (PE), pre-beta cells (pre-B; or immature beta cells) and beta cells (β-cells). Specific details for implementing the invention

[0112] The present invention may be more easily understood by reference to the following detailed description of preferred embodiments of the invention and the examples included herein. However, it should be understood that before the compounds, compositions, and methods of the present invention are disclosed and described, the present invention is not limited to specific cell types, specific feeder cell layers, specific conditions, or specific methods, and that such variations may occur. Numerous modifications and changes thereto will be apparent to those skilled in the art. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments and is not intended to be limiting. All patent and non-patent publication references are incorporated herein by reference in their entirety.

[0113] Various cell compositions derived from pluripotent stem cells are described herein, and the applicant’s U.S. patent application numbers 10 / 486,408 (titled “METHODS FOR CULTURE OF HESC ON FEEDER CELLS”, filed August 6, 2002); 11 / 021,618 (titled “DEFINITIVE ENDODERM”, filed December 23, 2004); 11 / 115,868 (titled “PDX1 EXPRESSING ENDODERM”, filed April 26, 2005); 11 / 165,305 (titled “METHODS FOR IDENTIFYING FACTORS FOR DIFFERENTIATING DEFINITIVE ENDODERM”, filed June 23, 2005); 11 / 573,662 (English title "METHODS FOR INCREASING DEFINITIVE ENDODERM DIFFERENTIATION OF PLURIPOTENT HUMAN EMBRYONIC STEM CELLS WITH PI-3 KINASE INHIBITORS", filed August 15, 2005); 12 / 729,084 (English title "PDX1-EXPRESSING DORSAL AND VENTRAL FOREGUT ENDODERM", filed October 27, 2005); 12 / 093,590 (English title "MARKERS OF DEFINITIVE ENDODERM", filed November 14, 2005); 11 / 993,399 (English title "EMBRYONIC STEM CELL CULTURE COMPOSITIONS AND METHODS OF USE THEREOF", filed June 20, 2006); 11 / 588,693 (English title "PDX1-EXPRESSING DORSAL AND VENTRAL FOREGUT ENDODERM", filed October 27, 2006);11 / 681,687 (English title "ENDOCRINE PROGENITOR / PRECURSOR CELLS, PANCREATIC HORMONE-EXPRESSING CELLS AND METHODS OF PRODUCTION", filed March 2, 2007); 11 / 807,223 (English title "METHODS FOR CULTURE AND PRODUCTION OF SINGLE CELL POPULATIONS OF HESC", filed May 24, 2007); 11 / 773,944 (English title "METHODS OF PRODUCING PANCREATIC HORMONES", filed July 5, 2007); 11 / 860,494 (English title "METHODS FOR INCREASING DEFINITIVE ENDODERM PRODUCTION", filed September 24, 2007); 12 / 099,759 (English title "METHODS OF PRODUCING PANCREATIC HORMONES", filed April 8, 2008); 12 / 107,020 (English title "METHODS FOR PURIFYING ENDODERM AND PANCREATIC ENDODERM CELLS DERIVED FORM HUMAN EMBRYONIC STEM CELLS", filed April 21, 2008); 12 / 618,659 (English title "ENCAPSULATION OF PANCREATIC LINEAGE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS", filed November 13, 2009); 12 / 765,714 and 13 / 761,078 (both English titles "CELL COMPOSITIONS FROM DEDIFFERENTIATED REPROGRAMMED CELLS", filed April 22, 2010 and February 6, 2013);11 / 838,054 (English title "COMPOSITIONS AND METHODS USEFUL FOR CULTURING DIFFERENTIABLE CELLS", filed August 13, 2007); 12 / 264,760 (English title "STEM CELL AGGREGATE SUSPENSION COMPOSITIONS AND METHODS OF DIFFERENTIATION THEREOF", filed November 4, 2008); 13 / 259,15 (English title "SMALL MOLECULES SUPPORTING PLURIPOTENT CELL GROWTH", filed April 27, 2010); PCT / US11 / 25628 (English title "LOADING SYSTEM FOR AN ENCAPSULATION DEVICE", filed February 21, 2011); 13 / 992,931 (English title "AGENTS AND METHODS FOR INHIBITING PLURIPOTENT STEM CELLS", filed December 28, 2010); and U.S. Design Application No. 29 / 408,366 (filed December 12, 2011); 29 / 408,368 (filed December 12, 2011); 29 / 423,365 (filed May 31, 2012); and 29 / 447,944 (filed March 13, 2013); and U.S. Provisional Application No. 61 / 774,443 (English title "SEMIPERMEABLE MACRO IMPLANTABLE CELLULAR ENCAPSULATION DEVICES", filed March 7, 2013); 61 / 775,480 (English title "CRYOPRESERVATION, HIBERNATION AND ROOM TEMPERATURE STORAGE OF ENCAPSULATED PANCREATIC ENDODERM CELL AGGREGATES", filed March 8, 2013);and can be confirmed in 61 / 781,005 (English title "IN VITRO DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO PANCREATIC ENDODERM CELLS (PEC) AND ENDOCRINE CELLS", filed March 14, 2013).;

[0114] definition

[0115] The numerical ranges expressed herein include the listed endpoints and are to be understood as including all integers between the endpoints of the mentioned numerical ranges.

[0116] Unless otherwise noted, the terms used herein should be understood in accordance with the ordinary usage by those skilled in the art. Furthermore, for the purposes of this specification and the appended claims, unless otherwise indicated, all numbers expressing amounts of components, percentages or ratios of substances, reaction conditions, and other figures used in the specification and claims should be understood in all cases as being modified by the term “about.” Accordingly, unless otherwise indicated, the numerical parameters described in the following specification and appended claims are approximations that may vary depending on the desired properties sought to be obtained by the present invention. At a minimum, and without intending to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be interpreted in terms of at least the number of reported significant digits and by applying ordinary rounding techniques.

[0117] The practice of the embodiments described herein uses the ordinary techniques of cell biology, molecular biology, genetics, chemistry, microbiology, recombinant DNA, and immunology, unless otherwise indicated.

[0118] The term “cell” as used herein also refers to an individual cell, a cell line, or a culture derived from such cells. “Culture” refers to a composition comprising isolated cells of the same or different types. The terms “culture,” “group,” or “cell group” as used herein may and are interchangeable, and their meaning will be apparent from the context. For example, the term “group” may be a cell culture of more than one type of cell having the same characteristics, or a culture of more than one type of cell having different identifying characteristics, and, for example, a group in one context may be a subgroup in another context. The term “subgroup” refers to a subset of a cell culture or group when used to describe a specific cell type within the cell culture or cell group.

[0119] As used herein, "totipotent stem cells" refer to cells capable of differentiating into any cell that constitutes an organism, such as cells produced from the fusion of an egg and a sperm cell. Cells produced from the first few divisions of a fertilized egg may also be totipotent. These cells can differentiate into embryonic and extraembryonic cell types. Pluripotent stem cells, such as ES cells, can result in any fetal or adult cell type. However, they cannot develop into a fetus or an adult animal on their own because they lack the potential to develop into extraembryonic tissues. Extraembryonic tissues are derived, in part, from the extraembryonic endoderm and can be further classified into the parietal endoderm (Reichert membrane) and the visceral endoderm (which forms part of the yolk sac). Both the parietal endoderm and the visceral endoderm support embryonic development but do not form embryonic structures themselves. Other extraembryonic tissues also exist, including the extraembryonic mesoderm and extraembryonic ectoderm.

[0120] In some embodiments, “pluripotent cells” are used as starting material for differentiation into endoderm lineages, more particularly pancreatic endoderm type cells. As used herein, “pluripotent” or “pluripotent cells” or equivalents refer to cells capable of both proliferation in cell culture and differentiation into various lineage-restricted cell populations exhibiting pluripotency, for example, both pluripotent ES cells and induced pluripotent stem (iPS) cells can result in each of the three embryonic cell lineages. However, pluripotent cells cannot produce a whole organism; that is, pluripotent cells are not pluripotent.

[0121] In certain embodiments, the pluripotent cells used as starting material are stem cells, including hES cells, hEG cells, iPS cells, and even parthenogenetic cells. As used herein, “embryo” refers to a series of developmental stages of an organism that begins as a monozygote and ends as a multicellular structure that no longer contains pluripotent or pluripotent cells other than developed gametes. In addition to embryos derived by gamete fusion, the term “embryo” refers to embryos derived by somatic cell nuclear transfer. In another embodiment, the pluripotent cells are not derived from an embryo or are not derived immediately from an embryo, for example, iPS cells are derived from non-pluripotent cells, for example, pluripotent cells or finally differentiated cells. The human pluripotent stem cell lines used herein include hESCs and iPSCs, e.g., CyT49, CyT25, CyT203, CyT212, BG01, BG02, BG03, or any of those listed in Tables 4 and 5, or any currently known, publicly available, or to be manufactured thereafter.

[0122] Human pluripotent stem cells can also be defined or characterized by the presence of several transcription factors and cell surface proteins, including transcription factors Oct-4, Nanog, and Sox-2, which form a core regulatory complex that ensures the suppression of genes leading to differentiation and the maintenance of pluripotency; and cell surface antigens, such as glycolipid SSEA3, SSEA4, and keratin sulfate antigens, Tra-1-60 and Tra-1-81, and alkaline phosphatase.

[0123] As used herein, the phrases “induced pluripotent stem cell,” “iPS cell,” or “iPSC” refer to a type of pluripotent stem cell artificially produced from non-pluripotent cells, typically adult somatic cells or terminally differentiated cells, such as fibroblasts, hematopoietic cells, myocytes, neurons, epidermal cells, etc., by inserting a specific gene or gene product referred to as a reprogramming factor. See [Takahashi et al., Cell 131:861-872 (2007)]; [Wernig et al., Nature 448:318-324 (2007)]; [Park et al., Nature 451:141-146 (2008)]. Such methods for producing iPSCs and subsequently known methods are known, and how iPSCs are derived or produced does not limit the invention herein. Induced pluripotent stem cells are substantially similar to human pluripotent stem cells, such as hES cells, in many respects, including the expression of specific stem cell genes and proteins, chromatin methylation patterns, doubling time, culture formation, teratoma formation, viable chimera formation, and efficacy and differentiation ability. Human iPS cells provide a source of pluripotent stem cells without the associated use of embryos.

[0124] As used herein, “reprogramming,” “reprogrammed,” or equivalents refer to a process that confers upon a cell the ability to form offspring of one or more new cell types in culture or in vivo, which is measurably increased compared to what would be the case under the same conditions without reprogramming. In certain embodiments described herein, somatic cells are “reprogrammed” into pluripotent cells. In certain aspects, somatic cells are reprogrammed when, after sufficient proliferation, a measurable proportion of cells in a cell culture in vivo or in vitro exhibits phenotypic characteristics of the new pluripotent cell type. Without reprogramming, such somatic cells would not produce offspring exhibiting phenotypic characteristics of the new pluripotent cell type. If somatic cells can produce offspring exhibiting phenotypic characteristics of the new pluripotent cell type even without reprogramming, the proportion of offspring from these somatic cells exhibiting phenotypic characteristics of the new pluripotent cell type is measurably greater than before reprogramming.

[0125] As used herein, the phrase “differentiation programming” refers to a process of changing cells to form offspring of one or more new cell types in culture or in vivo that would not be so under the same conditions without differentiation reprogramming. Such processes include differentiation, dedifferentiation, and transdifferentiation. Thus, as used herein, the phrase “differentiation” refers to a process in which a less specialized cell becomes a more specialized cell type. In contrast, the phrase “dedifferentiation” refers to a cellular process in which a partially or finally differentiated cell reverts to an earlier developmental stage, such as a pluripotent or pluripotent cell. Furthermore, in contrast, the phrase “transdifferentiation” refers to a process of transforming one differentiated cell type into another differentiated cell type.

[0126] As used herein, “pluripotent” or “pluripotent cell” or equivalents refer to cell types that can result in a limited number of other specific cell types. That is, pluripotent cells are assigned to one or more embryonic cell fates and, therefore, in contrast to pluripotent cells, cannot result in each of the three embryonic cell lineages, as well as extraembryonic cells. Pluripotent somatic cells are more differentiated compared to pluripotent cells, but are not finally differentiated. Therefore, pluripotent cells have higher efficacy than pluripotent cells. Efficacy-determining factors that can be used to reprogram somatic cells or to generate iPS cells include, but are not limited to, factors such as Oct-4, Sox2, FoxD3, UTF1, Stella, Rex1, ZNF206, Sox15, Myb12, Lin28, Nanog, DPPA2, ESG1, Otx2, or combinations thereof.

[0127] As used herein, “unipotent,” “unipotent,” “unipotent cell,” or equivalents refer to a cell type capable of yielding only one other lineage cell. For example, immature beta cells as described herein have the ability to differentiate only into insulin beta cells and have no potential to differentiate into, for example, glucagon (alpha) cells, somatostatin (delta) cells, and pancreatic polypeptide (gamma) cells. In contrast, endocrine progenitor cells, PDX1-positive pancreatic endoderm cells, definitive endoderm cells, or mesoendodermal cells, and hES cells are all pluripotent or pluripotent (hESC) cells capable of yielding pancreatic alpha, beta, delta, and gamma islet cells, respectively. Similarly, pancreatic alpha, beta, delta, and gamma islet cells are lineage cells of endocrine progenitor cells, PDX1-positive pancreatic endoderm cells, definitive endoderm cells, or mesoendodermal cells, and hES cells.

[0128] As used herein, “monohormonal” and “multihormonal” cells refer to cells that express only one hormone (e.g., immature beta cells and beta cells express only the insulin protein and not the glucagon or somatostatin protein), or cells that express more than one hormone or multiple hormones (e.g., endocrine precursor or progenitor cells have subgroups of cells that express two, three, or four or more hormones on the same cell). As used herein, "ERBB receptor tyrosine kinase activator" includes, but is not limited to, 16 or more different EGF family ligands that bind to ERBB receptors: EGF (Epidermal Growth Factor), AG or AREG (Amphiregulin), and TGF-alpha (Transforming Growth Factor-alpha), Btc (Betacellulin), HBEGF (Heparin-binding EGF), and Ereg (Epiregulin), neuregulin (or heregulin), such as neuregulin-1, -2, -3 and -4 (or heregulin-1, -2, -3 and -4). However, the present invention conceives any ligand capable of binding to any one of the four ERBB receptors or a combination thereof to induce the formation of homo- and heterodimeric receptor complexes (named for activation of the endogenous kinase domain and subsequent phosphorylation). Also refer to Table 13.

[0129] The term "cell lineage" as used herein refers to all stages of cell type development from the earliest progenitor cells to fully mature cells (i.e., specialized cells). For example, "definitive endoderm lineage cells," "PDX1-negative endoderm lineage cells," "PDX1-positive pancreatic endoderm lineage cells," "endocrine progenitor lineage cells," "endocrine lineage cells," or "immature beta lineage cells" refer to cells derived from or differentiated from definitive endoderm cells, PDX1-negative endoderm cells, PDX1-positive pancreatic endoderm cells, etc. Definitive endoderm cells are a lineage of mesoendodermal cells, which are one of their precursors. PDX-1-positive pancreatic endoderm cells are a lineage of definitive endoderm cells, which are one of their precursors. Endocrine progenitors are lineages of PDX1-positive pancreatic cells, definitive endoderm cells, and mesoendodermal cells, all of which are their precursors. Immature beta cells are lineages of endocrine progenitor cells, PDX1-positive pancreatic cells, definitive endoderm cells, and mesoendodermal cells, all of which are precursors thereof. Beta cells are, for example, the only lineage of immature beta cells. However, all endoderm lineage cells described herein are hES lineage cells.

[0130] As used herein, “progenitor cell” or “progenitor cell” may generally be any cell within a cell differentiation pathway capable of differentiating into a more mature cell. Thus, a progenitor cell may be a pluripotent cell, or it may be a partially differentiated pluripotent cell or a reversibly differentiated cell. The term “progenitor cell population” refers to a group of cells capable of developing into a more mature or differentiated cell type. A progenitor cell population may include pluripotent cells, cells of a restricted stem cell lineage (i.e., cells capable of developing only into less than the entire ectodermal lineage or, for example, cells of the neuronal lineage), and cells of a reversibly restricted stem cell lineage. Thus, the term “progenitor cell” or “progenitor cell” may be a “pluripotent cell” or a “pluripotent cell.”

[0131] "Endocrine progenitor / progenitor cell" as used herein refers to a pluripotent cell of a definitive endoderm lineage that can further differentiate into cells of the endocrine system, including but not limited to pancreatic islet hormone-expressing cells, which includes but is not limited to pancreatic islet hormone-expressing cells, and expresses at least one marker from the list consisting of Neurogenin 3 (NEUROG3), PDX1, PTF1A, SOX9, NKX6.1, HNF1b, GATA4, HNF6, FOXA1, FOXA2, GATA6, MYT1, ISLET1, NEUROD, SNAIL2, MNX1, IA1, RFX6, PAX4, PAX6, NKX2.2, MAFA, and MAFB. Endocrine progenitor / progenitor cell cannot differentiate into as many different cells, tissues, and / or organs as less clearly differentiated definitive endoderm lineage cells, such as PDX1-positive pancreatic endoderm cells or definitive endoderm cells or mesoendoderm cells. Endocrine progenitor / progenitor cells are described in detail in at least the applicant’s U.S. Patent No. 8,129,182.

[0132] As used herein, the terms “developed from pluripotent cells,” “differentiated from pluripotent cells,” “matured from pluripotent cells,” “produced from pluripotent cells,” “derived from pluripotent cells,” and equivalent expressions refer to the production of cell types differentiated from pluripotent cells in vitro or in vivo, for example, in the case of endocrine cells matured in vivo from transplanted PDX1 pancreatic endoderm cells as described in International Patent Application No. PCT / US2007 / 015536, English titled “METHODS OF PRODUCING PANCREATIC HORMONES.” All such terms refer to the progression of cells from a stage with the potential to differentiate into two or more different cell lineages to a stage of specialized and finally differentiated cells. Such terms may be used interchangeably for the purposes of this invention. In order to selectively regain the ability to differentiate into pluripotent or at least more than one cell lineage, the embodiments described herein devise culture conditions that allow such differentiation to be reversible.

[0133] The term "feeder cell" refers to a culture of cells that grow in vitro, secrete one or more factors into the culture medium, and can be used to support the growth of another cell of interest within the culture. As used herein, "feeder cell layer" may be used interchangeably with the term "feeder cell." The feeder cell may comprise a monolayer in which the feeder cells grow on top of each other after covering the surface of the culture dish in a complete layer, or may comprise a cluster of cells. In a preferred embodiment, the feeder cell comprises an adherent monolayer.

[0134] Similarly, embodiments in which pluripotent cell cultures or aggregated pluripotent suspension cultures are grown in a prescribed medium or culture system that does not use feeder cells are "feeder-free." Feeder-free culture methods increase the scalability and reproducibility of pluripotent cell cultures and reduce the risk of contamination by infectious agents, for example, from feeder cells or other animal-sourced culture components. Feeder-free methods are also described in U.S. Patent No. 6,800,480 by Bodnar et al. (assigned to Geron Corporation of Menlo Park, California). However, and in contrast to U.S. Patent No. 6,800,480, the embodiments described herein, whether pluripotent, multipotent, or differentiated cell cultures, are feeder-free and do not additionally contain an endogenous or exogenous extracellular matrix; that is, the cultures described herein are not only feeder-free but also lack an extracellular matrix. For example, in U.S. Patent No. 6,800,480, an extracellular matrix is ​​prepared by culturing fibroblasts, lysing the fibroblasts in situ, and then washing the residue after lysis. Alternatively, in U.S. Patent No. 6,800,480, an extracellular matrix may also be prepared from isolated matrix components selected from collagen, placental matrix, fibronectin, laminin, merosin, tenacin, heparin sulfate, chondroitin sulfate, dermatan sulfate, aggrecan, biglycan, thrombospondin, vitronectin, and decorin, or from a combination of such components.The embodiments described herein do not require producing an extracellular matrix by growing a feeder or fibroblast layer and lysing the cells to produce an extracellular matrix, or first coating the tissue culture vessel with an extracellular matrix component or a combination of extracellular matrix components selected from collagen, placental matrix, fibronectin, laminin, merosin, tenacin, heparin sulfate, chondroitin sulfate, dermatan sulfate, aggrecan, biglycan, thrombospondin, vitronectin, and decorin. Accordingly, the aggregate suspension cultures described herein for pluripotent, multipotent, and differentiated cells do not require a feeder layer, lysed feeder or fibroblasts to produce an extracellular matrix coating, exogenously added extracellular matrix, or matrix components, but rather use soluble human serum components as described in international application PCT / US2008 / 080516, English titled "METHODS AND COMPOSITIONS FOR FEEDER-FREE PLURIPOTENT STEM CELL MEDIA CONTAINING HUMAN SERUM," thereby overcoming the need for feeder cells or a feeder monolayer, as well as the need for an endogenous extracellular matrix from feeder or fibroblast cells or exogenously added extracellular matrix components.

[0135] As used herein, the terms “cluster,” “clump,” or “aggregate” may be used interchangeably and generally refer to a group of cells that have not aggregated to form a cluster after dissociating into single cells, or in which cell-to-cell contact is close. As used herein, “re-aggregated” refers to the case where a cluster, clump, and / or aggregate forms new cell-to-cell contact by re-aggregating into a cluster, clump, and / or aggregate after dissociating into smaller clusters, clumps, and / or aggregates or single cells. Typically, such dissociation is passive in nature (e.g., using a Pasteur pipette), but other means of dissociation are conceived. Aggregate suspension pluripotent or multipotent cell cultures are substantially as described in International Publications PCT / US2007 / 062755 (English title: "COMPOSITIONS AND METHODS FOR CULTURING DIFFERENTIAL CELLS") and PCT / US2008 / 082356 (English title: "STEM CELL AGGREGATE SUSPENSION COMPOSITIONS AND METHODS OF DIFFERENTIATION THEREOF").

[0136] "Single cell suspension" or its equivalent refers to a pluripotent, multipotent, or terminally differentiated single cell suspension or a single cell suspension derived from pluripotent or multipotent cells by any mechanical or chemical means. There are several methods for dissociating cell clusters from primary tissues, attached cells in cultures, and aggregates to form a single cell suspension, e.g., physical force (mechanical dissociation e.g., cell scraper, mastication with a narrow-bore pipette, microneedle aspiration, vortex dissociation, and forced filtration through a fine nylon or stainless steel mesh), enzymes (enzymatic dissociation e.g., trypsin, collagenase, Accutase™, etc.), or a combination of both. Additionally, methods and culture medium conditions capable of supporting single cell dissociation of pluripotent, multipotent, or differentiated cells are useful for expansion, cell sorting, and limited seeding for multi-well plate analysis, and enable the automation of culture procedures and clone expansion.

[0137] In a preferred embodiment, there are no products of animal source in the culture method or culture system. In another preferred embodiment, there are no xenos in the culture method. In a more preferred embodiment, one or more conditions or requirements for the commercial manufacture of human cell therapeutic agents are satisfied or exceeded by the culture method described herein.

[0138] A population of pluripotent cells may be further cultured in the presence of specific supplementary growth factors to obtain a population of cells that are of a different cell lineage or will develop into a different cell lineage, or may be selectively reversed to develop into a different cell lineage. The term “supplementary growth factor” is used in its broadest context and refers to a substance that promotes the growth of pluripotent cells and / or maintains cell viability and / or stimulates cell differentiation or / or stimulates the reversal of cell differentiation. Additionally, supplementary growth factors may be substances secreted by feeder cells into their medium. Such substances include, but are not limited to, cytokines, chemokines, small molecules, neutralizing antibodies, and proteins. Growth factors may also include intercellular signaling polypeptides that control cell development and maintenance, as well as tissue morphology and function. In a preferred embodiment, the supplementary growth factor is selected from the group comprising stem cell factor (SCF), oncostatin M (OSM), ciliary neurogenic factor (CNTF), interleukin-6 (IL-6) combined with soluble interleukin-6 receptor (IL-6R), fibroblast growth factor (FGF), bone morphogenetic protein (BMP), tumor necrosis factor (TNF), and granulocyte macrophage colony-stimulating factor (GM-CSF).

[0139] In a specific method for producing cells as described herein, a growth factor is removed from a cell culture or cell population after its addition. For example, a growth factor, such as activin A, activin B, GDF-8, or GDF-11, is added and may be removed within about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, or about 10 days after its addition. In some embodiments, the differentiation factor itself is not removed from the cell culture, and the means of removal is to omit it from the cell culture medium, for example, the cell culture medium containing activin is changed to one that does not contain activin.

[0140] Since the efficiency of the differentiation process can be adjusted by modifying specific parameters, including but not limited to cell growth conditions, growth factor concentrations, and the timing of the culture phase, the differentiation procedure described herein may result in the conversion of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or more than about 95% of pluripotent cells (including induced pluripotent cells) into pluripotent or differentiated cells, for example, definitive endoderm. Additionally, the conversion rate or efficiency rate may also refer to the differentiation of one type of pluripotent cell into further differentiated pluripotent cells, for example, the differentiation of a definitive endoderm into an foregut endoderm, a PDX1-positive foregut endoderm, a PDX1-positive pancreatic endoderm or a PDX1 / NKX6.1 co-positive pancreatic endoderm, an endocrine progenitor / precursor or an NGN3 / NKX2.2 co-positive endocrine progenitor / precursor, and hormone-secreting endocrine cells or INS, GCG, GHRL, SST, PP single-positive endocrine cells. In a process where the isolation of preprimitive glandular or mesoendodermal cells is used, a substantially pure population of preprimitive glandular or mesoendodermal cells may be recovered.

[0141] A general method for the production of endoderm lineage cells derived from hES cells is described in the related U.S. application and literature as indicated above [D'Amour et al. 2005 Nat Biotechnol. 23:1534-41] (published online on October 28, 2005); [D'Amour et al. 2006 Nat Biotechnol. 24(11):1392-401] (published online on October 19, 2006); [Kroon et al. (2008) Nat Biotechnol. 26 (4):443-452] (published online on February 20, 2008); [Kelly et al. (2011) Nat. Biotechnol. 29(8):750-6] (published online on July 31, 2011); and [Schulz et al. It is described in

[2012] PLosOne, 7(5): e37004] (published online on May 18, 2012). D'Amour et al. described a five-step differentiation protocol: Step 1 (resulting mainly in the production of definitive endoderm), Step 2 (resulting mainly in the production of PDX1-negative foregut endoderm), Step 3 (resulting mainly in the production of PDX1-positive foregut endoderm), Step 4 (resulting mainly in the production of pancreatic endoderm or pancreatic endocrine progenitors), and Step 5 (resulting mainly in the production of hormone-expressing endocrine cells).

[0142] The term "trophoectoderm" refers to pluripotent cells in which the expression of markers selected from the group including HAND1, Eomes, MASH2, ESXL1, HCG, KRT18, PSG3, SFXN5, DLX3, PSX1, ETS2, and ERBB genes is relatively high compared to the expression levels of HAND1, Eomes, MASH2, ESXL1, HCG, KRT18, PSG3, SFXN5, DLX3, PSX1, ETS2, and ERBB in non-trophoectoderm cells or cell populations.

[0143] The term "extra-embryonic endoderm" refers to pluripotent cells in which the expression of markers selected from the group containing SOX7, SOX17, THBD, SPARC, DAB1, or AFP genes is relatively high compared to the expression levels of SOX7, SOX17, THBD, SPARC, DAB1, or AFP in non-extra-embryonic endoderm cells or cell populations.

[0144] The term "pre-primitive gland cell" refers to pluripotent cells with relatively high expression levels of FGF8 and / or NODAL marker genes compared to BRACHURY low, FGF4 low, SNAI1 low, SOX17 low, FOXA2 low, SOX7 low, and SOX1 low.

[0145] The term "mesoderm cells" refers to pluripotent cells with relatively high expression levels of Brachiuri, FGF4, SNAI1 MIXL1 and / or WNT3 marker genes compared to SOX17, CXCR4, FOXA2, SOX7, and SOX1.

[0146] The term “definitive endoderm (DE)” refers to a pluripotent endoderm lineage cell capable of differentiating into cells of the intestinal tract or organs derived from the intestinal tract. According to certain embodiments, the definitive endoderm cell is a mammalian cell, and in a preferred embodiment, the definitive endoderm cell is a human cell. In some embodiments of the invention, the definitive endoderm cell expresses a specific marker or fails to significantly express a specific marker. In some embodiments, one or more markers selected from SOX17, CXCR4, MIXL1, GATA4, HNF3β, GSC, FGF17, VWF, CALCR, FOXQ1, CMKOR1, and CRIP1 are expressed in the definitive endoderm cell. In other embodiments, one or more markers selected from OCT4, alpha-fetoprotein (AFP), thrombomodulin™, SPARC, SOX7, and HNF4α are not expressed or are not significantly expressed in the definitive endoderm cell. Deterministic endoderm cell population and method for producing the same U.S. Application No. 11 / 021,618 It is also described in (English title "DEFINITIVE ENDODERM", filed on December 23, 2004).

[0147] The terms "PDX1-negative foregut endoderm cells" or "foregut endoderm cells" or equivalents thereof are cells that express SOX17, HNF1β (HNF1B), HNF4α (HNF4A), and FOXA1 markers but substantially do not express PDX1, AFP, SOX7, or SOX1. A population of PDX1-negative foregut endoderm cells and a method for producing the same are also described in U.S. Application No. 11 / 588,693 (English title "PDX1-expressing dorsal and ventral foregut endoderm", filed on October 27, 2006).

[0148] "PDX1-positive, dosal-biased, foregut endoderm cells" (dot PDX1-positive foregut endoderm cells) or simply "PDX1-positive endoderm" or equivalents thereof are cells expressing one or more markers selected from Table 1 and / or one or more markers selected from Table 2, and are also described in the related U.S. application 11 / 588,693 (English title "PDX1 EXPRESSING DOSAL AND VENTRAL FOREGUT ENDODERM", filed October 27, 2006) and also in U.S. application 11 / 115,868 (English title "PDX1-expressing endoderm", filed April 26, 2005).

[0149]

[0150] Markers expressed in both dorsal and ventral PDX1-positive foregut endoderm

[0151]

[0152]

[0153] Table 2

[0154] Markers expressed in the equi-biased PDX1-positive foregut endoderm

[0155]

[0156]

[0157]

[0158] The terms “pancreatic endoderm,” “of pancreatic epithelium,” “pancreatic epithelium” (all may be abbreviated as “PE”), “pancreatic progenitor,” “PDX-1 positive pancreatic endoderm,” or their equivalents, e.g., “pancreatic endoderm cells” (PEC), are all precursor or progenitor pancreatic cells. The PEC as described herein is a population of progenitor cells after stage 4 differentiation (approx. days 12–14) and comprises two or more major distinct populations: i) pancreatic progenitor cells expressing PDX1 and NKX6.1 but not CHGA (or CHGA negative, CHGA-), or “non-endocrine pluripotent progenitor subpopulation (CHGA-),” or “non-endocrine (CHGA-) subpopulation” or “non-endocrine (CHGA-) cells” or their equivalents; and ii) multihormonal endocrine cells (CHGA-positive, CHGA+) expressing CHGA, or "endocrine multipotent progenitor subpopulation (CHGA+)", or "endocrine (CHGA+) subpopulation" or "endocrine (CHGA+) cells" or equivalents thereof. PEC pancreatic progenitor subpopulations expressing PDX1 and NKX6.1 but not CHGA are also referred to as "non-endocrine multipotent pancreatic progenitor subpopulation (CHGA-)", or "non-endocrine progenitor subpopulation", "non-endocrine (CHGA-) subpopulation", "non-endocrine (CHGA-) subpopulation", "multipotent progenitor subpopulation", etc. The PEC multihormone endocrine cell subpopulation expressing CHGA is also referred to as "cells assigned to the endocrine system (CHGA+)," "endocrine cells," or "CHGA+ cells." Without being limited to theory, it is hypothesized that the cell population expressing NKX6.1 but not CHGA is the more active or therapeutic component of PEC, whereas the population of CHGA-positive multihormone endocrine cells is hypothesized to further differentiate and mature into glucagon-expressing islet cells in vivo. Reference [Kelly et al.(2011) Cell-surface markers for the isolation of pancreatic cell types derived from human embryonic stem cells, Nat Biotechnol. 29(8):750-756] (2011년 7월 31일에 온라인에서 공개됨) 및 [Schulz et al. (2012), A Scalable System for Production of Functional Pancreatic Progenitors from Human Embryonic Stem Cells, PLosOne 7(5): 1-17, e37004] 참조.

[0159] Sometimes, pancreatic endoderm cells are used without reference to the PEC described above, and are generally used to refer to at least stage 3 and 4 type cells. The usage and meaning will be clear from the context. Pancreatic endoderm derived from pluripotent stem cells of this manner, at least hES and hIPS cells, are distinguished from other endoderm lineage cell types based on differential or high expression levels of markers selected from PDX1, NKX6.1, PTF1A, CPA1, cMYC, NGN3, PAX4, ARX, and NKX2.2 markers, but do not substantially express genes that are hallmarks of pancreatic endocrine cells, e.g., CHGA, INS, GCG, GHRL, SST, MAFA, PCSK1, and GLUT1. Additionally, some "endocrine progenitor cells" expressing NGN3 may differentiate into other non-pancreatic structures (e.g., duodenum). Pancreatic endoderm or endocrine progenitor cell populations and methods thereof are also described in U.S. Patent Application No. 11 / 773,944 (English title “Methods of producing pancreatic hormones”, filed July 5, 2007), and U.S. Patent Application No. 12 / 107,020 (English title “METHODS FOR PURIFYING ENDODERM AND PANCREATIC ENDODERM CELLS DERIVED FORM HUMAN EMBRYONIC STEM CELLS”, filed April 21, 2008).

[0160] The terms "endocrine cell," "pancreatic islet hormone-expressing cell," "pancreatic endocrine cell," "pancreatic islet cell," or "pancreatic islet," or their equivalents, refer to cells that may be polyhormonal or monohormonal. Thus, the cells express one or more pancreatic hormones and possess at least some of the functions of human pancreatic islet cells. Pancreatic islet hormone-expressing cells may be mature or immature cells, further differentiated, or developmentally more assigned than the endocrine progenitor / precursor type cells from which they originated.

[0161] As used herein, “precisely specified endocrine cells,” “step 7 cultures,” or “immature endocrine cells” (including “immature beta cells”) refer to a population of endocrine cells produced in vitro that is capable of functioning in vivo, for example, immature beta cells secrete insulin in response to blood glucose when transplanted. Precisely specified endocrine cells or step 7 cultures may have additional characteristics including the following: when transplanted, precisely specified endocrine cells may develop and mature into functional pancreatic islet cells. Precisely specified endocrine cells may be enhanced for endocrine cells (or non-endocrine cells may be depleted). In a preferred embodiment, more than about 50% of the cells within the precisely specified endocrine cell population are CHGA+. In a more preferred embodiment, about 60%, 70%, 80%, 90%, 95%, more than 98%, or 100% of the cells within the precisely specified endocrine cell population are CHGA+. In a preferred embodiment, less than about 50% of the cells within the precisely specified endocrine cell population are CHGA-. In a more preferred embodiment, less than about 15% of the cells within the precisely specified endocrine cell population are CHGA-. In a more preferred embodiment, about 10%, 5%, 3%, 2%, 1%, less than 0.5%, or 0% of the cells within the precisely specified endocrine cell population are CHGA-. Furthermore, the expression of a specific marker, such as NGN3 expression during Step 3, may be suppressed in the precisely specified endocrine cells. The precisely specified endocrine cells may have increased expression of NGN3 at Step 5. The precisely specified endocrine cells may be monohormonal (e.g., INS alone, GCG alone, or SST alone). Precisely identified endocrine cells may co-express other immature endocrine cell markers, including NKX6.1 and PDX1.The precisely identified endocrine cells are monohormonal and may also co-express other immature endocrine cell markers, including NKX6.1 and PDX1. The precisely identified endocrine cells may have a higher proportion of monohormonal-expressing INS cells as a percentage of the total INS population. In a preferred embodiment, the precisely identified endocrine cells may have 50% or more monohormonal-expressing INS cells as a percentage of the total INS population. The precisely identified endocrine cells may be CHGA+ / INS+ / NKX6.1+ (triple positive). In a preferred embodiment, more than about 25% of the cells in the cell population are CHGA+ / INS+ / NKX6.1+ (triple positive). In a preferred embodiment, more than 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or 100% of the cells in the cell population are CHGA+ / INS+ / NKX6.1+ (triple positive).

[0162] The term “immature endocrine cell,” specifically “immature beta-cell,” or an equivalent thereof, refers to a cell derived from any other endocrine cell precursor, including endocrine progenitor / progenitor cells, pancreatic endoderm (PE) cells, pancreatic foregut cells, definitive endoderm cells, mesoendoderm cells, or any prior-derived cells described below, which expresses at least a marker selected from the group consisting of INS, NKX6.1, PDX1, NEUROD, MNX1, NKX2.2, MAFA, PAX4, SNAIL2, FOXA1, or FOXA2. Preferably, the immature beta-cells described herein express INS, NKX6.1, and PDX1, and more preferably, they co-express INS and NKX6.1. The terms “immature endocrine cell,” “immature pancreatic hormone-expressing cell,” or “immature pancreatic islet” or equivalents thereof refer, for example, at least unipotent immature beta cells, or pre-beta cells as described in FIG. 45, and do not include other immature cells, for example, these terms do not include immature alpha (glucagon) cells, or immature delta (somatostatin) cells, or immature epsilon (ghrelin) cells, or immature pancreatic polypeptide (PP).

[0163] A number of stem cell culture media or growth environments, including standardized media, conditioning media, feeder-free media, serum-free media, etc., are conceived in the embodiments described herein. As used herein, the term “growth environment” or “environment (milieu)” or its equivalent is an environment in which undifferentiated or differentiated stem cells (e.g., primate embryonic stem cells) proliferate in vitro. Features of such an environment include a medium in which the cells are cultured, and, if present, a supporting structure (e.g., a substrate on a solid surface). Methods for the culture or maintenance of pluripotent cells and / or the differentiation of pluripotent cells are described in PCT / US2007 / 062755 (English title “COMPOSITIONS AND METHODS USEFUL FOR CULTURING DIFFERENTIABLE CELLS”, filed February 23, 2007); It is also described in U.S. application number 11 / 993,399 (English title "EMBRYONIC STEM CELL CULTURE COMPOSITIONS AND METHODS OF USE THEREOF", filed December 20, 2007); and U.S. application number 11 / 875,057 (English title "Methods and compositions for feeder-free pluripotent stem cell media containing human serum", filed October 19, 2007).

[0164] The terms “essentially” or “substantially” mean the majority, minor, or reduced amount of a component or cell present in any cell population or culture, for example, the immature beta cell culture described herein is “essentially or substantially cells” or “immature beta cells that essentially or substantially express INS, NKX6.1, and PDX1 and essentially or substantially do not express NGN3.” Other examples include, but are not limited to, “essentially or substantially hES cells,” “essentially or substantially determinative endoderm cells,” “essentially or substantially foregut endoderm cells,” “essentially or substantially PDX1-negative foregut endoderm cells,” “essentially or substantially PDX1-positive pancreatic endoderm cells,” “essentially or substantially pancreatic endocrine progenitor cells,” “essentially or substantially pancreatic endocrine cells.”

[0165] With respect to cells in a cell culture or cell population, “substantially absent” means that a specific cell type that is not in such cell culture or cell population is present in an amount of about 10%, less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% of the total number of cells present in the cell culture or cell population.

[0166] The terms “reduced serum” or “serum-free” or equivalents thereof refer to cell cultures grown in a medium containing reduced serum, substantially without serum, or completely without serum. Under specific culture conditions, serum concentrations may range from about 0% (v / v) to about 10% (v / v). For example, in some differentiation processes, the serum concentration in the medium is less than about 0.05% (v / v), less than about 0.1% (v / v), less than about 0.2% (v / v), less than about 0.3% (v / v), less than about 0.4% (v / v), less than about 0.5% (v / v), less than about 0.6% (v / v), less than about 0.7% (v / v), less than about 0.8% (v / v), less than about 0.9% (v / v), less than about 1% (v / v), less than about 2% (v / v), less than about 3% (v / v), less than about 4% (v / v), less than about 5% (v / v), less than about 6% (v / v), less than about 7% (v / v), less than about 8% (v / v), less than about 9% (v / v), or about It may be less than 10% (v / v). In some processes, pro-primordial gland cells are grown without serum or without a serum substitute. In other processes, pro-primordial gland cells are grown in the presence of B27. In such processes, the concentration of B27 supplement may range from about 0.1% (v / v) to about 20% (v / v).

[0167] In another process, cell cultures are grown in the presence of B27. In this process, the concentration of B27 supplement may be in the range of about 0.1% (v / v) to about 20% (v / v), or may be a concentration greater than about 20% (v / v). In a specific process, the concentration of B27 in the medium is about 0.1% (v / v), about 0.2% (v / v), about 0.3% (v / v), about 0.4% (v / v), about 0.5% (v / v), about 0.6% (v / v), about 0.7% (v / v), about 0.8% (v / v), about 0.9% (v / v), about 1% (v / v), about 2% (v / v), about 3% (v / v), about 4% (v / v), about 5% (v / v), about 6% (v / v), about 7% (v / v), about 8% (v / v), about 9% (v / v), about 10% (v / v), about 15% (v / v), or about 20% (v / v). Alternatively, the concentration of the added B27 supplement can be measured in terms of multiples of the strength of a commercially available B27 stock solution. For example, B27 is available as a 50× stock solution from Invitrogen (Carlsbad, California). Adding a sufficient amount of this stock solution to a sufficient volume of growth medium produces a medium supplemented with the desired amount of B27. For example, adding 10 ml of 50× B27 stock solution to 90 ml of growth medium will produce a growth medium supplemented with 5× B27. The concentrations of B27 supplements in the medium are approximately 0.1×, approximately 0.2×, approximately 0.3×, approximately 0.4×, approximately 0.5×, approximately 0.6×, approximately 0.7×, approximately 0.8×, approximately 0.9×, approximately 1×, approximately 1.1×, approximately 1.2×, approximately 1.3×, approximately 1.4×, approximately 1.5×, approximately 1.6×, approximately 1.7×, approximately 1.8×, approximately 1.9×, approximately 2×, approximately 2.5×, approximately 3×, approximately 3.5×, approximately 4×, and approximately 4.It may exceed 5×, approximately 5×, approximately 6×, approximately 7×, approximately 8×, approximately 9×, approximately 10×, approximately 11×, approximately 12×, approximately 13×, approximately 14×, approximately 15×, approximately 16×, approximately 17×, approximately 18×, approximately 19×, approximately 20×, and approximately 20×.

[0168] In another aspect, when the insulin level requirements for differentiation are low, B27 is not used because B27 contains high levels of insulin. For example, the applicant determined the insulin levels in 100× B27 and ITS stock and in each 1× working stock solution within RPMI. Insulin levels were determined using the Mercodia Ultrasensitive Insulin ELISA kit according to the manufacturer's instructions. The assay was performed on 100× and 50× unopened B27 and ITS stocks, respectively, both of which were purchased from Life Technologies (Carlsbad, California). The results generated from the assay are presented in Table 3 below.

[0169] Table 3

[0170]

[0171] Table 3 indicates that approximately 3 µg / mL and 10 µg / mL of insulin are present in 1×B27 and 1×ITS, respectively. Furthermore, the insulin concentration in the 100× ITS stock is consistent with the insulin concentrations listed by the manufacturer. Since Life Technologies does not provide insulin concentrations for 50×B27, there is no comparison with the insulin concentrations mentioned by the manufacturer; however, the insulin concentration of approximately 160 µg / mL is accurate based on precise measurements of the 100× ITS stock performed simultaneously, which is based on the aforementioned literature [McLean et al. (2007)], indicating that both insulin and insulin-like growth factor (IGF) are well-established agonists of PI3-kinase-dependent signaling, suggesting that PI3-kinase inhibitors (e.g., LY 294002) would promote definitive endoderm formation by inhibiting the effectors of insulin / IGF. Refer to Figures 6A and B, specifically, SOX17 expression is reduced fourfold with 1 μg / mL of insulin. Insulin and / or IGF are present at biologically active levels in various medium supplements, such as KSR, FCS (fetal calf serum), FBS (fetal bovine serum), B27, and StemPro34, and can inhibit deterministic endoderm differentiation under these culture conditions (e.g., the aforementioned literature [Jiang et al. (2007)]).

[0172] As used herein, "exogenous" or "exogenously added" compounds, such as agents, components, growth factors, differentiation factors, etc., in the context of cultures or conditioning media refer to compounds added to a culture or medium to supplement any compound or growth factor that may or may not already be present in the culture or medium. For example, in some embodiments, cell cultures and / or cell populations do not contain exogenously added retinoids.

[0173] As used herein, “retinoid” refers to retinol, retinal or retinoic acid, as well as derivatives of any of these compounds. In a preferred embodiment, the retinoid is retinoic acid.

[0174] The terms "FGF family growth factor," "fibroblast growth factor," or "member of the fibroblast growth factor family" refer to an FGF selected from the group comprising FGF1, FGF2, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, and FGF23. In some embodiments, "FGF family growth factor," "fibroblast growth factor," or "member of the fibroblast growth factor family" refer to any growth factor that is homologous to and / or has a similar function to a known member of the fibroblast growth factor family.

[0175] The terms "TGFβ superfamily growth factor," "TGFβ superfamily ligand," or "TGFβ TGF-beta signaling pathway activator," or their equivalents, refer to TGF-beta1, TGF-beta2, TF-beta3, GDF-15, GDF-9, BMP-15, BMP-16, BMP-3, GDF-10, BMP-9, BMP-10, GDF-6, GDF-5, GDF-7, BMP-5, BMP-6, BMP-7, BMP-8, BMP-2, BMP-4, GDF-3, GDF-1, GDF-11, GDF8, Activin beta-C, beta-E, beta-A and beta-B, BMP-14, GDF-14, MIS, Inhibin alpha, Lefty1, Lefty2, GDNF, It refers to more than 30 structurally related proteins, including the subfamilies of neuterin, persephin, and artemin. See reference [Chang et al. (2002) Endocrine Rev. 23(6):787-823]. These ligands are typically synthesized as prepropeptides of about 400-500 amino acids (aa), and "TGFβ superfamily growth factor," "TGFβ superfamily ligand," "TGFβ TGF-beta signaling pathway activator," or equivalents thereof may be full-length proteins or proteolytic peptides thereof.

[0176] The term "ERBB ligand" refers to a ligand that binds to any one of the ErbB receptors and, such that this receptor can, in turn, dimerize with another ErbB receptor or function as a monomer, thereby activating the tyrosine kinase activity of the ErbB dimonomer, dimer, or heteromeric receptor. Non-limiting examples of ErbB ligands include neuregulin-1; splice variants and isoforms of neuregulin-1, including but not limited to HRG-β, HRG-α, Neu differentiation factor (NDF), acetylcholine receptor-induced activity (ARIA), glial growth factor 2 (GGF2), and sensory and motor neuron-derived factor (SMDF); neuregulin-2; splice variants and isoforms of neuregulin-2, including but not limited to NRG2-β; epiregulin; It includes biregulin.

[0177] The term "expression" as used herein refers to the production of an object or substance, as well as the level or quantity of the production of the object or substance. Accordingly, determining the expression of a specific marker refers to determining the relative or absolute amount of the expressed marker, or simply detecting the presence or absence of the marker.

[0178] The term “marker” as used herein refers to any molecule that can be observed or detected. For example, a marker may include, but is not limited to, nucleic acids, such as transcripts of specific genes, polypeptide products of genes, non-gene product polypeptides, glycoproteins, carbohydrates, glycolipids, lipids, lipoproteins, or small molecules (e.g., molecules with a molecular weight of less than 10,000 amu).

[0179] For most of the markers described herein, official Human Genome Organization (HUGO) gene symbols are provided. These symbols, developed by the HUGO Gene Nomenclature Committee, provide a unique abbreviation for each named human gene and gene product. These gene symbols are easily recognizable, and a person skilled in the art can easily associate them with the corresponding unique human gene and / or protein sequence.

[0180] According to the HUGO nomenclature, the following gene symbols are defined as follows: GHRL - ghrelin; IAPP - islet amyloid polypeptide; INS - insulin; GCG - glucagon; ISL1 - ISL1 transcription factor; PAX6 - paired box gene 6; PAX4 - paired box gene 4; NEUROG3 - neurogenin 3 (NGN3); NKX2-2 - NKX2 transcription factor related, locus 2 (NKX2.2); NKX6-1 - NKX6 transcription factor related, locus 1 (NKX6.1); IPF1 - Insulin promoter factor 1 (PDX1); ONECUT1 - Monocleavage domain, family member 1 (HNF6); HLXB9 - Homeobox B9 (HB9); TCF2 - Transcription factor 2, liver (HNF1b); FOXA1 - Forkhead box A1; HGF - Hepatocyte growth factor; IGF1 - Insulin-like growth factor 1; POU5F1 - POU domain, class 5, transcription factor 1 (OCT4); NANOG - Nanog homeobox; SOX2 - SRY (sex determination region Y) - box 2; CDH1 - Cadherin 1, type 1, E-cadherin (ECAD); T - Brachiuri homolog (BRACH); FGF4 - Fibroblast growth factor 4; WNT3 - wingless - type MMTV integration site family, member 3; SOX17 - SRY (sex determination region Y) - box 17; GSC - goosecoid; CER1 - (Cerberus 1, cysteine ​​knot superfamily, homolog (CER); CXCR4 - Chemokine (CXC motif) receptor 4; FGF17 - Fibroblast growth factor 17; FOXA2 - Forkhead box A2; SOX7 - SRY (sex determination region Y) - box 7; SOX1 - SRY (sex determination region Y) - box 1; AFP - Alpha-fetoprotein; SPARC - Secretory protein, acidic, cysteine-rich (osteonectin); and THBD - Thrombomodulin (TM), NCAM - Neuronal adhesion molecule; SYP - Synaptophysin; ZIC1 - Zic family member 1; NEF3 - Neurofilament 3 (NFM); SST - Somatostatin; MAFA - v-maf myofascial membrane Fibrosarcoma oncogene homolog A; MAFB - v-maf myofascial fibrosarcoma oncogene homolog B; SYP - synaptophysin; CHGA - chromogranin A (parathyroid secretory protein 1); NGN3 - neurogenin 3, NKX2.2 - NK2 Homeobox 2; NKX6.1 - NK6 Homeobox 1; ID1 - DNA binding inhibitor 1, GHRL - ghrelin / obestatin prepropeptide, GSK - glycogen synthase kinase, G6PC2 - glucose-6-phosphatase, UCN3 - urocortin 3, PCSK1 - proprotein converter subtilisin / kexin type 1, SLC30A8 - solute transporter family 30 (zinc transporter), member 8, and CADH1 - E-cadherin. The terms fibroblast growth factor 7 (FGF7) and keratinocyte growth factor (KGF) are synonymous.

[0181] The progression of pluripotent cells into various pluripotent and / or differentiated cells can be monitored by determining the relative expression of a gene or genetic marker characteristic of a specific cell by comparing it to the expression of a second gene or control gene, e.g., the Salim gene. In some processes, the expression of a specific marker is determined by detecting the presence or absence of the marker. Alternatively, the expression of a specific marker may be determined by measuring the level of the marker present within cells of a cell culture or cell population. In such processes, the measurement of marker expression may be qualitative or quantitative. One method for quantifying the expression of a marker produced by a marker gene is through the use of Quantitative PCR (Q-PCR). Methods for performing Q-PCR are well known in the art. Other methods known in the art may also be used to quantify marker gene expression. For example, the expression of a marker gene product can be detected by using an antibody specific to the marker gene product of interest.

[0182] Additionally, multiplex assays and / or methods are available to analyze multiple genes with high sensitivity and efficiency. For example, with at least the nCounter System (provided by Nanostring, Seattle, Washington, USA), users can currently analyze the expression levels of up to 800 genes simultaneously with sensitivity comparable to quantitative PCR systems and operation times of less than 15 minutes per reaction. Thus, total RNA within any sample (e.g., Step 4 PEC and Step 7 endocrine progenitor / precursor and endocrine cell cultures, respectively) can be isolated using the 6100 nucleic acid extractor (Applied Biosystems; Foster City, California, USA) (e.g., triple-linked), and approximately 100 ng per reaction is required for the quantification of gene expression using the nCounter System. Furthermore, instead of analog detection, the encounter system uses digital detection, in which each gene transcript is detected by a probe bound to a DNA fragment attached to a unique colored fluorescent string (molecular barcode). Therefore, the identification of these transcripts depends solely on the sequence of fluorescence on the string rather than fluorescence intensity. Secondly, the total number of transcripts in the sample is quantified by counting the total number of times a specific fluorescent string (barcode) is detected. Moreover, since this method does not require the amplification of target mRNA, the range is the biological expression range, typically three digits. Currently, this system can statistically significantly measure a 1.2-fold change in a single transcript as few as 20 copies (10 fM) per cell (p < 0.05). For genes expressed at levels ranging from 0.5 to 20 copies per cell, a 1.5-fold difference in expression level can be detected with the same level of confidence.

[0183] In some processes, for example, higher expression of the following genes compared to lower expression of other genes indicates specific cell populations: SOX17, SOX7, AFP, or THBD indicate the ectomorphic endoderm; NODAL and / or FGF8 indicate the pre-primordial line; Brachiuri, FGF4, SNAI1, and / or WNT3 indicate the mesomorph; CER, GSC, CXCR4, SOX17, and FOXA2 indicate definitive endoderm cells; SOX17, FOXA2, FOXA1, HNF1B, and HNF4A indicate the foregut endoderm (or PDX1-negative endoderm); PDX1, HNF6, SOX9, and PROX1 indicate the PDX1-positive endoderm; PDX1, NKX6.1, PTFA1, CPA, and cMYC indicate the pancreatic epithelium (PE or pancreatic progenitory); NGN3, PAX4, ARX, and NKX2.2 indicate endocrine progenitor / progenitor cells; INS, GCG, GHRL, SST, and PP indicate various endocrine cells; relatively high MAFA to MAFB gene expression indicates insulin-secreting endocrine cells; and relatively high MAFB to MAFA gene expression indicates glucagon-secreting endocrine cells. In a particular figure, only "signature" or "major" markers typical of these specific cell types of a particular lineage are presented. A person skilled in the art understands that other markers or genes, for example, genes that are constitutively expressed or expressed in all or most or the majority of cell types of a particular lineage or the entire lineage, are expressed but are not presented or described.

[0184] Method for producing induced pluripotent stem (iPS) cells

[0185] The embodiments described herein are not limited to any one type of iPS cell or any one method of producing iPS cells. The embodiments are not limited to or dependent on the level of production efficiency of iPS cells, as various methods exist. The embodiments described herein apply to the differentiation of iPS cells into endoderm-lineage cells and their use.

[0186] Research using specific nuclear reprogramming factors has allowed pluripotent stem cells or pluripotent-like stem cells to be derived from a patient's own somatic cells. These cells are also referred to as induced pluripotent stem (iPS) cells. The present invention describes various iPS cell lines provided by Shinya Yamanaka of Kyoto University. However, other iPS cell lines, e.g., those described by James Thomson et al., are included in the invention herein. See U.S. Publication 20090047263, International Publication WO2005 / 80598, U.S. Publication 20080233610, and International Publication WO2008 / 11882. Therefore, as used herein, "induced pluripotent stem (iPS) cells" refers to cells that are similar in properties to other pluripotent stem cells, e.g., hES cells, hEG cells, pPS (primate pluripotent stem) cells, parthenogenetic cells, etc.

[0187] Nuclear programming factors are described in U.S. Publication 20090047263, International Publication WO2005 / 80598, U.S. Publication 20080233610, and International Publication WO2008 / 11882 and have been used to induce the reprogramming of differentiated cells without using oocytes, embryos, or ES cells. The method of producing induced iPS cells from somatic cells by using a nuclear reprogramming factor similar to that used and described in the present invention is not particularly limited. In a preferred embodiment, the nuclear reprogramming factor is brought into contact with the somatic cells under an environment in which the somatic cells and induced pluripotent stem cells can proliferate. An advantage of the specific embodiment described herein is that induced pluripotent stem cells can be produced by bringing the nuclear reprogramming factor into contact with somatic cells in the absence of oocytes, embryos, or embryonic stem (ES) cells. By using nuclear reprogramming factors, the nucleus of a somatic cell can be reprogrammed to obtain iPS cells or "ES-like cells".

[0188] The pluripotent stem cells described herein, whether hES cells or iPS cells, may express any number of pluripotent cell markers, including but not limited to the following: alkaline phosphatase (AP); ABCG2; embryonic antigen-1 (SSEA-1); SSEA-3; SSEA-4; TRA-1-60; TRA-1-81; Tra-2-49 / 6E; ERas / ECAT5, E-cadherin; β.III-tubulin; alpha-smooth muscle actin (alpha-SMA); fibroblast growth factor 4 (Fgf4), Crypto, Dax1; zinc finger protein 296 (Zfp296); N-acetyltransferase-1 (Nat1); (ES cell-associated transcript 1 (ECAT1); ESG1 / DPPA5 / ECAT2; ECAT3; ECAT6; ECAT7; ECAT8; ECAT9; ECAT10; ECAT15-1; ECAT15-2; Fthl17; Sal14; Undifferentiated embryonic cell transcription factor (Utf1); Rex1; p53; G3PDH; Telomerase including TERT; Silencing X chromosome gene; Dnmt3a; Dnmt3b; TRIM28; F-box-containing protein 15 (Fbx15); Nanog / ECAT4; Oct3 / 4; Sox2; Klf4; c-Myc; Esrrb; TDGF1; GABRB3; Zfp42, FoxD3; GDF3; CYP25A1; Pluripotent-associated 2 (DPPA2); T-cell lymphoma breakpoint 1 (Tcl1); DPPA3 / Stellar; DPPA4, etc. It is understood that the present invention is not limited to these markers listed herein, but includes cell surface markers, antigens, and other gene products comprising EST, RNA (including microRNA and antisense RNA), DNA (including genes and cDNA), and parts thereof.

[0189] In one embodiment, the iPS cell line used herein contains the following nuclear reprogramming factor genes: Oct family genes, Klf family genes, and Sox family genes. In one iPS cell line, each of the following three genes is provided: Oct3 / 4, Klf4, and Sox2. In another iPS cell line, the gene products of each of the following three genes were used: Oct family genes, Klf family genes, and Myc family genes, e.g., Oct3 / 4, Klf4, and c-Myc. Thus, it is understood that the nuclear reprogramming factor may be present with the Myc family genes or may be absent from the Myc family genes.

[0190] Nuclear reprogramming factors described herein and known in the art may be used to generate iPS cells from differentiated adult somatic cells, and are not limited by the type of somatic cell being reprogrammed, that is, any type of somatic cell may be reprogrammed or dedifferentiated. Since reprogramming somatic cells does not require oocytes and / or embryos, the iPS cells may be mammalian cells, thus providing an opportunity to generate patient- or disease-specific pluripotent stem cells.

[0191] Viral, non-viral, and non-integrative viral methods for generating induced pluripotent stem cells (iPSCs) using adenovirus, plasmid, or Cre-loxP3 cleavage of reprogramming factors, or porcine BAC translocations, have been described. See [Stadtfeld, M., et al., Science 322, 945-949 (2008)]; [Okita, K. et al., Science 322, 949-953 (2008)]; [Kaji, K. et al. Nature 458, 771-775 (2009)]; [Soldner, F. et al. Cell 136, 964-977 (2009)]; and [Woltjen, K. et al. Nature 458, 766-770 (2009)]. Refer also to U.S. Patent Application No. 20100003757 by Mack, A. et al. (published January 7, 2010) and PCT / US2009 / 037429 by Shi et al. However, these methods have low reprogramming efficiency (<0.003%) and can leave residual vector sequences despite cleavage, which limits their therapeutic applications. For example, viral integration within the host genome and the overexpression of the aforementioned transcription factor have been associated with oncogenesis, and potentially residual transgene expression is a distinguishing feature between ES cells and iPS cells. References [Solder, F. et al., Cell 136:964-977 (2009)]; [Foster et al., Oncogene 24:1491-1500 (2005)]; and [Hochedlinger, K. et al., Cell 121:465-477 (2005)] see.

[0192] In another embodiment of the present invention, a method for generating iPSCs comprises an episomal vector derived from the Epstein-Barr virus. Refer to the literature [Yu, J. et al. Science 324, 797-801 (2009)] and U.S. application 20100003757 by Mac A et al. (published January 7, 2010). These methods require three separate plasmids containing a combination of seven factors including the oncogene SV40.

[0193] In another embodiment of the present invention, a method for generating iPSCs comprises protein-based iPSCs from mouse and human fetal and non-fetal cells. See [Zhou, H. et al. Cell Stem Cell 4, 381-384 (2009)]; and [Kim, D. et al. Cell Stem Cell 4, 472-476 (2009)]. Such methods involve using chemical treatment (e.g., valproic acid in the case of [Zhou et al. 2009]) or a number of treatment rounds ([Kim et al. 2009]).

[0194] In another embodiment of the present invention, a minicircle vector or plasmid, which is a supercoiled DNA molecule lacking bacterial replication origin and antibiotic resistance genes, may be used. See [Chen, Z.-Y. et al., Mol. Ther. 8, 495-500 (2003)]; [Chen, Z.-Y. et al., Hum. Gene Ther. 16, 126-131 (2005)]; and [Jia, F. et al., Nature Methods Advance Publication Online 7 February 2010]. These methods generate iPSCs with longer ectopic expression and higher transfection efficiency because the activation of exogenous silencing mechanisms is lower.

[0195] In another embodiment of the present invention, iPS cells may be generated from human patients with various diseases, including patients with diabetes, ALS, spinal muscular atrophy, and Parkinson's disease. See [Maehr et al. PNAS USA 106(37):15768-73 (2009)]; [Dimos et al., Science, 321:1218-21 (2008)]; [Ebert et al. Nature 457:277-80 (2009)]; [Park et al. Cell 134:877-886 (2008)]; and [Soldner et al., Cell 136:964-977]. One or more advantages of producing hIPS cells from patients with specific diseases is that the derived cells will contain the genotype and cellular response of these human diseases. Also refer to Table 4, which lists at least some existing human iPS cell lines. This information<National Institutes of Health (NIH) Stem Cell Registry> ,<Human Embryonic Stem Cell Registry> and<International Stem Cell Registry> It was derived from publicly available databases and literature, including, for example, the University of Massachusetts Medical School (located in Worcester, Massachusetts). These databases are periodically updated as cell lines become available and registrations are obtained.

[0196] Embodiments of the compositions and methods described herein comprise human pluripotent stem cells such as CyT49, CyT212, CyT203, CyT25 (marketed by ViaCyte Inc. (located at 3550 General Atomics Court, San Diego, California 92121) at least at the time of filing this application), hESCs including but not limited to BGO1, BG02, and MEL1, and induced pluripotent stem (iPS) cells such as iPSC-482c7 and iPSC-603 (marketed by Cellular Dynamics International, Inc. (Madison, Wisconsin)) and iPSC-G4 (hereinafter "G4") and iPSC-B7 (hereinafter "B7") (marketed by Shinya Yamanaka of the Center for iPS Cell Research at Kyoto University). The use of various differentiable primate pluripotent stem cells is envisioned, and research using these human IPS cells and other human IPS cells is described in detail in U.S. patent applications 12 / 765,714 and 13 / 761,078 (both titled "CELL COMPOSITIONS FROM DEDIFFERENTIATED REPROGRAMMED CELLS," filed on April 22, 2010, and February 6, 2013, respectively). Some of these human pluripotent stem cells are registered with national registries, such as the National Institutes of Health (NIH), and<NIH Human Stem Cell Registry> It is listed in (e.g., CyT49 registry number #0041). Information on CyT49 and other available cell lines can also be found on the World Wide Web at stemcells.nih.gov / research / registry.Other cell lines, e.g., BG01 and BG01v, are commercially available and distributed to third-party entities by WiCell® (catalog name, BG01) and ATCC (catalog number SCRC-2002), respectively, which are affiliates of the Wisconsin International Stem Cell (WISC) bank. While other cell lines described herein may not be registered or distributed to biological repositories, such as WiCell® or ATCC, such cell lines are publicly available directly or indirectly from principal researchers, laboratories, and / or institutions. Public requests for cell lines and reagents are common, for example, among technicians in the life sciences. Typically, the transport of such cells or materials is subject to standard material transport agreements between the owner of the cell line or material and the recipient. This type of material transport occurs frequently in research settings, particularly in the life sciences. In fact, through such agreements with commercial and non-profit industrial partners and collaborators, the applicant has routinely transported cells including CyT49 (2006), CyT203 (2005), Cyt212 (2009), CyT25 (2002), BG01 (2001), BG02 (2001), BG03 (2001), and BG01v (2004) since they were induced and characterized. The year in parentheses next to each cell line in the above list indicates the year in which the cell line or material became publicly available and immortalized (e.g., when a cell bank was established), and thus, since the establishment of these cell lines, no further destruction of embryos has been performed or required to prepare the compositions described herein and to carry out the methods described herein.

[0197] Tables 4 and 5 are, respectively, non-comprehensive lists of specific iPSCs and hESCs available worldwide for research and / or commercial purposes and suitable for use in the methods and compositions of the present invention. The information in Tables 3 and 4<National Institutes of Health (NIH) Human Stem Cell Registry> ,<Human Embryonic Stem Cell Registry> and<International Stem Cell Registry> It was derived from publicly available databases and literature, including, for example, the University of Massachusetts Medical School in Worcester, Massachusetts. These databases are periodically updated as cell lines become available and registrations are obtained.

[0198] Human iPSCs (at least iPSC-603 and iPSC-482-c7) described herein were provided by Cellular Dynamics International Inc. (Madison, Wisconsin, USA).

[0199] Table 4

[0200] List of human induced pluripotent stem (hIPS) cell lines

[0201]

[0202]

[0203]

[0204]

[0205]

[0206]

[0207]

[0208]

[0209]

[0210] Another advantage of using hIPS cells is that these cells will be an immunologically matched autologous cell population, and patient-specific cells will allow for the study of the origin and progression of the disease. Therefore, it is possible to understand the root causes of the disease, which can provide insights leading to the development of preventive and therapeutic treatments for the condition.

[0211] Pluripotent human embryonic stem (hES) cells

[0212] Some embodiments relate to a method for inducing definitive endoderm cells, ultimately any endoderm-lineage derived cell type (including but not limited to foregut endoderm, pancreatic endoderm, endocrine progenitor / progenitor cells and / or pancreatic islet hormone-expressing cells) using human embryonic stem (hES) cells as starting material. These hES cells may be cells derived from those obtained from morula, embryonic cell masses, or embryonic germ cells. Human embryonic stem cells may be maintained in a pluripotent state in culture without substantial differentiation using methods known in the art. Such methods are described, for example, in U.S. Patent Nos. 5,453,357; 5,670,372; 5,690,926; 5,843,780; 6,200,806 and 6,251,671.

[0213] In some processes, pluripotent stem cells, such as hES cells, are maintained on a feeder layer. In such processes, any feeder layer that allows the pluripotent cells to be maintained in a pluripotent state may be used. One feeder layer commonly used for the culture of human embryonic stem cells is a layer of mouse fibroblasts. More recently, a human fibroblast feeder layer has been developed for use in the culture of pluripotent cells (see U.S. Patent Application Publication No. 2002 / 0072117). An alternative process allows for the maintenance of pluripotent cells without using a feeder layer.

[0214] The pluripotent cells described herein may be maintained in culture in the presence or absence of serum, in the presence or absence of an extracellular matrix, or in the presence or absence of FGF. In some pluripotent cell maintenance procedures, serum substitutes are used. These and other methods for the culture and differentiation of pluripotent or multipotent cells, respectively, are described in PCT / US2007 / 062755 (filed February 23, 2007, with the English title "COMPOSITIONS AND METHODS FOR CULTURING DIFFERENTIAL CELLS") and PCT / US2008 / 080516 (filed October 20, 2008, with the English title "METHODS AND COMPOSITIONS FOR FEEDER-FREE PLURIPOTENT STEM CELL MEDIA CONTAINING HUMAN SERUM").

[0215] The methods described herein are useful for all hES cell lines, and at least those listed in Table 5, which are available for commercial purchase from WiCell on the World Wide Web at wicell.org / home / stem-cell-lines / order-stem-cell-lines / obtain-stem-cell-lines.cmsx or from verified companies. This information<National Institutes of Health (NIH) Stem Cell Registry> ,<Human Embryonic Stem Cell Registry> and<International Stem Cell Registry> It was derived from publicly available databases and literature, including, for example, (located at the University of Massachusetts Medical School in Worcester, Massachusetts). These databases are periodically updated as cell lines become available and registrations are obtained. At least 254<International Stem Cell Registry> There are commercially available iPSC cell lines listed and 1,211 commercially available hESC cell lines. Table 5 below is an example of potentially available pluripotent stem cells, including but not limited to all listed hESCs and iPSCs.

[0216] Table 5

[0217] List of human embryonic stem (hES) cell lines

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

[0224]

[0225]

[0226]

[0227]

[0228]

[0229]

[0230] Alternative methods to induce pluripotent stem cells

[0231] Methods exist to induce pluripotent stem cells, such as mammalian ES cells, without destroying embryos. Briefly, Advanced Cell Technology (Worster, Massachusetts, USA) published three scientific journal articles describing the induction of mouse and human ES cells from a single blastomere, leaving the embryo intact and thus not causing its destruction. In late 2005, Chung et al. first described a method for producing mouse ES cells from a single blastomere. See [Chung et al. (2006) Nature 439: 216-219] (published online on October 16, 2005). In [Chung et al. (2006)], it was described that a biopsy be taken from an embryo using micromanipulation techniques similar to those used in preimplantation genetic diagnosis; see page 217. At that time, Chung et al. (2006) co-cultured blastomer cell lines with other embryonic stem cells, but later developed a method that did not require this. See [Chung et al. (2008) Human Embryonic Stem Cell Lines Generated without Embryo Destruction, Cell Stem Cell 2: 113-117].

[0232] Preimplantation genetic diagnosis is used to analyze genetic abnormalities in embryos prior to implantation. This method is performed on early, normally developing embryos (e.g., at the 8-cell stage) when the genetic inputs of both parents can be studied by creating a hole in the zona pellucida and aspirating, extruding, or cutting one or two blastomeres through the opening. Genetic analysis using fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) is typically used in PGD to analyze chromosomal abnormalities and single-gene disorders, respectively. Subsequently, if no genetic abnormalities are found, the remaining intact embryos are implanted into the female patient for a normal pregnancy. As early as 2004, the literature [Staessen, C. et al. (2004), Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial, Hum. Reprod. Preimplantation genetic diagnosis techniques have been reported in various groups, including [Monni et al. (2004) Preimplantation genetic diagnosis for beta-thalassaemia: the Sardinian experience. Prenat Diagn 24: 949-954]. Thus, Jeong et al. (2006) described a method available for extracting blastomeres from early embryos without destroying the embryos.

[0233] Additionally, in August 2006, Klimanskaya et al., the second author of [Chung et al. (2006)] and also from Advanced Cell Technology, described a procedure demonstrating that a similar PGD technique enabled the induction of human ES cell lines from a single blastomer, although it was not as efficient (only 2% of isolated blastomers produced hES cell lines), and was not significantly different from what was originally described in [Chung et al. (2006)]. See [Klimanskanya et al. (2006) Human embryonic stem cell lines derived from single blastomeres, Nature 444, 481-485]. Klimanskaya et al. co-cultured the newly induced hES cell lines with other ES cells that Jung et al. (2006) mentioned as potentially important. Chung et al. (2006) noted that "it is unclear whether the success of the ES co-culture system in (his) study can be attributed to substances secreted by ES cells or whether cell-to-cell contact is necessary." See the right-hand paragraph on page 218 of the aforementioned reference [Chung et al. (2006)]. However, a subsequent study by the same Chung et al. in 2008 demonstrated that hES cell lines did not require co-culture with ES cells at all, as culturing isolated blastomeres in a medium containing laminin enhanced their ability to produce hESCs. See the reference published online on January 10, 2008 [Chung et al. (2008), Human Embryonic Stem Cell Lines Generated without Embryo Destruction, Cell Stem Cell (2):113-117, p.116].Furthermore, hES cells obtained in this manner had the same characteristics as other human pluripotent stem cells, including hES cells, such as being able to maintain an undifferentiated state for more than 6 months, exhibiting a normal karyotype and expression of pluripotent markers (including Oct-4, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, Nanog, and alkaline phosphatase), being able to differentiate, and forming derivatives of all three embryonic germ layers in vitro and in vivo in teratomas.

[0234] Therefore, it was known and available at the time when the induction of mouse ES cell lines from a single blastomere was first presented in the publication of Chung et al. (2006) that co-culturing a single blastomere with other ES cells was not deterministic as originally assumed, and that culturing them merely on laminene (a common component of many extracellular matrices (commercially available and / or prepared, for example, as feeder cells lysates), commonly used for growing mammalian cells and known for growing mammalian cells). Thus, it is entirely possible that a person skilled in the art could have induced an hES cell line from a single blastomere while preserving the embryo or preventing its destruction by taking the method of the aforementioned document [Chung et al. (2006)] and using the knowledge available as previously described in the aforementioned document [Straessen et al. (2004)].

[0235] pluripotent stem cells and aggregate suspensions of cells derived from pluripotent stem cells

[0236] In contrast to previously known tissue manipulation methods based on seeding individual cells into a polymer scaffold, matrix, and / or gel, the embodiments described herein may use aggregate cell aggregate suspensions formed from pluripotent stem cells, single cell suspensions, or differentiated single cell suspensions derived therefrom. A method for processing and / or producing stem cell aggregate suspensions and the differentiation of the cells thereof is PCT / US2007 / 062755 (filed February 23, 2007, English title “COMPOSITIONS AND METHODS FOR CULTURING DIFFERENTIAL CELLS”, currently U.S. Patents 8,211,699 and 8,415,158); and PCT / US2008 / 080516 (filed on October 20, 2008, with the English title "METHODS AND COMPOSITIONS FOR FEEDER-FREE PLURIPOTENT STEM CELL MEDIA CONTAINING HUMAN SERUM", currently U.S. Patent 8,334,138), and described in the aforementioned document [Schulz T. et al. (2012)].

[0237] The embodiments described herein relate to a method for generating suspended pluripotent cell aggregates from a pluripotent adherent culture by culturing pluripotent cells under adherent growth culture conditions that allow expansion in an undifferentiated state; dissociating the adherent pluripotent cell culture into a single-cell suspension culture; and contacting the single-cell suspension culture with a first differentiation culture condition that allows for the formation of suspended hES-derived cell aggregates by shaking the single-cell suspension culture until the single-cell suspension culture forms suspended pluripotent-derived cell aggregates, thereby generating suspended pluripotent-derived cell aggregates. In a preferred embodiment, shaking of the single-cell suspension culture is performed by rotation at about 80 rpm to 160 rpm. In other specific embodiments described herein, an rho-kinase inhibitor is used to facilitate pluripotent stem cell aggregation, growth, proliferation, expansion, and / or cell mass.

[0238] The phrases “substantially uniform” or “substantially identical in size or shape” or their equivalents refer to the width of the uniformity of the aggregates, which is about 20% or less. In another embodiment, the width of the uniformity of the aggregates is about 15%, 10%, or 5% or less.

[0239] In another embodiment, an hES cell aggregate suspension was cultured in a substantially serum-free medium, furthermore in the absence of exogenously added fibroblast growth factor (FGF). This is distinguished from U.S. Patent No. 7,005,252 of Thomson, J., which requires culturing hES cells in a medium that is serum-free but contains exogenously added growth factors (including FGF). In some embodiments, an iPS cell aggregate suspension is cultured in a substantially serum-free medium and / or in the absence of exogenously added fibroblast growth factor (FGF).

[0240] Although the exact number of cells per aggregate is not critical, a person skilled in the art will recognize that the size of each aggregate (and thus the number of cells per aggregate) is limited by the capacity of oxygen and nutrients diffusing into the central cell, and that this number may also vary depending on the cell type and the nutritional requirements of that cell type. Cell aggregates may contain a minimum number of cells per aggregate (e.g., two or three cells) or may contain hundreds or thousands of cells per aggregate. Typically, cell aggregates contain hundreds to thousands of cells per aggregate. For the purposes of the present invention, cell aggregates are typically about 50 micrometers to about 600 micrometers in size, but depending on the cell type, the size may be smaller or larger than this range. In one embodiment, cell aggregates are about 50 micrometers to about 250 micrometers in size, or about 75 to 200 micrometers in size, preferably about 100 to 150 micrometers in size.

[0241] Another embodiment describes the preparation of an EB. As used herein, the terms “EB,” “aggregate,” or equivalents refer to aggregates of differentiated and undifferentiated cells that appear when ES cells are overgrown in a monolayer culture, maintained as a suspension culture in an unspecified medium, or differentiated through a non-directed protocol toward multiple germ layer tissues. That is, as described herein, EB is not formed from a single-cell suspension of pluripotent stem cells, nor is EB formed from an adherent culture of pluripotent-derived multipotent cells. These features alone make the present invention clearly distinguishable from an EB.

[0242] In contrast to embryonic bodies, which are a mixture of differentiated and undifferentiated cells and typically consist of cells from various germ layers undergoing random differentiation, the cell aggregates described herein are essentially or substantially homocellular and exist as aggregates of pluripotent, multipotent, pluripotent, or unipotent type cells, e.g., embryonic cells, determinative endoderm, foregut endoderm, PDX1-positive pancreatic endoderm, pancreatic endocrine cells, etc.

[0243] The method described herein never requires the culture vessel to be coated with an extracellular matrix first, as described, for example, in U.S. Patent 6,800,480 (assigned to Geron Corporation) by Bodna et al. In some embodiments described herein, iPS cells may be cultured in the same manner as other pluripotent stem cells, e.g., hES and iPS cells, are cultured using soluble human serum as substantially described in the applicant’s U.S. Patent 8,334,138; and the aforementioned document [Schulz T. et al. (2012)].

[0244] The method described herein never requires exogenously added fibroblast growth factor (FGF) supplied from a source other than the fibroblast feeder layer, as described in U.S. Patent No. 7,005,252 of Thomson, J. (assigned to Wisconsin Alumni Research Foundation (WARF)).

[0245] pluripotent and differentiated cell compositions

[0246] The cell composition produced by the method described herein is a cell culture comprising pluripotent stem cells, pre-primordial glands, mesoderm, definitive endoderm, foregut endoderm, PDX1-positive foregut endoderm, PDX1-positive pancreatic endoderm or PDX1 / NKX6.1 co-positive pancreatic endoderm, endocrine progenitors / precursors or NGN3 / NKX2.2 co-positive endocrine progenitors / precursors, and hormone-secreting endocrine cells or INS, GCG, GHRL, SST, PP single-positive endocrine cells, wherein at least about 5-90% of the cells in the culture are produced pre-primordial glands, mesoderm, definitive endoderm, foregut endoderm, PDX1-positive foregut endoderm, PDX1-positive pancreatic endoderm or PDX1 / NKX6.1 co-positive pancreatic endoderm, endocrine progenitors / precursors or It includes cell cultures comprising NGN3 / NKX2.2 co-positive endocrine progenitors / precursors, and hormone-secreting endocrine cells or INS, GCG, GHRL, SST, PP single-positive endocrine cells.

[0247] Some embodiments described herein relate to compositions, such as cell populations and cell cultures, comprising pluripotent cells, such as stem cells and iPS cells, and multipotent cells, such as both pre-primordial glands, meso-endoderms, and definitive endoderms, as well as cells that are more differentiated but still multipotent, such as PDX1-positive foregut endoderm, PDX1-positive pancreatic endoderm or PDX1 / NKX6.1 co-positive pancreatic endoderm, endocrine progenitors / precursors or NGN3 / NKX2.2 co-positive endocrine progenitors / precursors, and hormone-secreting endocrine cells or INS, GCG, GHRL, SST, PP single-positive endocrine cells. For example, using the methods described herein, compositions comprising a mixture of pluripotent stem cells and other multipotent or differentiated cells may be produced. In some embodiments, compositions comprising at least about 5 multipotent or differentiated cells versus about 95 pluripotent cells are produced. In another embodiment, a composition comprising at least about 95 pluripotent or differentiated cells to about 5 pluripotent cells is produced. Additionally, a composition comprising different ratios of pluripotent or differentiated cells to pluripotent cells is conceived. For example, a composition is conceived comprising at least about 1 pluripotent or differentiated cell versus about 1,000,000 pluripotent cells, at least about 1 pluripotent or differentiated cell versus about 100,000 pluripotent cells, at least about 1 pluripotent or differentiated cell versus about 10,000 pluripotent cells, at least about 1 pluripotent or differentiated cell versus about 1,000 pluripotent cells, at least about 1 pluripotent or differentiated cell versus about 500 pluripotent cells, at least about 1 pluripotent or differentiated cell versus about 100 pluripotent cells, at least about 1 pluripotent or differentiated cell versus about 10 pluripotent cells, at least about 1 pluripotent or differentiated cell versus about 5 pluripotent cells, and up to about 1 pluripotent cell and at least about 1,000,000 pluripotent or differentiated cells versus about 1 pluripotent cell.

[0248] Some embodiments described herein relate to a cell culture or cell population comprising at least about 5% pluripotent or differentiated cells versus at least about 99% pluripotent or differentiated cells. In some embodiments, the cell culture or cell population comprises mammalian cells. In preferred embodiments, the cell culture or cell population comprises human cells. For example, a specific embodiment relates to a cell culture comprising human cells, wherein at least about 5% to at least about 99% of the human cells are pluripotent or differentiated cells. Another embodiment relates to a cell culture comprising human cells, wherein at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or more than 99% of the human cells are pluripotent or differentiated cells. In an embodiment in which the cell culture or cell population comprises human feeder cells, the percentages are calculated without considering the human feeder cells in the cell culture.

[0249] The compositions and methods described herein have several useful features. For example, cell cultures and cell populations comprising pluripotent cells, e.g., pre-primordial gland cells and / or meso-endoderm cells, as well as methods for producing such cell cultures and cell populations, are useful for modeling the early stages of human development. Additionally, the compositions and methods described herein may serve as therapeutic interventions for disease conditions, such as diabetes. For example, since pre-primordial gland cells and / or meso-endoderm cells serve as sources for only a limited number of tissues, they can be used in the development of pure tissue or cell types. In some processes for producing pre-primordial gland cells, the pluripotent cells used as starting materials are pluripotent stem cells, e.g., hES, hEG, or iPS cells.

[0250] trophoectomydium cells

[0251] By using the method described herein, a composition comprising trophoblast cells that are substantially free of other cell types can be produced. In some embodiments described herein, the trophoblast cell population or cell culture produced by the method described herein has substantially higher expression of a marker selected from the group comprising HAND1, Eomes, MASH2, ESXL1, HCG, KRT18, PSG3, SFXN5, DLX3, PSX1, ETS2, and ERBB genes compared to the expression levels of HAND1, Eomes, MASH2, ESXL1, HCG, KRT18, PSG3, SFXN5, DLX3, PSX1, ETS2, and ERBB in non-trophoblast cells or cell populations.

[0252] Pre-primitive gland cells

[0253] By using the method described herein, compositions comprising pre-primitive striae cells that are substantially free of other cell types may be produced. In some embodiments described herein, the pre-primitive striae cell population or cell culture produced by the method described herein substantially expresses the FGF8 and / or NODAL marker genes compared to BRACHURY, FGF4, SNAI1, SOX17, FOXA2, SOX7, and SOX1. Pre-primitive striae cells and methods for producing pre-primitive striae cells are described in detail in the applicant’s U.S. Patent 7,958,585 (titled “PREPRIMITIVE STREAK AND MESENDODERM CELLS”, granted July 26, 2011).

[0254] Extraembryonic cells

[0255] By using the method described herein, compositions comprising extraembryonic cells that are substantially free of other cell types can be produced. Primordial, visceral, and parietal endoderm cells are extraembryonic cells. Primordial endoderm cells give rise to visceral and parietal endoderm cells. Visceral endoderm cells are endoderm cells that form part of the yolk sac. Visceral endoderm cells function in both nutrient absorption and transport. Parietal endoderm cells are adjacent to the extraembryonic tissue known as the Reichert membrane. One of the roles of parietal endoderm cells is to produce basement membrane components. Together, visceral endoderm cells and parietal endoderm cells form what is often referred to as the extraembryonic endoderm. As the name implies, extraembryonic endoderm cells do not give rise to embryonic structures formed during development. In contrast, the definitive endoderm cells and other endoderm-lineage or pancreatic-lineage cells described herein are embryonic or derived from embryonic cells and give rise to tissues derived from the intestinal tract that are formed during embryonic development. In some embodiments described herein, the extraembryonic cell population or cell culture produced by the method described herein has substantially higher expression of a marker selected from the group comprising SOX7, SOX17, THBD, SPARC, DAB1, HNF4alpha, or AFP genes compared to the expression levels of at least SOX7, SOX17, THBD, SPARC, DAB1, or AFP (not expressed in other types of cells or cell populations, e.g., determinative endoderm).

[0256] Meso-endodermal cells

[0257] By using the method described herein, compositions comprising mesoendoderm cells that are substantially free of other cell types can be produced. In some embodiments described herein, the mesoendoderm cell population or cell culture produced by the method described herein has substantially higher expression of a marker selected from the group comprising FGF4, SNAI1, MIXL1, and / or WNT3 marker genes compared to SOX17, CXCR4, FOXA2, SOX7, and SOX1. Mesoendoderm cells and methods for producing mesoendoderm cells are described in detail in the applicant’s U.S. Patent 7,958,585 (titled “PREPRIMITIVE STREAK AND MESENDODERM CELLS”, granted July 26, 2011).

[0258] Screening method

[0259] In some embodiments, a screening method is used to obtain a specific cell population comprising pluripotent, multipotent, and / or differentiated cells, such as human pluripotent stem cells, induced pluripotent stem cells, pre-primordial gland cells, mesoendodermal cells, definitive endoderm cells, foregut endoderm or PDX1-negative foregut endoderm cells, PDX1-positive foregut endoderm or PDX1-positive pancreatic endoderm cells or pancreatic progenitor cells, endocrine progenitor / progenitor cells, and / or endocrine cells. Subsequently, a candidate differentiation factor is provided to the cell population. At a first time point, which is before or approximately the same time point as providing the candidate differentiation factor, marker expression is determined. Alternatively, marker expression may be determined after providing the candidate differentiation factor. At a second time point, which is after the first time point and after the step of providing the candidate differentiation factor to the cell population, the expression of the same marker is determined again. It is determined whether the candidate differentiation factor can promote the differentiation of pancreatic progenitor cells by comparing the expression of the marker at the first time point with the expression of the marker at the second time point. If the expression of the marker at the second time point increases or decreases compared to the expression of the marker at the first time point, the candidate differentiation factor can promote the differentiation of pancreatic progenitor cells.

[0260] Some embodiments of the screening method described herein utilize a cell population or cell culture comprising human definitive endoderm, PDX-1 negative foregut endoderm, PDX-1 positive foregut endoderm, PDX-1 positive pancreatic endoderm, or pancreatic progenitor or endocrine progenitor / progenitor cells. For example, the cell population may be a substantially purified population of PDX-1-positive pancreatic endoderm or pancreatic progenitor cells. For example, the cell population may be an enriched population of human pancreatic progenitor cells, wherein at least about 50% to 97% of the human cells in the cell population are human pancreatic progenitor cells, and the remainder consists of endocrine progenitor / progenitor or endocrine cells and other cell types. The enhancement of pancreatic progenitor cells is described in detail in the applicant’s U.S. patent application number 12 / 107,020 (English title “METHOD FOR PURIFYING ENDODERM AND PANCREATIC ENDODERM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS”, filed on April 21, 2008, and currently U.S. patent number 8,338,170) and the corresponding document [Kelly et al. (2011)].

[0261] In an embodiment of the screening method described herein, a cell population is brought into contact with a candidate (test) differentiation factor, or the candidate (test) differentiation factor is provided to the cell population in a different manner. The candidate differentiation factor may comprise any molecule that may have the potential to promote the differentiation of any of the aforementioned cells, e.g., human pancreatic progenitor cells. In some embodiments described herein, the candidate differentiation factor comprises a molecule known to be a differentiation factor for one or more cell types. In an alternative embodiment, the candidate differentiation factor comprises a molecule not known to promote cell differentiation. In a preferred embodiment, the candidate differentiation factor comprises a molecule not known to promote the differentiation of human pancreatic progenitor cells. For example, screening for factors that differentiate definitive endoderm is described in detail in the applicant’s U.S. Patent Application No. 12 / 093,590 (titled “MARKERS OF DEFINITIVE ENDODERM”, filed July 21, 2008).

[0262] In addition to determining the expression of one or more markers at a first time point, some embodiments of the screening method described herein envision determining the expression of one or more markers at a second time point, which is after the first time point and after providing candidate differentiation factors to a cell population. In such embodiments, the expression of the same marker is determined at both the first and second time points. In some embodiments, the expression of multiple markers is determined at both the first and second time points. In such embodiments, the expression of the same multiple markers is determined at both the first and second time points. In some embodiments, marker expression is determined at multiple time points, each which is after the first time point and after providing candidate differentiation factors to a cell population. In certain embodiments, marker expression is determined by Q-PCR. In other embodiments, marker expression is determined by immunocytochemistry.

[0263] In a specific embodiment of the screening method described herein, the markers determined to be expressed at the first and second time points are markers associated with the differentiation of pancreatic progenitor cells into cells that are precursors of the final differentiated cells constituting the pancreatic islet tissue. Such cells may include immature pancreatic islet hormone-expressing cells.

[0264] In some embodiments of the screening method described herein, sufficient time is allowed between providing a candidate differentiation factor to a cell population and determining marker expression at a second time point. The sufficient time between providing a candidate differentiation factor to a cell population and determining marker expression at a second time point may be as little as about 1 hour to as much as about 10 days. In some embodiments, the expression of one or more markers is determined multiple times after providing a candidate differentiation factor to a cell population. In some embodiments, sufficient time is at least about 1 hour, at least about 6 hours, at least about 12 hours, at least about 16 hours, at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, at least about 7 weeks, or at least about 8 weeks.

[0265] In some embodiments of the method described herein, it is further determined whether the expression of a marker at a second time point has increased or decreased compared to the expression of such marker at a first time point. An increase or decrease in the expression of one or more markers indicates that the candidate differentiation factor may promote the differentiation of endocrine progenitor / progenitor cells. Similarly, if the expression of multiple markers is determined, it is further determined whether the expression of multiple markers at a second time point has increased or decreased compared to the expression of such multiple markers at a first time point. An increase or decrease in marker expression may be determined by measuring or otherwise evaluating the amount, level, or activity of the markers within the cell populations at the first and second time points. Such determination may be relative to other markers, e.g., housekeeping gene expression, or may be absolute. In certain embodiments where marker expression is increased at time point 2 compared to time point 1, the increase is at least about 2 times, at least about 5 times, at least about 10 times, at least about 20 times, at least about 30 times, at least about 40 times, at least about 50 times, at least about 60 times, at least about 70 times, at least about 80 times, at least about 90 times, at least about 100 times, or at least about 100 times. In some embodiments, the increase is less than 2 times. In certain embodiments where marker expression is decreased at time point 2 compared to time point 1, the decrease is at least about 2 times, at least about 5 times, at least about 10 times, at least about 20 times, at least about 30 times, at least about 40 times, at least about 50 times, at least about 60 times, at least about 70 times, at least about 80 times, at least about 90 times, at least about 100 times, or at least about 100 times. In some embodiments, the decrease is less than 2 times.

[0266] Monitoring of pluripotent or differentiated cell production

[0267] The processing of pluripotent cells into multipotent cells, and further into multipotent or differentiated cells, such as pancreatic progenitor cells or hormone-endocrine secreting cells, can be monitored by determining the expression of markers characteristic of specific cells, including genetic and phenotypic markers, such as the expression of islet hormone, and the processing of proinsulin into insulin and C-peptide in endocrine cells. In some processes, the expression of a specific marker is determined by detecting the presence or absence of the marker. Alternatively, the expression of a specific marker can be determined by measuring the level of the marker present within cells of a cell culture or cell population. For example, in certain processes, the expression of a marker characteristic of immature pancreatic islet hormone-expressing cells is determined, as well as the absence of significant expression of a marker characteristic of pluripotent cells, determinative endoderm, foregut endoderm, PDX1-positive foregut endoderm, endocrine progenitor cells / precursors, extraembryonic endoderm, mesoderm, ectoderm, mature pancreatic islet hormone-expressing cells, and / or other cell types.

[0268] As described in relation to monitoring the production of other less differentiated cell types of definitive endoderm lineages, quantitative or semi-quantitative techniques, such as blot transfer methods and immunocytochemistry, may be used to measure marker expression. Alternatively, marker expression can be accurately quantified through the use of techniques such as Q-PCR or nanostring encounters, or related high-throughput multiplexing techniques capable of simultaneously analyzing and testing hundreds or more markers. Additionally, at the polypeptide level, it will be understood that many of the markers of pancreatic islet hormone-expressing cells are secreted proteins. Therefore, techniques for measuring extracellular marker content, such as ELISA, may be utilized.

[0269] In another embodiment, immunohistochemistry is used to detect proteins expressed by the aforementioned genes. In yet another embodiment, Q-PCR may be used in combination with immunohistochemistry techniques or flow cytometry to effectively and accurately characterize and identify cell types and to determine both the amount and relative proportion of such markers within the target cell type. In one embodiment, Q-PCR can quantify RNA expression levels in cell cultures containing mixed cell populations. However, Q-PCR cannot provide or quantify whether the target marker or protein is co-expressed on the same cell. In yet another embodiment, Q-PCR is used in combination with flow cytometry to characterize and identify cell types. Thus, by using the methods described herein, such as combinations thereof, complete characterization and identification of various cell types, including endoderm lineage type cells, can be achieved and demonstrated.

[0270] For example, in one preferred embodiment, a pancreatic progenitor or pancreatic endoderm or PDX-1 positive pancreatic endoderm expresses at least PDX1, Nkx6.1, PTF1A, CPA, and / or cMYC as demonstrated by Q-PCR and / or ICC, but to be identified as a PDX1-positive expressing cell, such cells at least co-express PDX1 and Nkx6.1 as demonstrated by ICC and do not express other markers including SOX17, CXCR4, or CER. Similarly, for the accurate identification of mature hormone-secreting pancreatic cells in vitro or in vivo, for example, in insulin-secreting cells, it is demonstrated by ICC that C-peptide (a product of the accurate processing of proinsulin in mature and functional β cells) and insulin are co-expressed.

[0271] Another method known in the relevant art may also be used to quantify marker gene expression. For example, the expression of a marker gene product can be detected by using an antibody specific to the marker gene product of interest (e.g., Western blot, flow cytometry analysis, etc.). In a specific process, the expression of a marker gene characteristic of hES-derived cells, as well as the absence of significant expression of a marker gene characteristic of hES-derived cells. Another method for characterizing and identifying hES-derived cell types is described in the relevant application as indicated above.

[0272] Summary of PDX1-Positive Pancreatic Endoderm Production (Stages 1 to 4) and In Vivo Insulin Production

[0273] Methods for producing specific endoderm-lineage and pancreatic endoderm-lineage cells are provided herein and discussed in other related applications, such as U.S. Patent Nos. 7,534,608; 7,695,965; and 7,993,920 (titled “METHODS OF PRODUCING PANCREATIC HORMONES”) and U.S. Patent No. 8,129,182 (titled “ENDOCRINE PROGENITOR / PRECURSOR CELLS, PANCREATIC HORMONE-EXPRESSING CELLS AND METHODS OF PRODUCTION”). See also Table 17 and Figures 42, 43, and 44.

[0274] Briefly, the method for directed differentiation of pluripotent stem cells, e.g., hES and iPS cells, herein may be described in at least four, five, six, or seven steps depending on the desired final stage cell culture (PEC or endocrine cells). Step 1 is the production of definitive endoderm from pluripotent stem cells and takes about 2 to 5 days, preferably 2 or 3 days. Pluripotent stem cells are suspended in a medium comprising RPMI, a TGFβ superfamily member growth factor, e.g., Activin A, Activin B, GDF-8, or GDF-11 (100 ng / mL), a Wnt family member or Wnt pathway activator, e.g., Wnt3a (25 ng / mL), and alternatively, a rho-kinase or ROCK inhibitor, e.g., Y-27632 (10 μM), to enhance growth and / or survival and / or proliferation and / or cell-cell adhesion. After approximately 24 hours, the medium is exchanged for another 24 hours (Day 1) to 48 hours (Day 2) with a medium containing RPMI + serum, e.g., 0.2% FBS, and TGFβ superfamily member growth factors, e.g., Activin A, Activin B, GDF-8, or GDF-11 (100 ng / mL), and alternatively, a rho-kinase or ROCK inhibitor. Alternatively, after approximately 24 hours in a medium containing Activin / Wnt3a, the cells are cultured for a subsequent 24 hours in a medium containing only Activin (i.e., a medium not containing Wnt3a). Importantly, the production of definitive endoderm requires cell culture conditions with low serum content, and thereby low insulin or insulin-like growth factor content. See reference [McLean et al. (2007) Stem Cells 25: 29-38]. The literature [McLean et al.] also indicates that exposing hES cells to insulin concentrations as low as 0.2 µg / mL at step 1 can be detrimental to the production of definitive endoderm. For example, at least the literature [Agarwal et al.In [Efficient Differentiation of Functional Hepatocytes from Human Embryonic Stem Cells, Stem Cells (2008) 26:1117-1127]; [Borowiak et al., Small Molecules Efficiently Direct Endodermal Differentiation of Mouse and Human Embryonic Stem Cells, (2009) Cell Stem Cell 4:348-358]; and [Brunner et al., Distinct DNA methylation patterns characterize differentiated human embryonic stem cells and developing human fetal liver, (2009) Genome Res. 19:1044-1056], a person skilled in the art substantially modified the stage 1 differentiation of pluripotent cells into determinative endoderm as described in the present invention and in the literature [D'Amour et al. (2005)]. To induce other endoderm-lineage cells, accurate differentiation, specification, characterization, and identification of the determinative endoderm are required. Definitive endoderm cells at this stage co-express SOX17 and HNF3β (FOXA2) and do not express at least HNF4α, HNF6, PDX1, SOX6, PROX1, PTF1A, CPA, cMYC, NKX6.1, NGN3, PAX3, ARX, NKX2.2, INS, GSC, GHRL, SST, or PP in a detectable manner. The absence of HNF4α expression in the definitive endoderm is at least [Duncan et al.(1994), Expression of transcription factor HNF-4 in the extraembryonic endoderm, gut, and nephrogenic tissue of the developing mouse embryo: HNF-4 is a marker for primary endoderm in the implanting blastocyst", Proc. Natl. Acad. Sci, 91:7598-7602] 및 [Si-Tayeb et al. (2010), Highly Efficient Generation of Human Hepatocyte-Like cells from Induced Pluripotent Stem Cells", Hepatology 51:297-305]에서 지지되고 상세하게 기재된다.

[0275] Step 2 utilizes the definitive endoderm cell culture from Step 1 and produces foregut endoderm or PDX1-negative foregut endoderm by incubating the suspension culture for 24 hours (Days 2 to 3) with a 1:1000 dilution of ITS in RPMI with low serum levels, e.g., 0.2% FBS, 25 ng KGF (or FGF7), and alternatively, a ROCK inhibitor. After 24 hours (Days 3 to 4), the medium is exchanged for another 24 hours (Days 4 to 5) to 48 hours (Day 6) to enhance cell growth, viability, and proliferation with the same medium that still contains a ROCK inhibitor but without a TGFβ inhibitor. The decisive step for the precise identification of the foregut endoderm is the removal of TGFβ family growth factors. Accordingly, a TGFβ inhibitor, such as 2.5 μM of TGFβ inhibitor No. 4 or 5 μM of SB431542 (a specific inhibitor of activin receptor-like kinase (ALK), a TGFβ type I receptor) may be added to the step 2 cell culture. Foregut endoderm or PDX1-negative foregut endoderm cells produced from step 2 co-express SOX17, HNF1β, and HNF4α, and do not co-express at least SOX17 and HNF3β (FOXA2), or HNF6, PDX1, SOX6, PROX1, PTF1A, CPA, cMYC, NKX6.1, NGN3, PAX3, ARX, NKX2.2, INS, GSC, GHRL, SST, or PP (which are hallmarks of definitive endoderm, PDX1-positive pancreatic endoderm or pancreatic progenitor cells or endocrine progenitor / precursor cells, as well as typically polyhormonal types of cells).

[0276] Step 3 (Days 5–8) for PEC production utilizes the foregut endoderm cell culture from Step 2 and produces PDX1-positive foregut endoderm cells in DMEM or RPMI for about 24 hours (Day 7) to 48 hours (Day 8) using 1% B27, 0.25 μM KAAD cyclopamine, a retinoid, such as 0.2 μM retinoic acid (RA), or a retinoic acid analog, such as 3 nM TTNPB (or CTT3, which is a combination of KAAD cyclopamine and TTNPB), and 50 ng / mL Nogin. Specifically, the applicant has used DMEM-high glucose since approximately 2003, and all patent and non-patent disclosures since this point in time have used DMEM-high glucose, even if they have not mentioned "DMEM-high glucose," etc. This is, in part, because manufacturers such as Gibbco have not named their DMEMs, e.g., DMEM (Catalog No. 11960) and Knockout DMEM (Catalog No. 10829), in this manner. It is noteworthy that since the filing date of this application, Gibbco has provided more DMEM products, but still does not label some of its high-glucose DMEM products, e.g., Knockout DMEM (Catalog No. 10829-018), with "high glucose." Therefore, in each instance where DMEM is described, it can be assumed that this refers to high-glucose DMEM, which was evident to others conducting research and development in this field. Further details regarding the use of exogenous high-glucose are described in Example 21. Again, a ROCK inhibitor or rho-kinase inhibitor, such as Y-27632, may be used to enhance growth, survival, and proliferation and to promote cell-to-cell adhesion.The PDX1-positive foregut cells produced from step 3 co-express PDX1 and HNF6, as well as SOX9 and PROX, and do not recognizably co-express markers indicating definitive endoderm or foregut endoderm (PDX1-negative foregut endoderm) cells or PDX1-positive foregut endoderm cells as described above in steps 1 and 2.

[0277] The above Step 3 method is one of four steps for PEC production. For the production of endocrine progenitors / precursors and endocrine cells as described in detail in Examples 9-24 below, activin, Wnt, and heregulin are used alone and / or in combination to inhibit NGN3 expression while maintaining good cell aggregate mass, in addition to nogin, KAAD-cyclopamine, and retinoids. See Examples 8, 9, and 10.

[0278] Step 4 (Days 8–14) PEC production utilizes the medium from Step 3 and replaces it with a medium containing 1% vol / vol B27 supplement in DMEM, plus 50 ng / mL KGF and 50 ng / mL EGF, and sometimes also 50 ng / mL Nogin and ROCK inhibitor, additionally containing activin alone or in combination with heregulin. This novel method results in pancreatic progenitor cells co-expressing at least PDX1 and NKX6.1, as well as PTF1A. These cells do not recognizably express markers indicating definitive endoderm or foregut endoderm (PDX1-negative foregut endoderm) cells as described above in Steps 1, 2, and 3. See Fig. 44.

[0279] Alternatively, cells from Step 4 may be further differentiated in Step 5 to produce endocrine progenitor or progenitor-type cells and / or single and multi-hormonal pancreatic endocrine-type cells in a medium containing DMEM + 1% vol / vol B27 supplement for about 1 to 6 days (preferably about 2 days, i.e., Day 13–15). The endocrine progenitor / progenitor cells produced from Step 5 co-express at least CHGA, NGN3, and Nkx2.2 and do not recognizably express markers indicating the definitive endoderm or foregut endoderm (PDX1-negative foregut endoderm) as described above in Steps 1, 2, 3, and 4 for PEC production. See FIG. 44.

[0280] For the production of PEC, the PDX1-positive pancreatic endodermis produced from step 4 is loaded and contained entirely within a macro-encapsulation device and implanted into a patient, and the PDX1-positive pancreatic endodermis cells mature in vivo into pancreatic hormone-secreting cells, or pancreatic islets, e.g., insulin-secreting beta cells (also referred to as “in vivo function”). The encapsulation of PDX1-positive pancreatic endodermis cells and the in vivo production of insulin are described in detail in U.S. Application No. 12 / 618,659 ('659 application) (English title “ENCAPSULATION OF PANCREATIC LINEAGE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS”, filed November 13, 2009). Application '659 claims priority to Provisional Patent Application No. 61 / 114,857 (titled “ENCAPSULATION OF PANCREATIC PROGENITORS DERIVED FROM HES CELLS”, filed November 14, 2008); and Provisional U.S. Patent Application No. 61 / 121,084 (titled “ENCAPSULATION OF PANCREATIC ENDODERM CELLS”, filed December 9, 2008); and current U.S. Patents 8,278,106 and 8,424,928. The methods, compositions, and apparatus described herein represent currently preferred embodiments, are exemplary, and are not intended to limit the scope of the invention. Variations and other uses within the scope of the disclosure, which are incorporated within the spirit of the invention, will occur to a person skilled in the art. Therefore, it will be apparent to those skilled in the art that various substitutions and modifications can be made to the invention disclosed herein without departing from the scope and spirit of the invention.

[0281] For example, activin A, a member of the TGFβ superfamily of growth factors or signaling proteins, is used to produce definitive endoderm from pluripotent cells, e.g., hES cells and iPS cells, but other members of the TGFβ superfamily, e.g., GDF-8 and GDF-11, may be used to produce definitive endoderm, as described in international application PCT / US2008 / 065686 (English title: "GROWTH FACTORS FOR PRODUCTION OF DEFINITIVE ENDODERM", filed June 3, 2008).

[0282] In another context, activin alone or activin in combination with Wnt and hereguline can suppress and inhibit the expression of NGN3 at high and low levels; at low levels alone or in combination with hereguline, or alternatively in combination with Wnt and hereguline at high levels, cell mass, and thus yield, can be maintained. See Examples 8, 9, and 10.

[0283] For PEC production, retinoic acid (RA) is used to differentiate PDX1-negative foregut endoderm cells at step 2 into PDX1-positive foregut cells at step 3. However, other retinoids or retinoic acid analogs, such as 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (or TTNPB) and similar analogs (e.g., 4-HBTTNPB) may be used. For endocrine and endocrine progenitor / progenitor cell production, retinoic acid or any analog thereof may also be added during steps 6 and / or 7 to induce hormone gene expression. See Examples 13 and 16.

[0284] Nogin is a protein that inactivates, for example, a member of the TGFβ superfamily of signaling proteins, such as bone morphogenetic protein-4 (BMP4). However, other BMP4 inhibitors, such as Codin and Twisted Gastrulation (Tsg), or anti-BMP neutralizing antibodies can effectively inhibit BMP signaling by preventing BMP from binding to its cell surface receptors. Alternatively, the gene for human nogin has been cloned and sequenced. See U.S. Patent No. 6,075,007. Analysis of the nogin sequence reveals a carboxyl-terminal region homologous to Kunitz-type protease inhibitors, which suggests that potentially other Kunitz-type protease inhibitors may have similar effects on BMP inhibition. Example 15 describes the use of nogin to increase the production of non-endocrine (CHGA-) subgroups.

[0285] Finally, the macro-encapsulation devices described in this application and application '659; U.S. design applications 29 / 447,944; 29 / 408,366; 29 / 408,368; 29 / 423,365; and 61 / 774,443 (titled “SEMIPERMEABLE MACRO IMPLANTABLE CELLULAR ENCAPSULATION DEVICES”, filed March 7, 2013) are merely exemplary and are not intended to limit the scope of the invention. In particular, variations in device design, such as device size, the plurality of chambers or subcompartments within the device, the plurality of ports, or even the mechanism for loading and extracting the device, are all included within the spirit of the invention. Accordingly, it will be apparent to a person skilled in the art that various substitutions and modifications to the encapsulation device, as well as to the differentiation method described herein, may be made without departing from the scope and spirit of the invention disclosed herein. See Examples 10, 12, and 18.

[0286] In relation to some of the methods for differentiating pluripotent cells into determinative endoderm cells, the aforementioned growth factors are provided to the cells such that the growth factors are present in the culture at a concentration sufficient to promote the differentiation of at least a portion of the pluripotent cells into determinative endoderm cells and pancreatic lineage cells. In some methods, the aforementioned growth factors are present in the cell culture at concentrations of at least about 5 ng / mL, at least about 10 ng / mL, at least about 25 ng / mL, at least about 50 ng / mL, at least about 75 ng / mL, at least about 100 ng / mL, at least about 200 ng / mL, at least about 300 ng / mL, at least about 400 ng / mL, at least about 500 ng / mL, at least about 1000 ng / mL, at least about 2000 ng / mL, at least about 3000 ng / mL, at least about 4000 ng / mL, at least about 5000 ng / mL, or greater than about 5000 ng / mL. Other agents or growth factors are present in the cell culture at concentrations of at least 0.1 mM or 10 mM or greater than these.

[0287] In a specific method, the pluripotent stem cell differentiation agent and / or growth factor is removed from the cell culture after its addition. For example, the growth factor may be removed about 1 day after its addition, about 2 days after its addition, about 3 days after its addition, about 4 days after its addition, about 5 days after its addition, about 6 days after its addition, about 7 days after its addition, about 8 days after its addition, about 9 days after its addition, or about 10 days after its addition. In a preferred method, the growth factor is removed about 4 days after its addition. The removal of the agent and / or growth factor may be achieved by exchanging the medium in the absence of the agent and / or growth factor, or by using another agent that inhibits the function of such agent and / or growth factor.

[0288] In one preferred embodiment, the step 3 cell culture comprises, but is not limited to, an agent capable of suppressing, inhibiting, or inhibiting cells entrusted to the endocrine system (CHGA+). Such an agent also comprises sufficient amounts of activin, heregulin, and WNT and combinations of these three to promote differentiation and / or induce the expression of markers indicating non-endocrine multipotent pancreatic progenitor subpopulations (CHGA-), and to suppress or minimize the expression of markers in cells entrusted to the endocrine system (CHGA+). Markers indicating cells entrusted to the endocrine system (CHGA+) include, but are not limited to, NGN3, NKX2.2, etc.

[0289] In another preferred embodiment, the cell culture of step 4 comprises, but is not limited to, an agent capable of suppressing, inhibiting, or inhibiting cells entrusted to the endocrine system (CHGA+). Such an agent also comprises sufficient amounts of activin and hereguline and combinations of these two to promote differentiation and / or induce the expression of markers indicating non-endocrine multipotent pancreatic progenitor subpopulations (CHGA-), and to suppress or minimize the expression of markers in cells entrusted to the endocrine system (CHGA+). Markers indicating cells entrusted to the endocrine system (CHGA+) include, but are not limited to, NGN3, NKX2.2, etc. Means for suppressing at least NGN3 during steps 3 and 4 are described in detail in Examples 8-21 below.

[0290] In one embodiment, the cell culture of step 4 is further differentiated in step 5 with at least Nogin, KGF, EGF, and Notch signaling or pathway inhibitors. Markers indicating endocrine differentiation include, but are not limited to, NGN3, NKX2.2, etc. In a preferred embodiment, agents that mimic or effectively mimic in vitro what is observed in in vivo developmental studies are used in steps 1-7. For example, steps 3 and 4 according to Table 17 herein use agents capable of delaying, repressing, inhibiting and / or inhibiting endocrine differentiation or markers indicating endocrine differentiation including, but not limited to, NGN3 and NKX2.2. During steps 5, 6, and / or 7, the cell culture is treated with agents capable of inducing, increasing, and / or promoting endocrine differentiation, for example, by using Notch pathway inhibitors such as gamma secretase inhibitors. In summary, cell culture conditions from steps 3 and 4 suppress the endocrine phenotype, whereas cell culture conditions from steps 5, 6, and / or 7 progressively induce an endocrine phenotype including, but not limited to, insulin (INS), glucagon (GCG), somatostatin (SST), pancreatic polypeptide (PP), ghrelin (GHRL), solute transporter family 30 member 8 (SLC30A8), glucose-6-phosphatase 2 (G6PC2), prohormone convertase 1 (PCSK1), and glucose kinase (GCK).

[0291] In one embodiment, PDX1-positive pancreatic endoderm cells are differentiated into endocrine and endocrine progenitor / progenitor cells by continuing the incubation of PDX1-positive pancreatic endoderm cells in the presence of a Notch signaling inhibitor, e.g., a gamma secretase inhibitor such as R04929097 (used alone or in combination with a retinoid such as retinoic acid). The presence of the Notch signaling inhibitor induces the expression of NGN3 during stage 5. In another embodiment, the gamma secretase inhibitor is provided when the differentiation process begins, e.g., at the pluripotent stage, and remains in the cell culture throughout the differentiation into pancreatic islet hormone-expressing cells. In yet another embodiment, the gamma secretase inhibitor is added after the start of differentiation, but before differentiation into the PDX1-positive foregut endoderm stage. In a preferred embodiment, a gamma secretase inhibitor is provided to a cell culture or cell population almost simultaneously with providing a differentiation factor that promotes the transition of the determinant endoderm into a PDX1-positive endoderm. In another preferred embodiment, the gamma secretase inhibitor is provided to the cell culture or cell population after a substantial portion of the cells within the cell culture or cell population have differentiated into PDX1-positive foregut endoderm cells.

[0292] In another embodiment, the cell culture from step 5 is further differentiated in steps 6 and 7. During these steps, an agent capable of precisely identifying endocrine progenitor / precursor or progenitor cells is used to differentiate into further developed or mature endocrine cells in vivo. Such agents include, but are not limited to, retinoids or retinoic acids, BMPs, nicotinamide, IGF, Hedgehog proteins, etc. In a preferred embodiment, TTNPB (4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid or arotenoid acid) is a selectively highly potent retinoic acid analog with affinity for the nuclear transcription factors retinoic acid receptors (RAR) α, β, and γ. TTNPB and other retinoic acids or retinoic acid analogs induce ligand-activated transcription of genes possessing retinoic acid response elements. Therefore, other agents or ligands capable of activating retinoic acid response elements or binding to any RAR are potentially useful and may be modified to the present invention to promote endocrine cell differentiation.

[0293] In another embodiment, the cell culture from Step 5, Step 6, or Step 7 may be further treated with Matrigel or Matrigel alone with an rho-kinase inhibitor to improve cell adhesion. Alternatively, the rho-kinase inhibitor may be added at any step of 5, 6, or 7 at a concentration sufficient to promote cell viability, cell mass, and yield. Alternatively, the cell culture may be dissociated and reassembled during Steps 6 and 7 or between Steps 6 and 7 to eliminate or deplete unwanted cell types, including but not limited to non-endocrine pluripotent pancreatic progenitor subpopulations (CHGA-). See Example 14.

[0294] In another embodiment, any of steps 1-7 may be extended for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 days or more, or shortened for 1, 2, 3, 4, 5, 6, 7 days or more. For example, in one preferred embodiment, according to Table 17, step 6 occurs over approximately 6 days, and step 7 occurs over approximately 9 days. However, both stages can be shortened to accommodate the production of endocrine progenitors / precursors, and can be lengthened and extended to 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 days or more to produce developmentally more advanced endocrine cells.

[0295] In another embodiment, a method for producing a developmentally more advanced PEC or pancreatic endocrine progenitors / precursors or pancreatic endocrine cells is provided. In one aspect of the invention, single pancreatic hormone-expressing endocrine cells that are co-positive for PDX1 and NKX6.1, e.g., immature beta cells co-expressing INS, PDX1, and NKX6.1, are provided. In another aspect, the developmentally advanced cells may be a PEC culture composed mainly of non-endocrine pancreatic progenitor cells expressing at least PDX and NKX6.1, but not or minimally composed of endocrine lineage-assigned cells (CHGA+) expressing at least CHGA+, NGN3, and / or NKX2.2. Such PEC cultures are considered developmentally advanced because they are considered to be more similar to what appears in vivo in developmental studies of pancreatic differentiation. Reference [Jorgensen et al. See [Rukstalis and Habener (2007), An Illustrated Review of Early Pancreas Development in the Mouse, Endocrine Reviews 28(6):685-705] and [Rukstalis and Habener (2009), Neurogenin3: A master regulator of pancreatic islet differntiation and regeneration, Islets 1(3): 177-184]. Another example of a developmentally advanced cell or cell culture is one in which the reaggregated cell culture is dissociated and reaggregated or reassembled to form a more homogeneous cell population. In one aspect of the invention, such a more homogeneous cell population is an early-stage cell type, e.g., PDX1 and NKX6.It is mainly composed of single hormone-expressing cells that are co-positive for 1, but does not include pancreatic endocrine progenitor / precursor or endocrine cells that include, but are not limited to, cells or subpopulations from stages 3 and 4 or non-endocrine multipotent pancreatic progenitor (CHGA-) cells or PEC or PEC subpopulations, or remainder / triple-negative cells (CHGA- / PDX1- / NKX6.1-), or multihormone-expressing cells (i.e., cells expressing more than one hormone from any one cell type).

[0296] In another embodiment, preferably, the cell culture provided herein is precisely specified to have specific and particular significance in the field of developmental biology. In the context of developmental biology, this is the mechanism by which cells acquire a unique fate or are specified or precisely identified. Since differentiation of cell cultures in vitro lacks the typical temporal configuration and signals for in vivo developmental studies, it is essential to use and rely on cell markers (surface or internal markers, e.g., transcription factors), particularly signature cell markers or prominent cell markers indicating specific cell types. Therefore, references to precisely specified cells, cell cultures, subgroups, and populations imply that these cells have a unique fate and that these fates are more definitively determined based on the profiles of marker expression, the markers they express, and also, importantly, the markers they do not express. The precise specification of cell cultures in vitro depends on in vivo developmental studies of similar cells, and thus, in one preferred embodiment, in vivo developmental studies serve as a guide for differentiation in vitro and the characterization of precisely specified cells.

[0297] In some embodiments of the invention described herein, exendin 4 is provided to a differentiating cell culture or cell population at approximately the same time as a gamma secretase inhibitor. In certain embodiments, exendin 4 is provided to be present in the cell culture or cell population at a concentration of at least about 0.1 ng / mL to 1000 ng / mL.

[0298] It will be understood that NGN3, NKX2.2, and / or PAX4 marker expression is induced across a wide range of different levels in endocrine progenitor / progenitor cells depending on differentiation conditions. Accordingly, in some embodiments described herein, the expression of NGN3, NKX2.2, and / or PAX4 markers in endocrine progenitor / progenitor cells or cell populations is at least about 2 to at least about 10,000 times higher than the expression of NGN3, NKX2.2, and / or PAX4 markers in non-endocrine progenitor / progenitor cells or cell populations, e.g., pluripotent stem cells, deterministic endoderm cells, PDX1-positive foregut endoderm cells, immature pancreatic ischial hormone-expressing cells, mature pancreatic ischial hormone-expressing cells, extraembryonic endoderm cells, mesodermal cells, and / or ectoderm cells. In another embodiment, the expression of NGN3, NKX2.2, and / or PAX4 markers in endocrine progenitor / progenitor cells or cell populations is at least about 4 times, and at least about 6 times to 10,000 times higher than the expression of NGN3, NKX2.2, and / or PAX4 markers in non-endocrine progenitor / progenitor cells or cell populations, e.g., pluripotent stem cells, deterministic endoderm cells, PDX1-positive foregut endoderm cells, immature pancreatic ischial hormone-expressing cells, mature pancreatic ischial hormone-expressing cells, extraembryonic endoderm cells, mesodermal cells, and / or ectoderm cells. In some embodiments, the expression of NGN3, NKX2.2 and / or PAX4 markers in endocrine progenitor / progenitor cells or cell populations is infinitely higher than the expression of NGN3, NKX2.2 and / or PAX4 markers in non-endocrine progenitor / progenitor cells or cell populations, e.g., pluripotent cells such as iPS cells and hES cells, deterministic endoderm cells, PDX1-positive foregut endoderm cells, immature pancreatic ischial hormone-expressing cells, mature pancreatic ischial hormone-expressing cells, extraembryonic endoderm cells, mesodermal cells and / or ectoderm cells.

[0299] Further embodiments of the present invention relate to a composition, such as a cell culture or cell population, comprising human cells including human endocrine progenitor / progenitor cells, wherein the expression of the NGN3 marker is greater than the expression of the AFP, SOX7, SOX1, ZIC1, NFM, MAFA, SYP, CHGA, INS, GCG, SST, GHRL, and / or PAX6 markers in at least about 2% of the human cells. In other embodiments, the expression of the NGN3 marker is greater than the expression of the AFP, SOX7, SOX1, ZIC1, NFM, MAFA, SYP, CHGA, INS, GCG, SST, GHRL, and / or PAX6 markers in at least about 5% to 98% of the human cells. In some embodiments, the percentage of human cells in a cell culture or population in which the expression of NGN3 is greater than the expression of AFP, SOX7, SOX1, ZIC1, NFM, MAFA, SYP, CHGA, INS, GCG, SST, GHRL, and / or PAX6 markers is calculated regardless of feeder cells.

[0300] It will be understood that some embodiments of the present invention relate to a composition, such as a cell culture or cell population, comprising human endocrine progenitor / progenitor cells, wherein the expression of NKX2.2 and / or PAX4 is greater than the expression of AFP, SOX7, SOX1, ZIC1, NFM, MAFA, SYP, CHGA, INS, GCG, SST, GHRL, and / or PAX6 markers in at least about 2% to at least about 98% of the human cells. In some embodiments, the expression of NKX2.2 and / or PAX4 is greater than the expression of AFP, SOX7, SOX1, ZIC1, NFM, MAFA, SYP, CHGA, INS, GCG, SST, GHRL, and / or PAX6 markers in at least about 5% to 98% of the human cells. In some embodiments, the percentage of human cells in a cell culture or population in which the expression of NKX2.2 and / or PAX4 is greater than the expression of AFP, SOX7, SOX1, ZIC1, NFM, MAFA, SYP, CHGA, INS, GCG, SST, GHRL, and / or PAX6 markers is calculated regardless of feeder cells.

[0301] By using the method described herein, a composition comprising endocrine progenitor / progenitor cells that are substantially free of other cell types can be produced. In some embodiments of the invention, the endocrine progenitor / progenitor cell population or cell culture produced by the method described herein is substantially free of cells significantly expressing AFP, SOX7, SOX1, ZIC1, and / or NFM markers. In some embodiments, the endocrine progenitor / progenitor cell population of the cell culture produced by the method described herein is substantially free of cells significantly expressing AFP, SOX7, SOX1, ZIC1, NFM, MAFA, SYP, CHGA, INS, GCG, SST, GHRL, and / or PAX6 markers.

[0302] In another method for producing immature pancreatic islet hormone-expressing cells disclosed herein, HGF is provided to the cells such that it is present in a cell culture or cell population at a concentration sufficient to promote the differentiation of at least a portion of endocrine progenitor / progenitor cells into immature pancreatic islet hormone-expressing cells. In some embodiments, HGF is present in the cell culture or cell population at a concentration of at least about 1 ng / mL, or at least about 5 ng / mL to 1000 ng / mL.

[0303] In another method for producing immature pancreatic islet hormone-expressing cells disclosed herein, IGF1 is provided to the cells such that it is present in a cell culture or cell population at a concentration sufficient to promote the differentiation of at least a portion of endocrine progenitor / progenitor cells into immature pancreatic islet hormone-expressing cells. In some embodiments, IGF1 is present in the cell culture or cell population at a concentration of at least about 1 ng / mL to 1000 ng / mL.

[0304] In a specific embodiment of the method for producing immature pancreatic islet hormone-expressing cells as described herein, one or more of nicotinamide, exendin 4, HGF, and IGF1 are provided after one or more previously provided differentiation factors are removed from the cell culture. In another embodiment, one or more of nicotinamide, exendin 4, HGF, and IGF1 are provided to a cell culture or cell population containing one or more differentiation factors that were previously provided or provided at approximately the same time as one or more of nicotinamide, exendin 4, HGF, and IGF1. In a preferred embodiment, the differentiation factors that were previously provided or provided at approximately the same time as one or more of nicotinamide, exendin 4, HGF, and IGF1 include, but are not limited to, DAPT, FGF-10, KAAD-cyclopamine, activin A, activin B, BMP4, and / or RA.

[0305] Further embodiments of the present invention relate to a composition, such as a cell culture or cell population, comprising human cells including human immature pancreatic islet hormone-expressing cells, wherein the expression of MAFB, SYP, CHGA, NKX2.2, ISL1, PAX6, NEUROD, PDX1, HB9, GHRL, IAPP, INS GCG, SST, PP, and / or C-peptide markers is greater than the expression of NGN3, MAFA, MOX1, CER, POU5F1, AFP, SOX7, SOX1, ZIC1 and / or NFM markers in at least about 2% of the human cells. In another embodiment, in at least about 5% of human cells, in at least about 10% of human cells to 95% of human cells, or in at least about 98% of human cells, the expression of MAFB, SYP, CHGA, NKX2.2, ISL1, PAX6, NEUROD, PDX1, HB9, GHRL, IAPP INS GCG, SST, PP, and / or C-peptide markers is greater than the expression of NGN3, MAFA, MOX1, CER, POU5F1, AFP, SOX7, SOX1, ZIC1 and / or NFM markers.

[0306] In a specific embodiment of the present invention, a cell culture and / or cell population comprising immature pancreatic islet hormone-expressing cells also comprises a medium comprising one or more secretory hormones selected from ghrelin, insulin, somatostatin, and / or glucagon. In another embodiment, the medium comprises C-peptide. In a preferred embodiment, the concentration of one or more secretory hormones or C-peptides in the medium is in the range of at least about 1 pmol of ghrelin, insulin, somatostatin, glucagon, or C-peptide per 1 µg of cell DNA to at least about 1000 picomoles (pmol) of ghrelin, insulin, somatostatin, glucagon, or C-peptide per 1 µg of cell DNA.

[0307] Method of producing insulin in the body

[0308] In some embodiments, the pancreatic progenitor cells or PDX-1-positive pancreatic endoderm-type cells or equivalents derived in vitro as described above are transplanted into a mammalian subject. These methods are described in detail in international application PCT / US2007 / 015536 ​​(titled "METHODS OF PRODUCING PANCREATIC HORMONES") and in the aforementioned document [Kroon et al. (2008)]. In a preferred embodiment, the mammalian subject is a human subject. A particularly preferred subject is one identified as having a pathological condition that limits the subject's ability to produce sufficient levels of insulin in response to physiologically high blood glucose concentrations. A wide range of blood glucose levels constituting physiologically high blood glucose levels for any specific mammalian species can be easily determined by a person skilled in the art. Any persistent blood glucose level causing an accredited disease or pathological condition is considered to be a physiologically high blood glucose level.

[0309] Further embodiments of the present invention relate to in vivo insulin-secreting cells derived from in vitro pluripotent stem cells or their progeny, e.g., pluripotent cells, such as PDX-1 positive foregut endoderm cells, PDX-1 positive pancreatic endoderm or pancreatic progenitor cells, endocrine progenitor / precursor cells, such as NGN3 positive endocrine progenitor / precursor cells, or functionally differentiated hormone-secreting cells, such as insulin, glucagon, somatostatin, ghrelin, or pancreatic polypeptide-secreting cells. Any of the aforementioned terminally differentiated or pluripotent cells may be transplanted into a host or mammal and may mature into physiologically functional hormone-secreting cells, such as insulin-secreting cells, in response to host blood glucose levels. In a preferred embodiment, the cells do not form a teratoma in vivo, and if so, remain localized in the transplantation area and can be easily excised or removed. In a particularly preferred embodiment, the cell does not contain any karyotype abnormalities during the in vitro differentiation process, in vivo when transplanted into a mammal, or when matured in vivo and developed into a functional island.

[0310] In addition, although the embodiments described herein relate to engineered or genetically modified pluripotent cells, pluripotent or differentiated cells derived from pluripotent cells, such as human iPS cells, based on the description provided herein, since iPS cells exhibit physiological and gene marker expression profiles similar to those of hES cells and hES-derived cells, they are expected to have similar physiological characteristics in vivo.

[0311] Method of encapsulating pancreatic striatum

[0312] In some embodiments, the pluripotent, multipotent, and differentiated cell compositions described herein may be encapsulated within a biological and / or non-biological mechanical device, wherein the encapsulated device separates and / or isolates the cell compositions from a host.

[0313] A method of encapsulation is described in detail in U.S. application 61 / 114,857 (filed November 14, 2008, with the English title "ENCAPSULATION OF PANCREATIC PROGENITORS DERIVED FROM HES CELLS") and U.S. application 61 / 121,086 (filed December 12, 2008, with the English title "ENCAPSULATION OF PANCREATIC ENDODERM CELLS").

[0314] In one embodiment, the encapsulation device contains pluripotent derived cells, e.g., PDX-1 positive foregut endoderm cells, PDX-1 positive pancreatic endoderm or progenitor cells, endocrine or endocrine progenitor / precursor cells, e.g., NGN3 positive endocrine progenitor / precursor cells, or functionally differentiated hormone-secreting cells, e.g., insulin, glucagon, somatostatin, ghrelin, or pancreatic polypeptide-secreting cells, within a semipermeable membrane, wherein the membrane prevents the passage of the transplanted cell population to keep them within the device, while simultaneously allowing the passage of specific secreted polypeptides, e.g., insulin, glucagon, somatostatin, ghrelin, pancreatic polypeptide, etc. Alternatively, the device has a plurality of membranes including an angiogenic membrane.

[0315] Use of agents to enhance and promote the growth, survival, proliferation, and cell-cell adhesion of human pluripotent stem cells, e.g., hES cells and iPS cells

[0316] Cellular regulation can be influenced by the transmission of extracellular signals across membranes, which in turn regulate intracellular biochemical pathways. Protein phosphorylation represents a process in which intracellular signals propagate from molecule to molecule, ultimately leading to a cellular response. These signaling cascades are highly regulated and often redundant, as evidenced by the presence of numerous protein kinases as well as phosphatases. In humans, protein tyrosine kinases are known to play a significant role in the development of numerous disease states, including diabetes and cancer, and have also been reported to be associated with a wide range of congenital syndromes. Serine threonine kinases, such as Rho kinases, constitute a class of enzymes that, if inhibited, may be relevant for the treatment of human diseases, including diabetes, cancer, various inflammatory cardiovascular disorders, and AIDS. Most inhibitors identified to date act on the ATP-binding site. These ATP-competitive inhibitors have demonstrated selectivity through their ability to target poorly conserved regions of the ATP-binding site.

[0317] The Rho kinase family of small GTP-binding proteins contains more than 10 members, including Rho AE and G, Rac 1 and 2, Cdc42, and TC10. Inhibitors are often referred to as ROK or ROCK inhibitors or Rho-kinase inhibitors, and these terms are used interchangeably herein. The effector domains of RhoA, RhoB, and RhoC have identical amino acid sequences and appear to have similar intracellular targets. Rho kinases act as major downstream mediators of Rho and exist in two isoforms: α (ROCK2) and β (ROCK1). Rho kinase family proteins have a catalytic (kinase) domain in their N-terminal domain, a coiled-coil domain in their middle region, and a putative pleckstrin-homologous (PH) domain in their C-terminal region. The Rho-binding domain of ROCK is located at the C-terminal portion of the coiled-coil domain, and the binding of Rho in its GTP-binding form results in the enhancement of kinase activity. The Rho / Rho-kinase-mediated pathway plays a crucial role in signal transduction initiated by numerous agonists, including angiotensin II, serotonin, thrombin, endothelin-1, norepinephrine, platelet-derived growth factor, ATP / ADP and extracellular nucleotides, and urotensin II. Through the modulation of their target effectors / substrates, Rho kinase plays a vital role in various cellular functions, including smooth muscle contraction, actin cytoskeleton organization, cell adhesion and motility, and gene expression. Due to the role Rho kinase plays in mediating numerous cellular functions thought to be associated with the pathogenesis of atherosclerosis, inhibitors of this kinase may also be useful in the treatment or prevention of various atherosclerotic cardiovascular diseases and may be involved in endothelial contraction.

[0318] In some embodiments, agents that promote and / or support cell growth, survival, proliferation and cell-cell adhesion, including but not limited to Rho-kinase inhibitors Y-27632, Fasudil (also referred to as HA1077), H-1152P and ITS (insulin / transferrin / selenium; Gibbco), Wf-536, Y-30141 (described in U.S. Patent No. 5,478,838) and derivatives thereof, and antisense nucleic acids for ROCK, RNA interference-inducing nucleic acids (e.g., siRNA), competitive peptides, antagonist peptides, inhibitory antibodies, antibody-ScFV fragments, dominant-negative variants and expression vectors thereof, are added to various cell culture medium conditions. Additionally, since other small molecule compounds are known as ROCK inhibitors, such compounds or derivatives thereof may also be used in the present invention (see, for example, U.S. Patent Application Nos. 20050209261, 20050192304, 20040014755, 20040002508, 20040002507, 20030125344 and 20030087919, and International Patent Publication Nos. 2003 / 062227, 2003 / 059913, 2003 / 062225, 2002 / 076976 and 2004 / 039796).

[0319] In the present invention, one or a combination of two or more ROCK inhibitors may also be used. These agents function, in part, by promoting the re-association of dissociated hES cells, iPS cells, or differentiated cell cultures, e.g., determinative endoderm, foregut endoderm, pancreatic endoderm, pancreatic epithelium, pancreatic progenitor populations, endocrine progenitor populations, etc. Similarly, the agents may function when cell dissociation is not performed. Increased growth, survival, proliferation, and cell-to-cell adhesion of human pluripotent stem cells were achieved (in the presence or absence of extracellular matrix components, serum, fibroblasts, FGF, or activin) regardless of whether the cells were produced from cell aggregates in suspension or from adhesion plate cultures. Increased survival of these cell populations facilitates and improves purification systems using cell sorters, and thus allows for improved cell recovery. The use of a Rho kinase inhibitor, such as Y27632, can also allow for the expansion of differentiated cell types by promoting survival during serial passage of dissociated single cells or from cryopreservation. Although a Rho kinase inhibitor, such as Y27632, has been tested on human pluripotent stem cells (e.g., hES and iPS cells) and their differentiated cells, the Rho kinase inhibitor can be applied to other cell types, such as epithelial cells, including but not limited to those of the intestine, lung, thymus, and kidney, as well as neuronal cell types such as pigment retinal epithelium.

[0320] As long as the concentration achieves the desired effect, for example, enhancing, increasing, and / or promoting cell growth, survival, proliferation, and cell-cell adhesion, the concentration of the ROCK inhibitor in the cell culture medium is not limited to that described in the following examples. A person skilled in the art will recognize that optimization of various ROCK inhibitors under various conditions may be necessary. For example, when using Y-27632, the preferred concentration may be in the range of about 0.01 to about 1000 μM, more preferably about 0.1 to about 100 μM, even more preferably about 1.0 to about 50 μM, and most preferably about 5 to 20 μM. When Fasudil / HA1077 is used, it may be used at about two or three times the concentration of Y-27632 mentioned above. When H-1152 is used, it may be used in an approximate fraction of the aforementioned Y-27632 concentration, for example, in an amount of about 1 / 10, 1 / 20, 1 / 30, 1 / 40, 1 / 50, or 1 / 60. The concentration of the ROCK inhibitor used will, in part, depend on the biological activity and efficacy of the inhibitor and the conditions under which the inhibitor is used.

[0321] The time and duration of treatment with a ROCK inhibitor may or may not be limited depending on whether the desired effect, such as growth, survival, proliferation (cell mass), and cell-cell adhesion, is enhanced and / or increased and / or promoted. However, the addition of a ROCK inhibitor may also affect differentiation in an unexpected way, as better described in Example 7. The following examples describe human pluripotent stem cell cultures and / or differentiated cell cultures treated for about 12 hours, 24 hours, 48 ​​hours, or longer.

[0322] The density of human pluripotent stem cell cultures treated with a ROCK inhibitor is also not limited, as long as it is a density at which the desired effects, such as cell growth, survival, proliferation, and cell-cell adhesion, are enhanced and / or increased and / or promoted. The cell density of seeded cells may be adjusted according to various factors, including but not limited to the use of adhesion or suspension culture, the specific formulation of the cell culture medium used, growth conditions, and the intended use of the cultured cells. An example of a cell culture density is 0.01 × 10⁻⁶. 5 cells / ml, 0.05×10⁶ 5 cells / ml, 0.1×10 5 cells / ml, 0.5×10 5 cells / ml, 1.0×10⁶ 5 cells / ml, 1.2×10 5 cells / ml, 1.4 × 10⁶ 5 cells / ml, 1.6×10 5 cells / ml, 1.8×10 5 cells / ml, 2.0×10⁶ 5 cells / ml, 3.0×10⁶ 5 cells / ml, 4.0×10⁶ 5 cells / ml, 5.0×10⁶ 5 cells / ml, 6.0×10⁶ 5 cells / ml, 7.0×10⁶ 5 cells / ml, 8.0×10⁶ 5 cells / ml, 9.0×10⁶ 5 cells / ml, or 10.0×10⁶ 5 cells / ml, or a value exceeding this, e.g., 5×10⁶ 7 Cells / mL or values ​​greater than or equal to, but not limited to, any values ​​in between, were cultured with good cell growth, survival, proliferation, and cell-cell adhesion.

[0323] Use of agonists that activate members of the TGFβ receptor family

[0324] In another embodiment, an agent that activates a member of the TGFβ receptor family, including a member of the TGFβ superfamily of growth factors, is described herein. As used herein, "members of the TGFβ superfamily" or equivalents thereof refer to more than 30 structurally related proteins comprising a subfamily including TGFβ1, TGFβ2, TF-β3, GDF-15, GDF-9, BMP-15, BMP-16, BMP-3, GDF-10, BMP-9, BMP-10, GDF-6, GDF-5, GDF-7, BMP-5, BMP-6, BMP-7, BMP-8, BMP-2, BMP-4, GDF-3, GDF-1, GDF-11, GDF8, activin βC, βE, βA and βB, BMP-14, GDF-14, MIS, inhibin alpha, Lefty1, Lefty2, GDNF, neuteurin, percepin, and artemin. Reference [Chang et al. See (2002) Endocrine Rev. 23(6):787-823.

[0325] Members of the TGFβ family may be replaced or used in combination with TGFβ signaling pathway activators, which are compounds that stimulate one or more polypeptides or interactions involved in transforming cellular properties or causing changes in cellular properties in response to TGFβ family members. The TGFβ signaling pathway includes the TGFβ family members themselves. Members of the TGFβ superfamily transmit signals to the nucleus by transmitting signals through type II and type I serine-threonine kinase receptors and intracellular effectors known as Smads. These receptors belong to two subfamilies known as type I and type II receptors, which act cooperatively to bind to ligands and transform signals (Attisano et al., Mol Cell Biol 16 (3), 1066-1073 (1996)). Ligands bind to type I and type II receptors on the cell surface and promote the activation of type I receptors through phosphorylation. In turn, these activated complexes activate intracellular Smads, which assemble into multi-subunit complexes that regulate transcription. Members of the TGF-beta superfamily are divided into two signaling subfamilies: those functionally related to the TGFβ / activin subfamily and those related to the BMP / GDF subfamily. Most TGFβ ligands are thought to bind to the type II receptor first, after which these ligand / type II receptor complexes recruit or phosphorylate the type I receptor (Mathews, LS, Endocr Rev 15:310-325 (1994); Massague, Nature Rev: Mol Cell Biol. 1, 169-178 (2000)). After the type II receptor kinase phosphorylates and activates the type I receptor kinase, the type I receptor kinase phosphorylates and activates Smad proteins. TGFβ / activin ligands can bind to TGFβ and activin type II receptors and activate Smad-2 and -3. Nodal and lephthyl signal through these activin-type pathways.BMP / GDF ligands can bind to BMP type II receptors and activate Smad 1, 5, and 8. See [Derynck, R et al. Cell 95, 737-740 (1998)]. Upon ligand stimulation, Smad translocates into the nucleus and functions as a component of the transcription complex.

[0326] TGFβ signaling is regulated positively and negatively through various mechanisms. Positive regulation amplifies the signal to a level sufficient for biological activity. TGFβ superfamily ligands bind to type II receptors, which recruit and phosphorylate type I receptors. Subsequently, type I receptors phosphorylate receptor-regulatory SMADs (R-SMADs, e.g., SMAD1, SMAD2, SMAD3, SMAD5, and SMAD8), which can then bind to common mediators, such as Smads or co-SMADs. R-SMAD / coSMAD complexes accumulate in the nucleus, where they act as transcription factors and participate in the regulation of target gene expression. For example, growth differentiation factors include 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, and 15. In one preferred embodiment, GDF8 and GDF11 are members of the TGFβ family that are also TGFβ signaling pathway activators (positive regulators). They act by binding to the extracellular ligand binding domain of the ActRII receptor and forming a complex with ActRI, leading to the inhibition of the Smad7 negative regulator and the phosphorylation of the Smad2 / Smad3 complex. The Smad2 / Smad3 complex associates with Smad4 to regulate the expression of specific genes.

[0327] As with the use of any agent, the concentration of any TGFβ superfamily member in the cell culture medium is not limited to that described in the following examples, as long as the concentration can achieve the desired effect, such as activating a member of the TGFβ receptor family. For example, when using activin, e.g., activin A and / or B, or GDF8 and GDF-11, the preferred concentration may be in the range of about 10 to about 300 nM, more preferably about 50 to about 200 nM, even more preferably about 75 to about 150 nM, and most preferably about 100 to 125 nM. A person skilled in the art can test any concentration and determine the efficacy of such concentration using standard techniques in the relevant art, and can evaluate differentiation, for example, by determining the expression and non-expression of a panel of gene markers for any cell type.

[0328] Use of agents that produce endocrine cells

[0329] In one embodiment, the present invention provides a method for producing pancreatic endoderm-lineage type populations and / or subpopulations, specifically PECs and / or pancreatic endocrine-lineage cells, by using a Notch pathway inhibitor, comprising but not limited to a gamma-secretase inhibitor, in an amount sufficient to promote endocrine differentiation and / or induce the expression of a specific marker that is a hallmark of endocrine cells and indicates endocrine differentiation. Numerous gamma-secretase inhibitors have been described. See, for example, U.S. Patent Nos. 6,756,511; 6,890,956; 6,984,626; 7,049,296; 7,101,895; 7,138,400; 7,144,910; and 7,183,303. Gamma secretase inhibitors are readily available, for example, from Calbiochem (La Jolla, California): Gamma secretase inhibitor I, (GSI I), Z-Leu-Leu-norleucine-CHO; Gamma secretase inhibitor II; Gamma secretase inhibitor III, (GSI III), N-benzyloxycarbonyl-Leu-leucinal; Gamma secretase inhibitor IV, (GSI IV), N-(2-naphtoyl)-val-phenylalanal; Gamma secretase inhibitor V, (GSI V), N-benzyloxycarbonyl-Leu-phenylalanal; Gamma secretase inhibitor VI, (GSI VI), 1-(S)-endo-N-(1,3,3)-trimethylbicyclo[2.2.1]hept-2-yl)-4-fluorophenylsulfonamide; Gamma secretase inhibitor VII, (GSI VII), menthyloxycarbonyl-LL-CHO; gamma secretase inhibitor IX, (GSI IX), (DAPT), N--[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester; gamma secretase inhibitor X, (GSI X), {1S-benzyl-4R-[1-(1S-carbamoyl-2-phenethylcarbamoyl)-1S-3-methylbutylcarbamoyl]-2R-hydroxy-5-phenylpentyl}carbamic acid tert-butyl ester; gamma secretase inhibitor XI, (GSI XI), 7-amino-4-chloro-3-methoxyisocoumarin;Gamma secretase inhibitor XII, (GSI XII), Z-Ile-Leu-CHO; gamma secretase inhibitor XIII, (GSI XIII), Z-Tyr-Ile-Leu-CHO; gamma secretase inhibitor XIV, (GSI XIV), Z-Cys(t-Bu)-Ile-Leu-CHO; gamma secretase inhibitor XVI, (GSI XVI), N-[N-3,5-difluorophenacetyl]-L-alanyl-S-phenylglycine methyl ester; gamma secretase inhibitor XVII, (GSI XVII), WPE-III-31C; Gamma secretase inhibitor XIX, (GSI XIX), (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-((3S)-2-oxo--5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine-3-yl)-butyramide; Gamma secretase inhibitor XX, (GSI XX), (dibenzazepine (DBZ)), (S,S)-2-[2-(3,5-difluorophenyl)acetylamino]-N-(5-methyl-6-oxo-6,7-dihydro--5H-dibenzo[b,d]azepine-7-yl)propionamide, gamma secretase inhibitor XXI, (GSI XXI), (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2-,3-dihydro-1H-benzo[e][1,4]diazepine-3-yl)-propionamide; gamma40 secretase inhibitor I, N-trans-3,5-dimethoxycinnamoyl-ile-le-leucinal; Gamma-40 secretase inhibitor II, N-tert-butyloxycarbonyl-Gly-Val-valinal; and isovaleryl-VV-Sta-A-Sta-OC3.;

[0330] In one aspect, gamma-secretase inhibitors are selected from the group consisting of one or more of the following, wherein the renal disease is glomerular renal disease or tubular renal disease: Z-Leu-Leu-norleucine-CHO, N-benzyloxycarbonyl-Leu-leucinal, N-(2-naphtoyl)-val-phenylalanal, N-benzyloxycarbonyl-Leu-phenylalanal, 1-(S)-endo-N-(1,3,3)trimethylbicyclo[2.2.1]hept-2-yl)-4-fluorophenylsulfonamide, menthyloxycarbonyl-LL-CHO, N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester, {1S-Benzyl-4R-[1-(1S-Carbamoyl-2-Phenethylcarbamoyl)-1S-3-Methylbutylcarbamoyl]-2R-Hydroxy-5-Phenylpentyl}carbamic acid tert-butyl ester, 7-Amino-4-Chloro-3-Methoxyisocoumarin, Z-lle-Leu-CHO, Z-Tyr-lle-Leu-CHO, Z-Cys(t-Bu)-lle-Leu-CHO, N-[N-3,5-Difluorophenacetyl]-L-Alanyl-S-Phenylglycine methyl ester, (2S,3R)-3-(3,4-Difluorophenyl)-2-(4-Fluorphenyl)-4-Hydroxy-N-((3S)-2-Oxo- -5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine-3-yl)-butyramide, (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2-,3-dihydro-1H-benzo[e][1,4]diazepine-3-yl)-propionamide, N-trans-3,5-dimethoxycinnamoyl-Ile-leucinal, N-tert-butyloxycarbonyl-Gly-Val-valinal, isovaleryl-VV-Sta-A-Sta-OCH3. In one aspect of the present invention, about 0.5 to 10 mM, 0.5 to 5 mM, 0.5 to 3 mM, preferably 0.5 to 1 mM of a gamma secretase inhibitor is used in any one or all of steps 1-7 described herein, and according to Tables 8 and 17.

[0331] In one embodiment, insulin growth factor (IGF) is part of a complex system that cells use to communicate with their physiological environment and can therefore be used to differentiate PSCs into PEC and / or pancreatic endocrine-lineage cells. This complex system (often referred to as the IGF "axis") consists of two cell-surface receptors (IGF1R and IGF2R), two ligands (insulin-like growth factor 1 (IGF-1) and insulin-like growth factor 2 (IGF-2)), a family of six high-affinity IGF-binding proteins (IGFBP-1 to IGFBP-6), as well as associated IGFBP degrading enzymes (collectively referred to as proteases). IGF is known to bind to the insulin receptor IGF1R, the insulin-related receptor IGF-2, and possibly other receptors. Accordingly, in one aspect of the invention, growth factors binding to these receptors include, but are not limited to, IGF1 and IGF2, because any growth factor, agonist, or morphogen binding to any one of these receptors or a combination thereof has potentially the same physiological effects as described and expected herein. In one aspect of the invention, about 5 to 200 ng / mL, 10 to 100 ng / mL, 10 to 75 ng / mL, preferably 10 to 50 ng / mL, preferably 20 to 50 ng / mL of IGF is used in any one or all of steps 1-7 described herein, and according to Tables 8 and 17.

[0332] In one embodiment, platelet-derived growth factor (PDGF) is used to differentiate PSCs into cells entrusted to the PEC and / or endocrine system (CHGA+). PDGF is a major protein growth factor that has been extensively described as a potent mitotic promoter for various types of cells. PDGF belongs to a family of dimeric isoforms of polypeptide chains A, B, C, and D that act through different tyrosine kinase receptors (PDGFR-α and PDGFR-β). In one aspect of the invention, the ligand is PDGF or a functional equivalent thereof, comprising but not limited to PDGFaa, PDGFab, or PDGFbb that binds to two types of receptors. In one aspect of the present invention, PDGF of about 5 to 100 ng / mL, 10 to 75 ng / mL, 10 to 50 ng / mL, preferably 10 to 20 ng / mL is used in any one or all of steps 1-7 described herein, and according to Tables 8 and 17.

[0333] In one embodiment, nicotinamide (also known as niacinamide and nicotinamide) is an amide of nicotinic acid (vitamin B3 / niacin) and is used to differentiate PSCs into PEC and / or pancreatic endocrine-lineage cells. Nicotinic acid, also known as niacin, is converted to nicotinamide in vivo, and while niacin and nicotinamide are identical in their vitamin functions, nicotinamide is not identical to niacin in pharmacological and toxic effects. Accordingly, other vitamin B or vitamin B derivatives that function similarly to nicotinamide are embodied in the present invention. In one aspect of the present invention, nicotinamide at about 5 to 100 ng / mL, 10 to 75 ng / mL, 10 to 50 ng / mL, preferably 10 to 20 ng / mL is used in any one or all of steps 1-7 described herein, and according to Tables 8 and 17.

[0334] In another embodiment, a Hedgehog family protein is used to differentiate PSCs into PEC and / or pancreatic endocrine-lineage cells. The Hedgehog family of vertebrate intercellular signaling molecules provided by the present invention consists of four or more members including, but not limited to, Desert Hedgehog (Dhh), Sonic Hedgehog (Shh), Indian Hedgehog (Ihh), and Moonrat Hedgehog (Mhh). In one aspect, Hedgehog protein at a concentration of about 5 to 200 ng / mL, 10 to 200 ng / mL, 10 to 150 ng / mL, preferably 10 to 100 ng / mL is used in any or all of steps 1-7 described herein, and according to Tables 8 and 17.

[0335] Although the invention has been described generally, further understanding may be gained by referring to specific embodiments provided herein for illustrative purposes only and not intended to be limiting.

[0336] Examples

[0337] The foregoing relates to preferred embodiments of the present invention, and it should also be understood that numerous variations may be made therein without departing from the scope of the invention. The present invention is further described by the following examples, which should not be construed as limiting the scope of the invention in any way. Conversely, it should be clearly understood that after reading this specification, one can rely on various other embodiments, modifications, and equivalents therein that present themselves to a person skilled in the art without departing from the spirit of the invention and / or the scope of the appended claims.

[0338] Example 1

[0339] Differentiation of human iPS cells into pancreatic progenitor and endocrine cells via deterministic endocrine and endocrine intermediates

[0340] Human induced pluripotent stem (iPS) cells were differentiated from suspension aggregates using a four-step procedure over a course of about two weeks (or 14 days) to generate a population of pancreatic cell types including pancreatic progenitors, endocrine progenitors, and hormone-expressing endocrine cells. The human iPS cell lines used herein were provided by S. Yamanaka of Kyoto University, Japan, and Cellular Dynamics International, Inc. (CDI).

[0341] The iPS cells described herein were first provided by Shinya Yamanaka and subsequently by CDI. Undifferentiated iPS cells were grown on mitotically inactivated mouse embryonic fibroblasts in DMEM / F12 containing 20% ​​knockout serum replacement, or preferably on feeder-free (without a fibroblast feeder cell layer). Differentiation was initiated by dissociating the undifferentiated iPS cells into single cells using accutase, and cell samples were taken for RNA isolation and analysis. Cells were resuspended at 1-2 million cells / mL in RPMI + 0.2% vol / vol FBS containing a 1:5000 dilution of insulin-transferrin-selenium (ITS), Activin A (100 ng / mL), wnt3a (50 ng / mL), and 10 μM of the rho-kinase or ROCK inhibitor Y-27632, placed in ultra-low attachment 6-well plates, placed on a spinning platform, and spun at approximately 100 rpm. The cultures were spun at 100 rpm for the remainder of the differentiation process while changing the medium daily. The growth, passage, and proliferation of iPSCs were substantially as described in U.S. Patent Nos. 7,961,402 and 8,211,699.

[0342] The method described herein for producing pluripotent cells, e.g., hES or iPS cells, and aggregate suspension cultures of cells derived from pluripotent cells is substantially the same as described in PCT / US2007 / 062755 (filed February 23, 2007, with the English title "Compositions and methods for culturing differential cells") and PCT / US2008 / 080516 (filed October 20, 2008, with the English title "Methods and compositions for feeder-free pluripotent stem cell media containing human serum").

[0343] The method described herein can be facilitated by first coating a culture vessel with an extracellular matrix, for example, as described in U.S. Patent 6,800,480 (assigned to Geron Corporation) by Bodnar et al. Like other methods for culturing other pluripotent stem cells, e.g., hES and iPS cells, this method can be cultured using soluble human serum, substantially as described in U.S. Application PCT / US2008 / 080516 (filed October 20, 2008, with the English title "Methods and compositions for feeder-free pluripotent stem cell media containing human serum").

[0344] The method described herein can be facilitated by exogenously added fibroblast growth factor (FGF) supplied from a source other than the fibroblast feeder layer, as described in Thomson, Jay’s U.S. Patent No. 7,005,252 (assigned to the Wisconsin Alumni Research Foundation (WARF)).

[0345] During the first 24 hours of rotation, single cells attached to their respective different formed cell aggregates, and sufficient cell samples were taken for RNA isolation and analysis. The cell aggregates ranged in diameter from approximately 60 to 120 micrometers. About 1 day (or 24 hours) after placing the iPS cells on the rotation platform, the culture was fed RPMI + 0.2% vol / vol FBS containing a 1:5000 dilution of ITS, Activin A (100-200 ng / mL), and Wnt3a (50-100 ng / mL) for about 1 day (0:00 to Day 1), and then placed in the same medium without Wnt3a for additional days (Days 1 to 2). Cell samples were taken daily for RNA isolation and analysis. After 2 days of differentiation, the culture was supplied with RPMI + 0.2% vol / vol FBS containing a 1:1000 dilution of ITS, KGF (or FGF7, 25 ng / mL), and TGFβ inhibitor No. 4 (2.5 μM) for 1 day (or 24 hours, days 2 to 3). For the next 2 days (days 3 to 5), the same growth factor cocktail medium was supplied to the iPS cell aggregate suspension, except that the TGFβ inhibitor was removed from the culture medium. Again, at the end of these steps (step 2, or day 5), cell samples were taken for RNA isolation. For Step 3 (Days 5 to 8), the cell culture medium was changed to DMEM + 1% vol / vol B27 supplement containing TTNPB [4-[E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid] (3 nM), KAAD-cyclopamine (0.25 μM), and Nogin (50 ng / mL). Again, at the end of these steps (Step 3, Day 8), cell samples were taken for RNA isolation and analysis.For Step 4 (Days 8 to 14), the medium was changed to DMEM + 1% vol / vol B27 supplement containing Nogin (50 ng / mL), KGF (50 ng / mL), and EGF (50 ng / mL). Again, at the end of Step 4 (or Day 14), cell samples were taken for RNA isolation and analysis.

[0346] Real-time PCR was performed to measure gene expression for various marker genes during the differentiation process. The gene expression of specific markers or genes was first standardized against the average expression levels of the housekeeping genes, cyclophyllin G and TATA-binding protein (TBP). Subsequently, the standardized relative gene expression was displayed in a bar graph relative to the expression levels in undifferentiated iPS cells, thereby indicating the upregulation of the various differentiation markers. In the case of OCT4, gene expression was standardized to the lowest sample (Day 14) within the dataset, thus indicating the downregulation of the gene during the differentiation process.

[0347] Figures 2a-1 are bar graphs showing the relative gene expression of identified genes (e.g., Oct4, Brachiuri, Cer1, GSC, FOXA2, FOXA1, HNF6, PDX1, PTF1A, NKX6.1, NGN3, and INS) relative to the expression levels of the same genes in undifferentiated iPS cells. The expression levels of the genes were standardized against a set of housekeeping genes (control), and comparing the gene expression levels at two different time points indicated whether there was upregulation or downregulation for these genes or expression markers. In the case of OCT4 (Figure 2a), gene expression was standardized, and the lowest level expression sample was set to 1 (Day 14). Thus, as indicated in Figure 2a, the relative expression level of OCT4 represents multiple downregulation (Y-axis) during the differentiation process (X-axis, stages 0 to 4, or Day 0 to Day 14).

[0348] As shown in Fig. 2a, OCT4 (POU5F1) is expressed at high levels in undifferentiated iPS cells and exhibits subsequent downregulation during the differentiation process (Days 0 to 14). On Day 14, the expression level of OCT4 decreased by more than 3,000-fold from the expression level observed in undifferentiated cells. In contrast, there was a transient upregulation of Brachiuri gene (Brachiuri, Fig. 2b) expression during the first two days (Days 1 and 2). The transient upregulation of Brachiuri was a result of the directed differentiation of pluripotent / iPS cells into the mesoendodermis by the application of Activin A and wnt3a. The differentiation of the mesoendodermis into the definitive endoderm during Days 2 and 3 by sustained exposure to Activin A was indicated by the upregulation of CER1, GSC, and FOXA2 towards the end of Stage 1 on Day 3 (Fig. 2c-e). During stage 2, the definitive endoderm was further directed to differentiate into the enteroventricular endoderm, as indicated by the upregulation of FOXA1 on day 6 of differentiation, the maintenance of FOXA2 expression, and the downregulation of CER1 and GSC (Fig. 2c-f). During stage 3, when exposed to retinoids, cyclopamine, and nogin, the enteroventricular endoderm was further directed to differentiate into the late foregut / PDX1-expressing endoderm, as indicated by the upregulation of HNF6 and PDX1 on day 8 (Fig. 2g-h). During stage 4, when exposed to KGF and EGF, the late foregut / PDX1-expressing endoderm was further directed to differentiate into the pancreatic progenitor, endocrine progenitor, and hormone-expressing endocrine cells, as indicated by the upregulation of PTF1A, NKX6-1, NGN3, and INS on day 14 (Fig. 2i-l).

[0349] Example 2

[0350] RHO-kinase inhibitors promote the growth, survival, proliferation, and cell-cell adhesion of IP cells.

[0351] The method for differentiating various hES and iPS cell lines is substantially as described herein and Example 1. In addition to the culture conditions described for steps 1, 2, 3, 4, and 5, apoptosis inhibitors and / or Rho-kinase or ROCK inhibitors were added to the culture medium to enhance and promote growth, survival, proliferation, and cell-cell adhesion during differentiation. Typically, about 10 μM of a Rho-kinase inhibitor, e.g., Y-27632, was added to the cell culture for each step. Alternatively, a Rho-kinase inhibitor was added at least to steps 1 and 2 and steps 4 and 5, or any combination thereof. The morphology and gene marker expression profiles of the differentiated iPS suspension (aggregate) cell cultures are substantially similar to those of suspension cell cultures derived from hES cells.

[0352] Figures 3 and 4 show the immunocytochemistry (ICC) of iPS cell cultures from steps 4 and 5, respectively. Figure 3 shows cell aggregates from step 4 expressing typical gene markers characteristic of the PDX1-positive pancreatic endoderm (also referred to as pancreatic epithelium or pancreatic progenitor), including PDX1 / NKX6.1 co-positive cells. Although not shown in Figure 3, step 4 cells do not express hormone-secreting proteins or gene markers, such as insulin (INS), glucagon (GCG), somatostatin (SST), and pancreatic polypeptide (PP), which are more typical of step 5 cells. Figure 4 shows cell aggregates of hormone-expressing cells from step 5. These ICC results were further confirmed using QPCR. However, because QPCR is a whole-population study of the total level of RNA expressed in a sample or cell culture, it cannot definitively indicate that any single cell expresses multiple markers.

[0353] Example 3

[0354] Encapsulation of IPS-derived pancreatic progenitors

[0355] To date, methods for producing IPS cells and sources for producing IPS cells have been reported. However, differentiating any IPS cells into any functionally differentiated cells for potential use in cell therapy to treat specific diseases, e.g., diabetes, has not been sufficiently described.

[0356] To determine whether step 4 PDX1-positive pancreatic endodermal or pancreatic progenitor cell cultures derived from human iPS cells could sufficiently develop and mature into glucose-sensitive insulin-secreting cells in vivo, pancreatic progenitor populations substantially as described in Examples 1 and 2 were loaded into a macroencapsulation device substantially similar to that described in U.S. Application 12 / 618,659 (titled "ENCAPSULATION OF PANCREATIC LINEAGE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS," filed November 13, 2009); and U.S. Patent Nos. 7,534,608 and 7,695,965 (titled "METHODS OF PRODUCING PANCREATIC HORMONES"). Briefly, approximately 5–10–20 µl of gravity-settled cell suspension aggregates were loaded into each device, substantially about 3 × 10⁶ 6 There were dogs' cells.

[0357] Subsequently, the encapsulated cells within the device were prepared for transplantation into mammals, immune-impaired SCID / Bg mice, but may be transplanted into larger animals including rats, pigs, monkeys, or human patients. The method of transplanting the encapsulated cells and the device is substantially as described in U.S. Patent Application No. 12 / 618,659, U.S. Patent No. 7,534,608, and 7,695,965, including pancreatic progenitor cells transplanted on a GELFOAM matrix and transplanted under the epididymal fat pad (EFP).

[0358] Although immunosuppression was not essential in these studies, in certain animals, immunosuppression may be necessary for an initial transient period until the striae within the apparatus are sufficiently mature and responsive to glucose. In some mammals, immunosuppressive therapy may be for about 1, 2, 3, 4, 5, 6 weeks or longer, and will depend on the mammal.

[0359] The transplanted cells were allowed to differentiate and further mature in vivo. To determine whether the transplanted cells possess normal physiological functions, such as those of naturally occurring beta cells, for example, the level of human insulin will be determined by testing the level of human C-peptide. Human C-peptide is cleaved or processed from human pro-insulin; therefore, specifically detecting human C-peptide rather than endogenous mouse C-peptide indicates that insulin secretion originates from the transplanted (exogenous) cells. The animals with the graft will be tested for human C-peptide levels approximately every 2, 3, or 4 weeks by injecting a bolus of arginine or glucose, preferably glucose. Subsequently, the matured beta cells (derived from differentiated pluripotent iPS cells) must be physiologically functional and responsive to glucose, no different from naturally occurring or endogenous beta cells. Typically, the average baseline (threshold) level or an amount of human C-peptide greater than 50 pM is an indicator of the function of current beta cells from transplanted progenitors.

[0360] Similar to the literature [Kroon et al. (2008)], U.S. Application 12 / 618,659, and U.S. Patent Nos. 7,534,608; 7,695,965 and 7,993,920, encapsulated pancreatic progenitors derived from hIPS cells are expected to mature into functional pancreatic islet clusters containing endocrine, acinar, and tubular cells, no different from naturally occurring islets. Purified or enhanced pancreatic progenitors derived from pre-transplant hIPS cells are also expected to mature and develop into functional pancreatic islets in vivo and produce insulin. Specific embodiments for the purification and enrichment of various differentiated cell populations are described in more detail in U.S. Application 12 / 107,020 (titled “METHODS FOR PURIFYING ENDODERM AND PANCREATIC ENDODERM CELLS DERIVED FROM HES CELLS”, filed April 8, 2008, and currently U.S. Patent 8,338,170). It is further anticipated that pancreatic progenitors derived from cryopreserved hIPS cells can be thawed prior to transplantation and modified in a culture, thereby maturing in vivo to produce insulin. Hypoglycemia may be improved in diabetic animals transplanted with pancreatic progenitors derived from hIPS cells.

[0361] In summary, pancreatic progenitor cells derived from fully encapsulated hIPS cells within a macroencapsulation device are expected to mature into physiologically functional pancreatic islets and produce insulin in response to glucose in vivo.

[0362] Example 4

[0363] Pancreatic progenitor and hormone-secreting cell composition

[0364] Differentiated hIPS cell populations were analyzed using flow cytometry for PDX1-positive pancreatic endoderm or pancreatic progenitor cell content (Step 4); and endocrine or endocrine progenitor / progenitor cell content (Step 5), as presented in Tables 6a, 6b, and 7, respectively. Table 6b contains the same dataset as in Table 6a but is presented similarly to that in Table 10 for comparison. The populations in Table 6a overlap with each other; for example, the total cell count exceeds 100% because the total number of PDX1+ and NKX6.1+ cells overlaps with that of the NKX6.1+ / PDX1+ / CHGA- cell population (the 5th column of Table 6a). Table 6b includes PDX1+ alone and triple-negative (remainder) data not presented in Table 6a. Some of these iPEC grafts, as well as others using substantially similar agents, were transplanted into animals to determine in vivo function, but human serum C-peptide levels were not robust enough for any potential therapeutic purpose (data not presented). The values ​​presented are the percentage of total cells belonging to a given population. The very small populations of pancreatic progenitors (NKX6.1(+) / PDX1(+) / chromogranin A(-)) and NKX6.1+ / PDX1- / CHGA- within the suspension cell aggregates were consistent with those observed in pancreatic progenitor cell suspension aggregates derived from hES cells and aggregated at the ESC stage, as described in U.S. Application 12 / 264,760 (English title: "STEM CELL AGGREGATE SUSPENSION COMPOSITIONS AND METHODS OF DIFFERENTIATION THEREOF", filed November 4, 2008).The levels of endocrine and / or endocrine progenitor / progenitor cells were also substantially consistent with those obtained from hES-derived cell cultures in U.S. Application 12 / 107,020 (English title: "METHODS FOR PURIFYING ENDODERM AND PANCREATIC ENDODERM CELLS DERIVED FROM HES CELLS", filed April 8, 2008). Similar to hES-derived cell suspension aggregates, varying the concentrations of various growth factors in the culture medium at a specific differentiation stage (e.g., stage 4) should increase and / or decrease specific populations of pancreatic endoderm, endocrine, PDX1-positive endoderm, or non-pancreatic cell types.

[0365]

[0366] Step 4 Pancreatic progenitor cell composition (percentage of total cells)

[0367]

[0368]

[0369] Step 4 Pancreatic progenitor cell composition (percentage of total cells)

[0370]

[0371] Table 7

[0372] Step 5 Endocrine cell composition (percentage of total cells)

[0373]

[0374] Example 5

[0375] PEC receptor tyrosine kinase

[0376] The methods described above are substantially similar to those described in Table 8 below, which were adapted from the aforementioned document [Schulz et al., (2012)]. These methods and other methods described herein can be found in the applicant’s numerous patent and non-patent publications, including U.S. Patent Nos. 7,964,402; 8,211,699; 8,334,138; 8,008,07; and 8,153,429.

[0377] Table 8

[0378] Standard production method for manufacturing pancreatic endoderm cells (PEC) derived from hESCs

[0379]

[0380] hESC Agg. : hESC aggregates; XF HA : DMEM / F12 containing GlutaMAX supplemented with 10% v / v xeno-free knockout serum replacement, 1% v / v non-essential amino acids, 0.1 mM 2-mercaptoethanol, 1% v / v penicillin / streptomycin (all Life Technologies), 10 ng / mL heregulin-1β (Peprotech), and 10 ng / mL activin A (R&D Systems); SP : StemPro® hESC SFM (Life Technologies); r0.2FBS : RPMI 1640 (Mediatech); 0.2% FBS (HyClone), 1× Glutamax-1 (Life Technologies), 1% v / v penicillin / streptomycin; ITS : 1:5000 or 1:1000 diluted insulin-transferrin-selenium (Life Technologies); A100 : 100 ng / mL Recombinant Human Activin A (R&D Systems); W50 : 50 ng / mL recombinant mouse Wnt3A (R&D Systems); K25: 25 ng / mL Recombinant Human KGF (R&D Systems); IV : 2.5 μM TGF-β RI kinase inhibitor IV (EMD Bioscience); db : DMEM High Glucose (HI Glucose) supplemented with 0.5× B-27 supplement (Life Technologies), 1× Glutamax, and 1% v / v penicillin / streptomycin (Hyclone); CTT3 : 0.25 μM KAAD-cyclopamine (Toronto Research Chemicals) and 3 nM TTNPB (Sigma-Aldrich); N50 : 50 ng / mL Recombinant Human Nogin (R&D Systems); K50 : 50 ng / mL Recombinant Human KGF (R&D Systems); E50 : 50 ng / mL Recombinant Human EGF (R&D Systems); No supply : Indicates that it was not resupplied to the cell on the specified day; db , DMEM (high-glucose).

[0381] When the above methods were applied to iPS cells and pancreatic progenitors transplanted into animals, the applicant did not consistently obtain the same robust in vivo function compared to when the same methods were applied to hESCs and hES-derived pancreatic progenitors. It was unexpected that iPS cells, which are human pluripotent stem cells possessing the morphology and gene-expression patterns of hESCs and capable of forming both embryoids in vitro and teratomas in vivo, would indicate that they can form cells from all three germ layers. At least, refer to the literature [Yu et al. (2007)]; U.S. Patent Application Publication No. 2009 / 0047263, International Patent Application Publication No. WO2005 / 80598; U.S. Patent Application Publication No. 2008 / 0233610; and International Patent Application Publication No. WO2008 / 11882. These references state that iPS cells meet the definitional criteria of ESCs. Therefore, it is expected that iPS cells can replace ESCs in an in vitro differentiation protocol that yields hES-derived pancreatic progenitor cells that further mature and develop into sufficiently functional glucose-responsive cells in vivo. However, due to the inconsistency in in vivo functionalization data using the above method, the applicant has sought to explore a unique differentiation medium formulation for pancreatic progenitor and / or pancreatic endoderm cells (PEC), namely stage 4 cells derived from hiPSCs (or "iPEC"), that can provide substantially similar robust levels of in vivo function to those consistently observed for PECs derived from hESCs.

[0382] The applicant has previously reported that the endocrine cells (CHGA+ cells) present in the PEC are multihormonal endocrine cells and are not a subgroup of cells within the PEC that result in islets containing glucose-responsive insulin-secreting cells in vivo. See the aforementioned reference [Kelly et al. (2011)]. Rather, the non-endocrine cell population (CHGA- cells), particularly those co-expressing NKX6.1 and PDX-1, is considered to be the PEC that actually results in functional islets in vivo. Accordingly, the applicant investigated whether adjusting, changing, or mutating the relative ratios of the endocrine and non-endocrine subgroups would affect subsequent in vivo function.

[0383] Previous efforts to elucidate receptor-ligand signaling within hESCs have successfully identified growth factors that promote self-renewal and enabled the development of regulated culture conditions. See the aforementioned literature [Wang et al (2007)]. Wang et al. identified heregulin-1β as a ligand that influences hESC self-renewal by binding to ERBB3 and inducing dimerization with ERBB2. ERBBs are receptor tyrosine kinases (RTKs), which are widely expressed transmembrane proteins that act as receptors for growth factors and other extracellular signaling molecules. Upon ligand binding, tyrosine phosphorylation at specific residues within the cytoplasmic tail and the initiation of a signaling cascade for the binding of other protein substrates involved in RTK-mediated signaling proceed to these proteins. RTKs function in various developmental processes, including the regulation of cell survival, proliferation, and motility, and their role in cancer formation is well documented. It is also known that ERBB tyrosine kinase receptors are expressed throughout the development of the human fetal pancreas, but the specific roles of particular ERBB receptors and their ligands are unknown. See [Mari-Anne Huotari et al. (2002) ERBB Signaling Regulates Lineage Determination of Developing Pancreatic Islet Cells in Embryonic Organ Culture, Endocrinology 143(11): 4437-4446].

[0384] Due to the role of ERBB RTK signaling in pluripotent stem cell self-renewal and its expression in human fetal pancreas, as demonstrated in the aforementioned literature [Wang et al. (2007)], and due to ERBB RTK expression in human fetal pancreas, the applicant shifted from efforts to identify receptors and ligands capable of improving PEC characteristics during differentiation to investigating potential activation of RTKs in in vitro pancreatic endoderm cells (PEC) derived from hESCs, expansion through the promotion of self-renewal, or some other unknown mechanisms promoting maturation into physiologically functional islet hormone-secreting cells in vivo. PECs were generated from dividing aggregates in suspension substantially as described in Table 8, except for the following modifications.

[0385] Four PEC samples were generated for RTK blotting analysis. "Steady-state" samples of PEC aggregates within db-N50 K50 E50 were collected at the end of Step 4 (or d13). "Depleted" samples represented d12 PEC aggregates collected on d13, fed with db medium alone (no growth factors) (DMEM high-glucose or DMEM high-glucose supplemented with 0.5× B-27 supplement (Life Technologies)). Two "pulse" samples were cultured with db medium on d12, followed by db-K50 E50 medium or db medium containing 2% FBS on d13, 15 minutes prior to harvest. These conditions were intended to detect RTKs active under Step 4 conditions, and to determine which responses could be elicited by pulses of KGF, EGF, insulin (present in B27 supplement), or serum. Serum pulses are intended as photospectral growth factor stimulation, and potentially RTKs that are present in PEC and can be activated but are not stimulated under current stage 4 conditions have been identified.

[0386] Essentially, RTK analysis was performed as previously described in the aforementioned literature [Wang et al, (2007)]. Briefly, the Proteome Profiler™ Human Phospho-RTK Antibody Array (R&D Systems) was used according to the manufacturer's instructions. Protein lysates were prepared in 1% NP-40, 20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 2.0 mM EDTA, 1.0 mM sodium orthovanadate, 10 µg / mL aprotinin, and 10 µg / mL leupeptin. 500 µg of fresh protein lysates were incubated overnight with nitrocellulose membranes dotted with 42 anti-RTK antibodies and 5 negative control antibodies, as well as 8 anti-phosphotyrosine positive control spots (Fig. 5a). The arrayed antibodies capture the extracellular domains of both phosphorylated and non-phosphorylated RTKs, and the bound phospho-RTKs are detected by chemiluminescence as pan-anti-phospho-tyrosine antibodies conjugated to horseradish peroxidase (HRP). Refer to Figure 5 for the RTK array, as well as Table 9 below for the list of RTKs in the array.

[0387] Table 9

[0388] List of RTKs for PEC Receptor Tyrosine Kinase (RTK) Analysis

[0389]

[0390]

[0391] RTK blot (Fig. 6A) indicated that insulin- and IGF1-receptors (IR and IGF1R, respectively) were phosphorylated and activated under all conditions, similar to what was previously observed with hESC. See reference [Wang et al. (2007)]. The EGF receptor (EGFR (also known as ERBB1)) was phosphorylated under steady-state conditions, which was expected in the presence of EGF in the Step 4 medium. Indeed, low-level phosphorylation of ERBB2 was detected under both steady-state and depletion conditions. Phosphorylation of both EGFR and ERBB2 was elevated under their respective pulse conditions, confirming the assay's ability to detect pulse-responsive activation of ligands. Phosphorylated VEGFR3 was also detected under all conditions and was elevated in pulse samples. This suggests that PEC produces endogenous VEGFR3 ligands, with possible candidates being VEGF-C and D. Serum pulses appeared to activate additional receptors, including low-level ERBB3 phosphorylation. The detection of phosphorylated ERBB2 / 3 suggests that hereguline-like EGF-family members can activate signaling in PEC. TIE-2 is one of two angiopoietin receptors and appears to be phosphorylated to low levels in response to serum. Angiopoietin 1 and angiopoietin 4 are known to be activating ligands of TIE-2, whereas angiopoietin 2 and angiopoietin 3 function as context-dependent competitive antagonists. The HGF-receptor (HGFR) was also phosphorylated in response to serum pulses, suggesting that hepatocyte growth factor can also elicit signaling in PEC. Finally, while low-level phosphorylation of ephrin B2 RTK (EPHB2) was detected, ephrin / Eph signaling is a membrane-bound cell-to-cell signaling system and is unlikely to be readily utilized in PEC differentiation. Interestingly, ERBB4 was not phosphorylated.Therefore, RTK analysis highlighted several receptors in PEC that are phosphorylated or can be phosphorylated in response to different conditions, e.g., serum. These results suggest that various soluble ligands can elicit RTK signaling in PEC and potentially influence cell proliferation, differentiation, and / or specificity, and thus potentially influence subsequent maturation into functional pancreatic islets in vivo.

[0392] Example 6

[0393] Heregulin and FGF2 growth factor affect PEC derived from hESC composition

[0394] Considering the RTK analysis in which specific RTKs were proven to be activated (or phosphorylated) under specific conditions as described above in Example 5, and because at least ERBB2 and ERBB3 appeared to be activated in PEC (after 13 days of differentiation from stages 1-4), the applicant attempted to determine the effect of heregulin when applied to stage 3 and 4 cells.

[0395] Preliminary studies were conducted using hereguline and FGF. In some of these studies, the Rho-kinase inhibitor Y-27632 was included. These preliminary studies indicated that treating pluripotent stem cells with 10 ng / mL hereguline-1β (the same concentration and hereguline isomer as disclosed in [Wang et al. (2007)]) for 1 day in Step 1 increased the cell aggregate size of hES-derived cell aggregates in suspension culture compared to the aggregate size of hES-derived cells in suspension culture without hereguline-1β (Hrg1β). The increase in cell aggregate size is advantageous in that it results in higher cell mass for subsequent transplantation and functional testing in animals. Additionally, when Hrg1β was increased from 10 ng / mL to 50 ng / mL in Step 3, the aggregate disk size increased. These results were also observed when another growth factor, FGF2, was used at 50 ng / mL in step 3 compared to cultures in the absence of FGF2. An increase in cell aggregate size was also observed when step 3 cultures were exposed to FGF2 for an additional day, for example, when exposed to 50 ng / mL FGF2 for 3 days compared to 2 days.

[0396] Table 10 provides a summary of the flow cytometry analysis of PEC cells treated with Hrg1β and FGF2 in Step 3. Endocrine cells are labeled as CHGA-positive (or CHGA+) cells, and non-endocrine cells are labeled as CHGA-negative (or CHGA-) cells. Endocrine (CHGA+) and non-endocrine (CHGA-) cells may stain positive for other markers, e.g., PDX1 and / or NKX6.1. Cells that do not stain for any of the tested markers are labeled as triple-negative cells or the remainder (CHGA- / NKX6.1- / PDX1).

[0397]

[0398] Flow cytometry analysis of PECs derived from hESCs and treated with heregulin and / or FGF2

[0399]

[0400] Hg , heregulin-β; FGF2 , fibroblast growth factor 2; Hrg10 , 10 ng / mL heregulin-1β; Hrg50 , 50 ng / mL heregulin-1β; 2d FGF-50, 50 ng / mL of FGF2 for 2 days of Step 3; 3d FGF2-50, 50 ng / mL of FGF2 for 3 days in Step 3

[0401] To determine whether the increase in cell aggregate size affected the PEC subgroups, the composition of the PEC subgroups was analyzed by flow cytometry. Compared to control cultures in which Hrg1β and FGF2 were not used to differentiate cells, the PEC non-endocrine subgroup (CHGA-) increased from 54.01% to 61.2% with the addition of 10 ng / mL Hrg1β at Step 3 and from 54.01% to 64.2% with the addition of 50 ng / mL Hrg1β at Step 3. The endocrine subgroup (CHGA+) was not significantly affected by treatment with 10 ng / mL Hrg1β, but was even more so with 50 ng / mL. At the same time, the relative levels of the remaining cells decreased, and were even more so with 50 ng / mL Hrg1β. Therefore, the increase in cell aggregate size upon Hrg1β treatment was largely attributed to the increase in the non-endocrine subgroup compared to the endocrine and other subgroups.

[0402] The effect of FGF2 on the step 3 cultures was similar to that of Hrg1β, but was more pronounced than that for Hrg1β. For example, the PEC non-endocrine subgroup (CHGA-) increased as it did for Hrg1β. The main effect of FGF2 on these cultures was a substantial decrease in the endocrine subgroup. In some cases, these cells were almost undetectable after 3 days of treatment (32.9% → 0.33%). Thus, the increase in cell aggregate size for the FGF2-treated cultures was largely attributed to the increase in the non-endocrine subgroup, and in some cases, to the increase in the remaining subgroup (13.1% → 22.7% for 3 days in step 3).

[0403] Therefore, it appears that hereguline and / or FGF2 play a specific role in the cells within the PEC population. This is unexpected considering that in the aforementioned literature [Wang et al (2007)], hereguline alone was reported to play a role in cell regeneration when used in the context of pluripotent stem cells.

[0404] Example 7

[0405] Method for improving in vivo graft function of PEC by treating IP-derived cell cultures with heregulin

[0406] Because the method according to Table 8 did not provide robust in vivo function in animals when applied to iPSCs to produce iPECs, the applicant explored other methods for producing iPECs. Variations to the standard method as described in Table 8 include, but are not limited to: optimization of the number of times any iPSC is passaged; adjustment of BMP signaling levels; adjustment of iPSC suspension aggregation parameters (e.g., shear force, rotation speed, etc.) during expansion and differentiation; optimization of the concentration, use time, and use duration of growth factors, e.g., Wnt, activin, and rho-kinase inhibitors; and treatment with other growth factors (e.g., ERBB ligands) during various stages 1 to 4 of the differentiation protocol as candidates to improve cell mass, proliferation, differentiation, survival, etc. A number of these replicate experiments were tested alone or in combination to determine how the differentiation method of iPSCs during stages 1-4 could be optimized. With this optimized differentiation method, a population of iPECs is produced that resulted in robust glucose-responsive insulin-secreting cells in vivo, similar to what has been observed and reported for hESCs upon transplantation. Table 11 below describes baseline conditions in the presence or absence of hereguline that were proven to differentiate iPSCs into iPECs (which subsequently mature into glucose-responsive islet cells in vivo). The baseline conditions were similar to those described in Examples 1, 2, and 5 of the present invention, as well as in Table 8, except that hereguline was added in steps 3 and 4. Although 30 ng / mL of Hrg1β was used, concentrations in the range of 10 ng / mL to 50 ng / mL, or even exceeding 50 ng / mL, are appropriate. Additionally, the addition of the rho-kinase inhibitor Y-27632 was maintained in the differentiation cultures as described in Example 2.

[0407]

[0408] Comparison of baseline and hereguline differentiation medium formulations for producing pancreatic endoderm cells (PEC) derived from iPSCs

[0409]

[0410] iPSC Aggs : iPSC aggregates; KSR : Knock-out serum (Life Technologies); F10 : 10 ng / mL bFGF (R&D Systems); A10 : 10 ng / mL Activin A (R&D Systems); A100 : 100 ng / mL Activin A; r0.2FBS : RPMI 1640 (MediaTech); 0.2% FBS (Hyclone), 1× Glutamax-1 (Life Technologies), 1% v / v penicillin / streptomycin; ITS : Insulin-transferrin-selenium diluted to 1:5000 or 1:1000 (Life Technologies); A100 : 100 ng / mL Recombinant Human Activin A (R&D Systems); K25 : 25 ng / mL Recombinant Human KGF (R&D Systems); CTT3 : 0.25 μM KAAD-cyclopamine (Toronto Research Chemicals) and 3 nM TTNPB (Sigma-Aldrich); N50 : 50 ng / mL Recombinant Human Nogin (R&D Systems); K50 : 50 ng / mL Recombinant Human KGF (R&D Systems); E50 : 50 ng / mL Recombinant Human EGF (R&D Systems); Y10 : 10μM Y-27632; stock 20 mM, 2000×; H30 : 30 ng / mL hereguline (stock 100 ug / mL); db , DMEM (high-glucose)

[0411] To determine the effects of adding hereguline or hereguline and rho-kinase inhibitors to step 3 and 4 cell subpopulations, iPEC populations were analyzed by flow cytometry. Table 12 provides a summary of flow cytometry analyses of various iPEC populations using the formulations listed in Table 11, as well as these formulations modified by increasing the activin concentration to 200 ng / mL. Additionally, Table 12 indicates the general conditions used for each experimental set (baseline in the presence or absence of hereguline) and the relative percentages of cell types (endocrine, non-endocrine, PDX1 alone, and triple-negative or remaining cell subpopulations) within the iPEC populations. Table 12 also discloses data regarding the in vivo function of the cells produced in each experiment.

[0412] Table 12

[0413] iPEC composition from iPS-derived cell cultures treated with heregulin

[0414]

[0415] BL , baseline condition; hIPSC , human induced pluripotent stem cells; Hg30 , 30 ng / mL heregulin-1; St 3+4 , steps 3 and 4; hESC , human embryonic stem cells, CHGA, chromogranin A

[0416] Under specific conditions, the ratio of cell subpopulations within the PEC (hESC, E2354) and iPEC (E2314, E2344, E2347) populations was altered. For example, at times, the percentage of endocrine (CHGA+) cells decreased and the percentage of non-endocrine cells (CHGA- / NKX6.1+ / PDX1+) increased compared to baseline (no herregulin) conditions. Although herregulin appeared to be responsible for altering the ratio of endocrine cells relative to non-endocrine cells in these PEC and iPEC populations, in experiment #2380 (E2380), the level of endocrine (CHGA+) cells increased rather than decreased with the addition of herregulin.

[0417] To determine whether changes in the composition of the PEC and iPEC populations affected in vivo function, PEC and iPEC grafts from most of the experiments listed in Table 12 were implanted into mice substantially as described herein, and as previously described in the aforementioned literature [Schulz et al. (2012)] and [Kroon et al. (2008)] and other patents and non-specific publications of the applicant, including U.S. Patent Nos. 7,534,608; 7,695,965; 7,993,920 and 8,278,106. Briefly, the PEC and iPEC populations were encapsulated entirely in biodegradable semipermeable cell encapsulation devices (some of which contained microperforations). Such a device was manufactured by the applicant and is described in detail in U.S. Patent No. 8,278,106 (titled "ENCAPSULATION OF PANCREATIC CELLS FROM HUMAN PLURIPOTENT STEM CELLS," filed on November 13, 2009). The glucose-stimulated insulin secretion (GSIS) assay was initiated and performed approximately 56 days after transplantation. Blood was collected before glucose administration (fasting) and at combinations of 30 and / or 60 minutes after glucose administration. Graft function was evaluated by measuring human C-peptide concentrations in serum in response to glucose administration.

[0418] The amount of human C-peptide released into the serum indicates the amount of released insulin. C-peptide is a short peptide of 31 amino acids secreted by functional beta or insulin-secreting cells that links or connects the A and B chains of proinsulin and preproinsulin. As previously discussed in the literature [Kroon et al. (2008)], the human C-peptide dimension is de novo by transplanted cells ( de novoIt is suitable for evaluating the release of )--produced insulin. Therefore, the levels of human C-peptide in the serum of these animals are a measure of the in vivo function of mature PEC and iPEC grafts. Human C-peptide was detected in serum for at least 8 weeks after transplantation. During additional weeks of transplantation and fasting, glucose-stimulated C-peptide levels increased, with the peak level of C-peptide shifting from 60 minutes to 30 minutes after glucose administration, indicating a more rapid response to the glucose challenge as insulin cells mature. There were a few mice that were sacrificed due to non-functionality or poor health; however, these mice were otherwise within a cohort that exhibited high-functioning animals, suggesting engraftment failure rather than differentiation or inability of the transplanted cells.

[0419] Figures 7a-c show human C-peptide levels in serum after glucose administration for all experiments indicated in Table 12, excluding E2344. Figures 7a-c indicate that grafts resulting from hereguline treatment generally have higher serum human C-peptide levels compared to the baseline control. For example, in Figure 7a, in Experiment 2380, there is an approximately 5-fold increase in grafts resulting from hereguline treatment compared to those prepared without hereguline (baseline) (933 pM vs. 200 pM 60 minutes after glucose administration). Since Experiment 2354 (Figure 7c) does not show higher levels of serum C-peptide in grafts resulting from hereguline treatment compared to the baseline control, hereguline appears to have a lesser effect on PEC produced from hESCs. Furthermore, when comparing PECs derived from hESCs (CyT203) and iPECs derived from iPSCs, the iPEC grafts exhibit in vivo function comparable to that of the PEC grafts (e.g., compare Figs. 7a and 7b (iPSC grafts) with Fig. 7c (CyT203 hESC)). Thus, the iPEC grafts are as robust as the PEC grafts. Additionally, the relative ratio of endocrine to non-endocrine cells, which appeared to affect some of the iPEC populations (e.g., E2314, E2347, and E2354), did not appear to affect in vivo function, as E2380, which lacked the same migration between endocrine and non-endocrine subpopulations, also exhibited good function (see Figs. 7a-c).

[0420] In addition to testing for glucose-stimulated insulin secretion, mature iPEC grafts were tested to determine whether they could maintain normoglycemic levels similar to those maintained by PEC derived from hESCs when the host animal's beta cells were destroyed. This involved destroying the transplanted mouse beta cells using the beta cytotoxic streptozotocin (STZ), which exhibits greater cytotoxicity to mouse beta cells compared to human beta cells. Randomized non-fasting blood glucose was measured for each mouse before and after STZ treatment. When the iPEC graft was in vitro transplanted on day 13 after STZ treatment, hyperglycemia (noting blood glucose spikes) resumed, demonstrating control of glycoglycemia by the iPEC graft rather than by the endogenous mouse pancreas (see Figures 8a and 8b).

[0421] Furthermore, synergistic effects were observed when hereguline and rho-kinase inhibitors were administered during differentiation stages 1–4 (see Table 11). For example, iPSCs treated with hereguline at stages 3 and 4 without rho-kinase inhibitors resulted in visually poor cell masses that made transplantation impossible. Further support for the synergy of hereguline and rho-kinase inhibitors was evident in some experiments, e.g., E2356 and E2380, where baseline conditions with only rho-kinase inhibitors did not function as robustly as grafts with both rho-kinase inhibitors and hereguline (see Figures 7a and b). Since the addition of hereguline alone provided insufficient cell mass for transplantation, and the addition of only rho-kinase inhibitors (baseline conditions) resulted in poor in vivo function, treatment with hereguline and rho-kinase inhibitors appears not to be additive. Therefore, providing hereguline alone or rho-kinase inhibitor alone is not substantially similar to the combined effect of the two. That is, neither one alone results in robust glucose responsiveness in vivo, but when combined, they induce glucose responsiveness similar to that of hES-derived cells. Thus, providing both hereguline and rho-kinase inhibitor appears to be synergistic, as the combined effect is greater than the sum of their individual effects. Specifically, iPECs treated with rho-kinase inhibitor and hereguline matured in vivo, exhibited glucose-stimulated insulin secretion, and were able to maintain normal blood glucose levels in a diabetic mouse model (see Figs. 7a-b and 8a-b).

[0422] ERBB functionality requires ligand binding, receptor dimerization, and receptor trafficking. Variability in each process can lead to different regulation of receptors and the downstream signals they control. For example, distinct ERBB ligands bind to ERBB receptors with different affinities, thereby altering the patterns and dynamics of ERBB dimerization. Table 13 illustrates several possible different combinations of ligand-receptor binding complexes. A review of the complexity of these systems is provided in the literature [Oda, et al. (2005) A comprehensive pathway map of epidermal growth factor receptor signaling, Mol. Syst. Biol., 1 (2005)] and [Lazzara et al. (2009) Quantitative modeling perspectives on the ERBB system of cell regulatory processes, Experimental Cell Research 315(4):717-725].

[0423]

[0424] ERBB receptor tyrosine kinase and its ligand

[0425]

[0426] ERBB receptor tyrosine kinase: ErbB1 (Her1, or also named the epidermal growth factor receptor (EGFR); ErbB2 (Human epidermal growth factor receptor, or also named Her2; or Neu); ErbB3 (also named Her3), ErbB4 (also named Her4), ERBB Ligand: EGF , epidermal growth factor; TGFα , conversion growth factor α; HB-EGF , heparin-bound EGF-like growth factor; EPR , epiregulin; EPG , Epigen; AR , ampyregulin, Hrg1 , heregulin-1 or neuregulin-1; Hrg2 , heregulin-2 or neuregulin-2; Hrg3 , heregulin-3 or neuregulin-3; Hrg4 , hereguline-4 or neuregulin-4; hereguline is used interchangeably with neuregulin.

[0427] Huotari et al. suggested that neuregulin-4 can modulate the relative levels of endocrine cell subpopulations by increasing the number of somatostatin (delta) cells at the expense of glucagon (alpha) cells, and that neuregulin-4 did not affect the ratio of exocrine (e.g., amylase) to endocrine (e.g., β-insulin, α-glucagon, δ-somatostatin, PP-pancreatic polypeptide) cells. However, these studies were performed by incubating neuregulin-4 on whole-tissue organ tissue cultures obtained from E12.5-day mice. These mouse ex vivo graft cell populations were more differentiated than the stage 3 (e.g., PDX1-negative foregut endoderm) and / or stage 4 (PDX1-positive foregut endoderm) cell populations described herein. Since neuregulin-4 binds only to ERBB4 RTK, under these circumstances, only the endocrine subgroup of whole-tissue mouse cultures can be regulated by neuregulin-4. Therefore, treating step 3 (PDX1-negative foregut endoderm) and / or step 4 (PDX1-positive foregut endoderm) cells as described herein with different ERBB ligands, e.g., Hrg1, is not expected to regulate relative endocrine subgroups as in fuotari, as has already been shown that Hrg1 binds to ERBB3 and induces dimerization of ERBB2 / 3. However, due to the low expression of ERBB2 and 3 in PEC as shown in Fig. 6, it was unclear whether step 3 and 4 type cells would express low or high levels of ERBB2 and 3 to bind to Hrg1.

[0428] Additionally, in another context, the applicant described that Hrg1 bound to ERBB 2 / 3 and promoted self-renewal of pluripotent stem cells (see reference [Wang et al. (2007)]). While it is possible for Hrg1 to act with the same ability in the context of stages 3 and 4, the applicant previously described that most of the cell expansion for PEC production occurs during the pluripotent stem cell stage (stage 0). During stage 0, hESCs grow, passage, and expand for about two weeks. Therefore, most cell expansion or self-renewal that causes cell expansion does not occur during stages 1-4. See the aforementioned reference [Schulz et al. (2012)]. Furthermore, assuming that ERBB2 / 3 is present during stages 3 and 4, it can be expected to have the same effect (self-renewal) on pluripotent stem cells, in contrast to how herregulin affects directional differentiation. Differences in function appear to depend on the context, namely pluripotent stem cells versus endoderm or pancreatic-lineage cell types.

[0429] In summary, the delivery of hereguline or hereguline and rho-kinase inhibitors to foregut endoderm (step 3) and PDX1-expressing pancreatic endoderm cells (the end of step 3 and step 4) in vitro produced PEC and iPEC populations, which, upon transplantation, mature and develop into glucose-responsive insulin-secreting cells in vivo (see Figures 7 and 8). Such use of hereguline or hereguline and rho-kinase inhibitors is reported for the first time herein. Such use and effects are not recognized from those previously described in patent or non-patent literature.

[0430] Example 8

[0431] Activin inhibits NGN3 expression and the production of cells entrusted to the endocrine system in pancreatic endoderm cell (PEC) cultures.

[0432] Pancreatic endoderm cells, or “PEC”, are a population of pancreatic cells composed mainly of two distinct subgroups: (i) a non-endocrine pluripotent pancreatic progenitor subgroup (CHGA-) (hereinafter “non-endocrine (CHGA-”)) that develops and matures in vivo to result in glucose-responsive insulin-secreting beta cells; and (ii) a subgroup of cells transferred to the endocrine lineage (CHGA+) (hereinafter “endocrine (CHGA+”)) that may result in other non-insulin-secreting or islet-supporting cells during in vivo maturation. The non-endocrine (CHGA-) subgroup is CHGA-negative and is mostly PDX1 and NKX6.1 positive, whereas the subgroup of cells transferred to the endocrine lineage is CHGA-positive and is mostly PDX1 and NKX6.1 negative. The non-endocrine (CHGA-) subpopulation takes about 8 to 12 weeks or more to develop and mature into glucose-responsive insulin-secreting beta cells in amounts that allow for systemic detection of insulin response (as assessed by ELISA for C-peptide) in vivo. However, during normal embryonic development, glucose-responsive cells take less than 8 weeks to develop and mature in vivo. Therefore, it is still desirable to obtain (1) a PEC population with increased non-endocrine (CHGA-) subpopulation, and / or (2) a true endocrine (CHGA+) cell population that is glucose-responsive and / or advanced in development in vitro (e.g., has specific signature markers that are accurately identified and consistent with those described for similar pancreatic populations in vivo), and / or (3) a progenitor cell population that can shorten and / or reduce the time of development and maturation in vivo.

[0433] With respect to the first objective, it is desirable to obtain a PEC population in which differentiation into endocrine-assigned cells (CHGA+) is inhibited, similar to what occurs naturally in vivo, while the non-endocrine (CHGA-) subpopulation is maintained intact. The following examples describe a method for producing such a PEC population.

[0434] During normal in vivo development, the transcription factor Neurogenin-3 (NGN3) is the master regulator of endocrine cell development, and it is believed that, for example in in vivo pancreatic endoderm-lineage cells, the expression of NGN3 does not occur until after the upregulation of PDX1 and NKX6.1. See [Rukstalis and Habener (2009), Neurogenin3: A master regulator of pancreatic islet differentiation and regeneration, Islets 1(3): 177-184]. According to Table 8, at step 3, retinoic acid (RA) or a retinoid analog, 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid or "TTNPB" (or "TT3" in Table 8) is used to induce PDX1 expression. However, at the same time, retinoic acid also induces early NGN3 expression that initiates endocrine specificity. Therefore, inhibition, suppression, or inhibition of NGN3 during steps 3 and / or 4 may provide a key to minimizing the endocrine-assigned cell (CHGA+) subpopulation within the PEC and / or obtaining endocrine cells at later developmental stages in vitro and / or in vivo. Importantly, any inhibitor, suppressor, or inhibitor of NGN3 should not simultaneously inhibit, suppress, or inhibit non-endocrine (CHGA-) cells, and preferably increase these subpopulations during PEC production in vitro.

[0435] The ability of various growth factors to suppress the expression of genes such as NGN3 during stages 3 and 4 was explored. One candidate growth factor was activin, which possesses various functions in stem cell expansion differentiation. For example, at low levels (e.g., 10 ng / mL), activin helps maintain pluripotent stem cell pluripotency and cell proliferation. At higher levels (e.g., 100 ng / mL), activin acts as a differentiation growth factor responsible for definitive endoderm production in stage 1 (see, e.g., Table 8). To test its effect on suppressing cells entrusted to the endocrine lineage (CHGA+) during PEC production, the applicant first tested activin at an intermediate concentration of approximately 50 ng / mL during standard adherent differentiation. At this level, activin was able to suppress NGN3 expression without suppressing PDX1 and NKX6.1 gene expression in PEC (compare Figures 9d-e with Figures 9a-b). However, when the same level of Activin was used with more scalable cell aggregate suspension cultures during Step 3, the total cell mass was dramatically reduced, and in some cases, cell aggregates were eradicated (compare the control group versus Activin-treated cell aggregates in Figure 10). A similar reduction in cell aggregates was observed in the case of Activin at 25 ng / mL as in 50 ng / mL (data not presented).

[0436] In consideration of these results, lower concentrations of activin (e.g., 5 ng / mL and 10 ng / mL) were tested in steps 3 and 4. As shown in Fig. 11, at lower activin concentrations, cell aggregates were able to maintain cell mass and yield compared to the control group (Fig. 11B-C for day 8 and Fig. 11B-D for day 12 are compared to Fig. 11A for d8 and d12, the control group). Thus, activin levels of less than approximately 25 ng / mL are acceptable for maintaining cell mass and yield. Subsequently, the applicant performed flow cytometry analysis on these cell cultures to determine whether the low levels of activin during steps 3 and 4 had any effect on the composition of the cell aggregates; see Table 14. Table 14 indicates that low levels of activin do not decrease the production of the non-endocrine (CHGA-) subpopulation, and that when treatment is applied in both steps 3 and 4, it can actually increase this subpopulation (see Table 14 A5 Step 3 & 4 results). However, considering that very similar percentages of endocrine (CHGA+) cells appear in the presence and absence of activin, it appears that differentiation into endocrine-assigned cells (CHGA+) is still being induced (see the endocrine column in Table 13). Therefore, while activin may suppress or inhibit NGN3 and NKX2.2 expression as observed by QPCR, it does not decrease the endocrine-assigned subpopulation (CHGA+) at lower levels (allowing cell mass to be maintained) when analyzed at the end of step 4. Advantageously, particularly when activin is used in steps 3 and 4, PDX1 alone and triple-negative subgroups are reduced compared to the control group.

[0437]

[0438] Low activin levels maintain the PEC non-endocrine subgroup.

[0439]

[0440] Example 9

[0441] Activin, heregulin, and WNT inhibit the production of cells entrusted to the endocrine system within PEC cultures.

[0442] Example 8 indicated that moderate levels of activin (e.g., 50 ng / mL) during steps 3 and 4 could inhibit or suppress NGN3 expression (Fig. 9), but these same levels did not maintain cell mass. Lower levels of activin (e.g., 5 and 10 ng / mL) could maintain cell mass (Fig. 11), but were insufficient to continue suppressing endocrine differentiation during step 4, as the percentage of endocrine lineage cells (CHGA+) remained substantially similar to that of the control group (Table 14, CHGA+ column) and the previous examples. Therefore, it appears that these low levels are insufficient to inhibit differentiation into endocrine lineage cells (CHGA+) primarily during step 3, as continued inhibition of differentiation of this subgroup through step 4 is still considered essential. See the aforementioned reference [Rukstalis et al. (2009)]. Therefore, additional growth factors were sought that could prevent cell loss and yield (i.e., counteract the effects of moderate to high levels of activin) while inhibiting the differentiation of endocrine-assigned cells (CHGA+) without affecting the production of non-endocrine multipotent pancreatic progenitor subpopulations.

[0443] Considering the above example which described that 30 ng / mL of hereguline during steps 3 and 4 often changes the relative levels of the endocrine (CHGA+) and non-endocrine (CHGA-) subgroups of PEC, the applicant tested what effect reducing the hereguline concentration would have on PEC production when combined with activin.

[0444] Pluripotent stem cells were differentiated using the standard protocol according to Table 8, except that during Step 3, Activin was included at 10 ng / mL or 20 ng / mL along with Heregulin at 2 ng / mL or 10 ng / mL, and during Step 4, Activin was reduced to 5 ng / mL, while Heregulin was 1 ng / mL for 2 days and then 10 ng / mL thereafter. As shown in Fig. 12 (Day 10 image; upper p...

Claims

Claim 1 A composition comprising a plurality of cell clusters for use in treating diabetes mellitus in human subjects, wherein the plurality of cell clusters comprises cells expressing PDX1 and C-peptide; the plurality of cell clusters comprises cells expressing glucagon; and at least 92.85% of the cells within the plurality of cell clusters express chromogranin A. Claim 2 A composition according to claim 1, wherein more than 98% of the cells within a plurality of cell clusters express chromogranin A. Claim 3 A composition according to claim 1 or 2, wherein a plurality of cell clusters comprises cells expressing NKX6.

1. Claim 4 A composition according to claim 1 or 2, wherein the diameter of the cell cluster is 60 μm to 120 μm. Claim 5 A composition according to claim 1 or 2, wherein a plurality of cell clusters comprises cells that express insulin. Claim 6 A composition according to claim 5, wherein the composition is in a device, and the device maintains a plurality of clusters within the device and allows the secreted insulin to pass out of the device. Claim 7 A composition according to claim 6, wherein the device comprises a semipermeable membrane. Claim 8 A composition according to claim 1 or 2, wherein a plurality of cell clusters comprises cells expressing somatostatin. Claim 9 delete Claim 10 delete